2000 Tandem Meeting Abstracts  by unknown
116
1 8
MONITORING CIRCULATING DENDRITIC CELL NUMBERS. AN ESSEN-
TIAL REQUIREMENT FOR CANCER IMMUNOTHERAPY PROGRAMMES
Hart, D.N.1; Vuckovic, S.1; Ho, C.S.1; López, J.A.1; Williams, N.1; Khalil,
D .1; Pyke, C.M.2; Rodwell, R.2; Hill, G.R.1; Taylor, K.A.2 1. Mater Medical
Research Institute, South Brisbane, Australia; 2. Mater Hospital , South Bris -
bane, Australia
Purpose of the study: Enumeration of blood DC in various clinical
scenarios including: surgical stress, stem cell mobilization and peripheral
blood stem cell transplantation (PBSCT). 
Methods: The monoclonal antibody CMRF-44 has been used to
evolve a flow cytometric assay to count total blood DC (I m m u n o l o g y
83:3708, 1997; B l o o d 89:3708, 1997). 
Results: The analysis of blood DC in 45 healthy adults yielded values of 3
to 25 x 106/L, reproducing the normal blood DC range previously described
(Blood 93:728, 1999). Further data established that the total steady state DC
count includes the CDw123dimCD11c+CMRF-44+ and CDw123high-
CD11c-CMRF-44+ subsets in similar proportions. Acute rises in DC num-
bers were documented during elective cholecistectomy. Although changes
were transient, they were statistically significant (p <0.0005). These changes
were correlated with the increment in cortisol levels, suggesting their link
with surgical stress, and they were independent from monocyte counts. DC
counts fell immediately after G-CSF in patients undergoing stem cell mobi-
lization with G-CSF ± cyclophosphamide, and remained low at the time of
peak CD34 counts (0.1 - 1.1x106/L on day 10). A rise in DC counts to or
above baseline levels was noted between days 18 and 35 and this was inde-
pendent of changes in monocyte counts or other leukocyte subsets. This late
rebound in peripheral blood DC numbers may provide a second window of
opportunity for the harvesting of blood DC. Blood DC counts recovered 20
or more days after PBSCT, independently of monocyte counts and signifi-
cantly after neutrophil and platelet recovery. 
Conclusions: 1) Circulating DC are mobilized rapidly into the peripheral
blood during surgical stress, prior to being recruited elsewhere, 2) blood DC
rebound above baseline late after stem cell mobilization with G-
CSF/cyclophosphamide and 3) blood DC counts are depressed after PBSCT.
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PHOTOCHEMICALLY TREATED MURINE DONOR LEUKOCYTES SUPPRESSES
GVHD, PROMOTES DONOR ENGRAFTMENT AND MAINTAIN GRAFT-
VERSUS-LEUKEMIA ACTIVITY IN MAJOR HISTOCOMPATIBILITY COM-
PLEX MISMATCHED RECIPIENTS
Talib, S.; Truitt, R.L.2; Johnson, B.D.2; Liu, W.1; Reames, A.1; McLaughlin,
J .1; Hanchett, J.1; Hearst, J.E.1 1. Cerus Corporation, Concord, CA; 2. Med -
ical College of Wisconsin, Milwaukee, WI
The donor T-cells that accompany hematopoietic stem cells during allogeneic
bone marrow transplantation can mediate both beneficial and deleterious clinical
effects.The proliferation of donor T-cells in vivo is the principal cause of GVHD.
New strategies are needed to control T-cell alloreactivities in order to make allo-
geneic transplantation safer and more effective. Such a strategy must be effective in
inhibiting the proliferation of T-cells without eliminating their beneficial GVL
effect. In this report, photochemical treatment (PCT) ex vivo with a synthetic pso-
ralen (S-59) and UVA light has been evaluated as a pharmacological approach to
achieve above stated goals. S-59 rapidly intercalates into and cross-links DNA upon
UVA illumination. Human leukocytes when treated with varying doses of S-59 +
UVA and then activated by either the mixed lymphocyte reaction (MLR) or by anti-
CD3 stimulation showed dose dependent inhibition in lymphocyte proliferation. At
optimum dose (9 nM and 3 J/cm2) where proliferation of lymphocytes was inhibited
>90%, cytokine synthesis (IL-2 and IFN-g) and cell surface antigen expression
(CD25 and CD69) remained unaffected. In addition, cytotoxic T-cell activity (CTL)
of the photochemically treated cell population is retained. 
In a murine model of MHC-mismatched BMT, the addition of PCT-treated T-
cells to T-cell depleted BM facilitated donor engraftment and complete chimerism
without causing acute or chronic GVHD (Truitt et al J.Immunol 1999, 163:5145-
5156)). Allospecific GVL reactivity was reduced but not eliminated after PCT treat-
ment. In an MHC-matched model using host-presensitized donor T-cells, PCT sig-
n i ficantly reduced GVH-associated mortality without eliminating GVL reactivity. 
Thus, PCT ex vivo offers a simple, rapid and inexpensive method to control the
fate of naive and primed T-cells in vivo. Based on these pre-clinical results a multi-
center phase 1 human safety study on allogeneic transplantation with haplo-identi-
cal donors has been initiated. 
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FIVE YEARS EXPERIENCE WITH HIGH-DOSE INTRAVENOUS MELPHA-
LAN AND AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANS-
PLANTATION FOR THE TREATMENT OF AL AMYLOIDOSIS
Sanchorawala, V.; Skinner, M.; Seldin, D.S.; Dember, L.M.; Finn, K.; Fish -
er, C.; Murakami, A.; LaValley, M.; Falk, R.; Wright, D.G. Boston Univer -
sity Medical Center, Boston, MA
AL Amyloidosis is a rare, progressive, multisystem disease associated
with a clonal plasma cell dyscrasia. Conventional therapy with low-dose
oral melphalan and prednisone rarely results in a complete hematologic
response or reversal of amyloid-related organ dysfunction, and median
survival is less than 18 mos. Between 6/94 and 10/99, we treated 170 AL
amyloidosis patients with high-dose intravenous melphalan(IVM) and
autologous peripheral blood stem cell transplantaion (SCT). Eligibility
criteria for treatment included measures of performance status (SWOG
0-3), cardiac function (LVEF>40%), baseline systolic blood pressure
(>90 mm Hg). 127 patients completed high-dose melphalan and trans-
plant prior to 10/98, for whom there was the possibility of at least 1 year
follow-up. Median age of these 127 patients was 56 (range 29-80). Over-
all survival of the 127 patients completing treatment before 10/98 was
76% at 1 year, 65% at 2 years and 60% at 3 years. Median survival has
not yet been reached. One year after treatment, 46% of 97 surviving
patients achieved a complete hematologic response (CR), e.g. there was
no evidence for persistence of a clonal plasma cell disorder. Survival was
significantly greater for patients who achieved a hematologic CR.
Improvement in amyloid-related organ dysfunction was also evident in a
substantial proportion of patients evaluated 1 year following IVM, par-
ticularly those with hematologic CR. For example, of 50 patients with
renal involvement who had proteinuria > 1 gm/24 hrs, 71% with a
hematologic CR experienced a >50% reduction in proteinuria vs 10% of
patients not in CR. In conclusion, this unique cumulative experience
indicates that IVM and SCT treatment results in hematologic CR, clini-
cal improvement and prolonged survival in a substantially greater pro-
portion of treated patients than has been reported for any other treat-
ment modality.
International Bone Marrow Transplant Registry/
Autologous Blood and Marrow Transplant Registry
Best Abstracts: Mortimer M. Bortin Award
PBMC FUNCTIONS (N = 6 )
% inhibition of lymphocyte proliferation (3H-Thymidine incorporation) 94.3 ± 5.7
IL-2 (pg/mL) % of control 82.1 ± 4.7
IFN-γ (pg/mL) % of control 91.1 ± 1.2
CD25 expression % of control 97.5 ± 9.4
CD69 expression % of control 111.8 ± 3.2
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IN VITRO GENERATION OF LEUKEMIA-REACTIVE ALLOGENEIC
DONOR T LYMPHOCYTES EXPRESSING A MUTANT NGFR AND HSV-TK
FOR CONTROLLED GRAFT-VERSUS-LEUKEMIA REACTION IN
RELAPSED ALL
Koehne, G.; Gallardo, H.F.; Latouche, J.B.; May, C.; Hirschberger, L.; Filip -
pa, D.A.; Sadelain, M.; O’Reilly, R.J. Memorial-Sloan Kettering Cancer Cen -
ter, New York, NY
To generate ALL-reactive donor T cells, we transduced the B7.1 gene
into CD80 and CD86 negative primary human T-ALL, using an MLV-
based monocistronic retroviral vector. Transduced cells were sorted to
high purity(>98%). In MLC, allogeneic T cells had a low stimulation
index (<2%) against B7.1 negative leukemia cells, whereas an index of 12
could be achieved after stimulation with gene-modified leukemia cells.
Since infusion of these cells might also induce GVHD, we transduced
the T cells proliferating in response to the transvected leukemic cells
with the dicistronic retroviral vector, termed NIT,encoding the cell-sur-
face marker LNGFR and HSV-TK. NIT+ cells were purified (>95%) by
immunoabsorption and used for functional analyses. In 5 1C r - r e l e a s e
assays, the B7.1 leukemia-sensitized NIT+ T cells lysed both, the B7.1+
m o d i fied ALL cells and the wild-type, B7.1 negative cells. In limiting
dilution analysis, we detected T cell frequencies of 1/4,582 and 1/4,534
against the B7.1 modified leukemia cells and the wild-type cells, respec-
tively. The frequency against third party leukemia cells was 1/319,903
and 1/56,480 against the autologous BLCL, indicating a preferential
recognition of the stimulating leukemia cells. We injected 20x10 6
leukemia-sensitized allogeneic NIT+ T cells i.v. into SCID-mice bearind
s.c. inoculated leukemia. 5 days after T cell injection, the tumors were
dissected and examined by FACS analysis, histology and immunopathol-
ogy. Leukemic xenografts were specifically infiltrated with the adoptive-
ly transferred NIT+, B7.1+ leukemia sensitized T cells. We, thus can
demonstrate that by using B7.1 modified leukemia cells as stimulators,
donor T cells can be preferentially sensitized and transduced with NIT,
permitting isolation of suicide vector-modified, leukemia-reactive T cells
for adoptive therapy.These leukemia-sensitized T lymphocytes infil t r a t e
in s.c. inoculated leukemia cells after i.v. injection in SCID-mice, indi-
cating their potential use for controlled graft-versus-leukemia reaction.
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EXPLOITING WT1 FOR ANTIGEN-SPECIFIC IMMUNOTHERAPY OF
LEUKAEMIA AND OTHER MALIGANCIES
Gao, L.; Bellantuono, I.; Dazzi, F.; Cotterill, L.; Ramirez, F.; Elsässer, A.;
Marley, S.; Goldman, J.M.; Stauss, H.J. Imperial School of Medicine, London,
United Kingdom
WT1 is an embryonic transcription factor that is not expressed in post-
natal life except for some cells of myo-epithelial origin including CD34+
bone marrow stem cells, renal podocytes, testicular Sertoli cells and ovar-
ian granulosa cells. Aberrant WT1 expression has been observed in
CML, AML and ALL as well as in other human malignancies, such as
renal cell carcinoma, breast cancer, ovarian cancer, melanoma and lung
cancer. Tumour cells express elevated levels of WT1, and there is evi-
dence that this may contribute to their exaggerated proliferation. 
We have explored the feasibility of exploiting WT1 as target for tumour-
s p e c i fic cytotoxic T lymphocytes (CTL). In order to circumvent possible
immunological tolerance against the self-protein WT1, CTL were raised
from allogeneic donors against peptide epitopes presented by HLA-A0201,
the most common HLA allele in the caucasian population. Two WT1 pep-
tides stimulated CTL that killed HLA-A0201-positive leukaemia cell lines
but not HLA-A0201-positive cell lines that did not express WT1. The
W T 1 - s p e c i fic CTL also showed killing of CD34+ cells from CML patients
but not of normal CD34+ bone marrow stem cells. This correlated with the
observation that the CTL inhibited colony formation by transformed
C D 3 4+ progenitor cells isolated from CML patients, whilst colony forma-
tion by normal CD34+ progenitor cells was unaffected. Western blotting
analysis showed that the selective CTL killing of leukaemia cells was due to
elevated WT1 expression in malignant cells compared to normal cells. 
The described in vitro data indicated that WT1 specific CTL can selec-
tively kill tumor cells without causing damage to normal cells. Furthermore,
preliminary in vivo experiments in a murine model indicate that the adop-
tive transfer of CTL specific for WT1 is safe and does not cause GVHD or
damage to normal tissues expressing low levels of this transcription factor. 
In summary, WT1 is an attractive target for CTL mediated
immunotherapy of leukaemias as well as renal cell carcinoma, breast can-
cer, ovarian cancer, melanoma and lung cancer. There is evidence that
tolerance to WT1 is incomplete, suggesting that WT1 based vaccina-
tion strategies may lead to tumour protective immune responses in
patients suffering from leukaemia and other cancers. 
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OUTCOMES OF 124 ALLOGENEIC NON-SIBLING TRANSPLANTS - A COM-
PARATIVE STUDY FROM THE AUSTRALASIAN BMT RECIPIENT REGISTRY
Nivison-Smith, I.1; Hawkins, P.2; Ma, D.D.3 1. ABMTRR, Darlinghurst,
Australia; 2. St Vincent’s Hospital, Darlinghurst, Australia; 3. Garvan Insti -
tute, Darlinghurst, Australia
Haemopoietic cell transplantation activity has been recorded by the
ABMTRR for Australia since 1992 and for New Zealand since 1998. 
Between 1992 and 1998, 58 allogeneic transplants were carried out
utilising stem cells from HLA-identical related non-sibling donors. Of
these, 2 donors were children of the recipient, 23 were parents and 33
were other relatives. The median age of recipients was 28, compared to
34 for the 1,184 matched sibling donor transplants carried out over the
same time period. The proportion of male recipients was 63.8%, com-
pared to 62.2% for matched siblings. The main indications for trans-
plant were CML (25.9%), AML (20.7%) and ALL (20.7%), similar to
indications for matched sibling transplants (CML 21.5%, AML 26.0%,
ALL 19.3%). Survival probability at 5 years was 47.9%, compared to
49.0% for matched sibling donor transplants. 
Between 1992 and 1998, 66 allogeneic transplants were carried out
utilising stem cells from 5/6 HLA-matched related non-sibling donors.
Of these, 10 donors were children of the recipient, 31 were parents and
25 were other relatives. The median age of recipients was 22, compared
to 30 for the 62 5/6 HLA-matched sibling donor transplants carried out
over the same time period. The proportion of male recipients was
57.6%, compared to 71.0% for 5/6 matched siblings. The main indica-
tions for transplant were ALL (31.8%), CML (19.7%) and AML
(18.2%), similar to indications for 5/6 matched sibling transplants (ALL
24.2%, CML 19.4%, AML 33.9%). Survival probability at 5 years was
47.1%, compared to 23.8% for 5/6 matched sibling donor transplants. 
In Australia between 1992 and 1998, allogeneic transplants using non-
sibling donors show similar demographic characteristics to those where a
sibling was a donor, and similar overall survival. The ABMTRR is a
valuable national resource providing a platform for analysis of transplant
procedures which are relatively infrequent. 
IBMTR/ABMTR: Best Abstracts, Oral Presentations
3
ALLOGENEIC PERIPHERAL BLOOD STEM CELL VERSUS BONE MAR-
ROW TRANSPLANTATION FOR CHRONIC MYELOID LEUKEMIA: A
COMPARATIVE STUDY
Azevedo, W.M.1; Fagundes, E.M.1; Lodi, F.M.1; Aranha, F.P.2; Vigoritto,
A . C .2; Souza, C.A.2 1. Hospital das Clínicas - UFMG, Belo Horizonte, Brazil;
2. Hospital das Clínicas - UNICAMP, Campinas, Brazil
We conducted a study to compare PBSC or BM as source of
hematopoietic progenitor cells for allogeneic transplantation in patients
with chronic myeloid leukemia (CML). The main end-points were: inci-
dence of acute GVHD, incidence of chronic GVHD, day + 100 mortali-
ty, overall survival (OS) and event-free survival(EFS). Event was trans-
plant related death and hematological relapse. Sixty pts underwent a
PBSC transplantation and 63 a BM transplantation. All donors were
HLA-identical siblings. The age varied from 4.6 to 56.9 years (median
34.4y) in the BM group and from 9.1 to 53.7 years (median 31.2y) in the
PBSC group. There were 36 female donors in the BM group and 28 in
the PBSC group(p = 0.04). The conditioning regimen was BuCy2.
GVHD prophylaxis was CSA/MTX. The median number of mononu-
cleated cells transplanted was 3.8 x 108/kg for the PBSC group and 2.9 x
1 08/kg for the BM group. RESULTS: The incidence of a-GVHD grad-
ed ≥2 was 25% for BM and 24% for PBSC (p = 0.95), the incidence of
extensive c-GVHD was 45% for BM and 67% for PBSC (p = 0.05). The
100-mortality was 16% for BM and 18% for PBSC (p = 0.90). The OS
for all pts was 55%±5% at 5 years. The OS for BM group was 61%±7 %
and for PBSC group was 45%±9% (p = 0.19). The EFS for all pts was
3 7 %±11% at 5 years and was 42%±13% and 41%±9% for BM group
and PBSC group respectively (p = 0.14). The major factor predictor for
lower OS was extensive c-GVHD (p = 0.03). Age, sex, sex of donors,
duration of disease, number of cells transplanted, institution where the
transplant was performed did not have significant impact on the results.
Conclusion: The incidence of c-GVHD in the PBSC group was higher
than in the BM group, but it was not transduced for longer survival and
event-free survival. 
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SELECTION OF ANTIGEN-SPECIFIC T-CELLS WITH PEPTIDE/MHC-
COATED MICROBEADS FOR ADOPTIVE CELLULAR IMMUNOTHERAPY
Wang, C.Q.1; Lee, P.P.2; Felio, K.1; Davis, M.M.2; Molldrem, J.J.1 1. M. D.
Anderson Cancer Center, Houston, TX; 2. Stanford University, Palo Alto, CA
Donor lymphocyte infusions (DLI) are currently given to transfer anti-
leukemia immunity and to restore immunity toward viral pathogens after
allogeneic transplant. However, GVHD occurs in 40% or more of these
patients. GVHD might be eliminated and GVL favored if T-cells with
s p e c i ficity for leukemia antigens could be selected for adoptive transfer.
PR1, a 9 aa peptide derived from proteinase 3, is an HLA-A2.1-restricted
peptide and PR1-specific cytotoxic T lymphocytes (CTL) preferentially
lyse myeloid leukemia cells. We have shown that PR1-specific CTL are
present at frequencies of 1/300,000 in normal donors. Therefore, to fir s t
expand PR1-specific CTL, short-term polyclonal CTL lines were elicit-
ed by pulsing 70 x 106 PBMC from 6 different healthy HLA-A2.1+
donors weekly with PR1-coated T2 cells plus interleukin-2. After 21 days
in culture, these PR1-pulsed CTL, quantified with a PR1-HLA-A2
tetramer conjugated to phycoerythrin (PE), comprised 2% to 8% of the
culture. To preferentially select PR1 antigen-specific T-cells, we devel-
oped and optimized a method using streptavidin-coated microbeads (Mil-
tenyi, Inc.). Beads were conjugated with PR1 myeloid leukemia peptide
plus HLA-A2.1 through the biotin-labeled heavy chain C-terminus.
PR1-pulsed short-term CTL lines were incubated for 30 minutes with
PR1/HLA-A2 coated microbeads and were selected using the magnetic
MACS column. Bead-selected and non-selected CTL were quantified by
FACS analysis using the PR1-HLA-A2 tetramer and compared to the
initial polyclonal CTL lines. Yields ranged from 85% to 100% and PR1-
s p e c i fic CTL purity ranged from 11% to 21% after selection (3- to 5-
fold increase in purity of antigen-specific CTL). Specific lysis of both
PR1-coated T2 cells and CML marrow cells increased in all 6 cultures
and background lysis of normal HLA-A2.1 normal marrow was eliminat-
ed compared to non-selected PR1-specific CTL. This method can be
used for the simple and rapid adoptive transfer of leukemia-specific CTL
to deliver GVL without GVHD. 
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HIGH DOSE 131-I MIBG INFUSION WITH MYELOABLATIVE
CHEMOTHERAPY FOR THE TREATMENT OF REFRACTORY NEURO-
B L A S T O M A
Yanik, G.A.; Sisson, J.C.; Levine, J.E.; Shulkin, B.; Shapiro, B.; Ferrara,
J.L.; Zempel, S.; Spaulding, S.; Hutchinson, R.J. University of Michigan, Ann
Arbor, MI
For nearly 20 years, low dosage (<2 mCi) 131-I MIBG infusions have
been used for scintigraphic localization of neuroblastoma. The potential
therapeutic benefit of high dose 131-I MIBG as conditioning for autolo-
gous transplantation for neuroblastoma is now examined. 
Methods: Four patients (age 5-7 years) with refractory neuroblastoma
were treated with high dose 131-I MIBG (12 mCi/kg) infusions plus
myeloablative chemotherapy, followed by autologous stem cell infusion.
All 4 patients had previously failed multiple cycles of multi-modal
chemotherapy (including anti-GD2 antibody in one patient) prior to
study entry. At the time of study entry, 3 patients had progressive disease
(bone plus marrow involvement) following relapse, and one patient had
persistent disease post induction chemotherapy. In all 4 cases, the
tumors concentrated MIBG activity at the time of study entry. 131-I
MIBG (12 mCi/kg) was administered via 90 minute intravenous infusion
on day -21 pre-transplant. Carboplatin (1500 mg/m2), etoposide (800
m g / m2), and melphalan (210 mg/m2) were administered day -7 to day -4
pretransplant, followed by autologous stem cell infusion. Peripheral
stem cells were administered in 2 cases and marrow in 2 others. 
Results: All 4 patients tolerated the 131-I MIBG infusion without
complication. Engraftment (ANC > 500 x 106/1) was noted on day +9,
+12, +13, and day +31 post transplant respectively. No hepatic vod, renal
dysfunction, pulmonary dysfunction, or other significant organ toxicity
was noted. All 4 patients achieved a complete remission based upon radi-
ographic studies (including MIBG scans), marrow analysis, and urine
catecholamines on day 100 post transplant. Complete remissions have
lasted 5+, 6, 9, and 9+ months. 
Conclusion: The use of high dosage 131-I MIBG, in combination
with myeloablative chemotherapy and autologous stem cell reconstitu-
tion, offers potential for achieving remission in high risk patients with
progressive or refractory disease.
IBMTR/ABMTR: Best Abstracts, Oral Presentations
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A PROGNOSTIC MODEL FOR CHRONIC GRAFT VERSUS HOST DISEASE (CGVHD)
Akpek, G.; Zahurak, M.L.; Piantadosi, S.; Vogelsang, G.B. The Johns Hop -
kins Oncology Center, Baltimore, MD
The incidence of cGVHD has been rising continuously parallel to the
increased use of transplantation from alternative donors and peripheral
blood stem cell collection. More than ninety percent of patients with
cGVHD suffers from an “extensive stage” disease, which comprises an
extremely heterogeneous population. Although it is highly reproducible,
the current classification system of cGVHD does not stratify patients for
outcome. We retrospectively analyzed the clinical features and disease-
related variables of cGVHD to identify the prognostic factors for survival
and form a basis for a new classification of cGVHD. The variables at the
time of diagnosis of cGVHD included the extent of skin, liver, mouth/eye
involvements, functional performance status, presence or absence of
infection, type and histology of cGVHD and platelet count. The end
point was overall survival (OS) after the diagnosis of cGVHD. Between
1982 and 1996, sixty nine patients with a median age of 32 (5 to 58) were
diagnosed with cGVHD at Johns Hopkins Oncology Center during their
follow-up after BMT from matched related or unrelated donors. Median
follow-up after the diagnosis of cGVHD for survivors was 8.6 years and
median OS of all patients was 7.4 years. Multivariate analysis demonstrat-
ed that extent of skin involvement, histology of cGVHD, and platelet
count at the diagnosis of cGVHD influenced the OS (Table). None of
the other variables independently affected the outcome. According to the
data presented here, diffuse skin involvement, lichenoid cGVHD and
platelet count being lower than 100K were associated with decreased sur-
vival in patients with cGVHD. A new simple staging system based on this
prognostic model may be useful in grouping these patients with similar
outcome. In this ongoing study, this prognostic model will be tested in a
second cohort of patients for partial validation.
4
HIGH DOSE CYCLOPHOSPHAMIDE, CARMUSTINE AND ETOPOSIDE
FOR NON-HODGKINS LYMPHOMA IS A SAFE AND EFFECTIVE CONDI-
TIONING REGIMEN FOR ALLOGENEIC PROGENITOR CELL TRANS-
P L A N T
Ballen, K.; Becker, P.; Emmons, R.; Doyle, P.; Heyes, C.; Quesenberry, P.;
Stewart, M. UMass Memorial Health Care, Worcester, ME
Many patients are unable to receive total body irradiation as part of
their conditioning for allogeneic progenitor cell transplant. High dose
cyclophosphamide (C), Carmustine (B), and Etoposide (V) is a
chemotherapy only conditioning regimen that has been used in autolo-
gous progenitor cell transplantation but has not been well evaluated in
the allogeneic setting. From 11/96 through 4/99 patients, ten patients
median age 37 years (range 30-50), received regimen of cyclophos-
phamide 750 mg/m2 q 12 hr x 8 doses (total 6 gm/m2), carmustine 112.5
m g / m2 q day x 4 doses (total 450 mg/m2), and etoposide 200 mg/m2 q 12
hours x 8 doses (total 1600 mg/m2). Patients were transplanted for lym-
phoma (2 Burkitts, 2 lymphoblastic, 1 mantle cell, 3 smalled cleaved, 1
large cell and 1 CLL), and all but one had advanced disease; 2 patients
received a prior transplant (1 auto/1 T depleted allo). All patients
received HLA identical sibling donor transplant. Five patients received
marrow as the progenitor cell source, 4 received G-CSF mobilized
peripheral blood stem cells and one received a combination of peripheral
blood and marrow derived stem cells. Cyclosporine and methotrexate
were used for GVHD prophylaxis. 100 day transplant-related mortality
was 10%, one patient died at Day 93 from multiorgan failure; there were
2 late deaths from chronic graft vs. host disease. Other toxicity was limit-
ed to mild veno occlusive disease of the liver (3 of 10, all mild) and oral
stomatitis. One patient with mantle cell lymphoma has relapsed. All
patients achieved trilineage engraftment and transfusion independence
with a median time to an ANC of 500 21 days (range 19-27) with mar-
row and 16 days (range 14-18) with peripheral blood stem cells. Overall
60% of patients are alive and disease free with a median followup of 30
months (range 18-37 months). These results appear superior or compa-
rable to TBI containing regimens. In summary; 1) CBV is well tolerated;
2) trilineage engraftment is achieved after CBV; 3) CBV may be used as
an alternative to a TBI containing regimen.
2
ALLOGENEIC STEM CELL OR BONE MARROW TRANSPLANTATION
(ALLO-BMT) FOR CHRONIC MYELOID LEUKEMIA (CML) USING IV BU
(BUSULFAN) AND CY (CYCLOPHOSPHAMIDE). 
Andersson, B.S.; Esfandiari, N.; Gajewski, J.L.; Tran, H.; Madden, T.;
Giralt, S.; Donato, M.; Talpaz, M.; Kantarjian, H.; Champlin, R.E. UT MD
Anderson Cancer Center, Houston, TX
Pre-BMT conditioning with oral BuCy for allo-BMT in CML
patients is convenient and efficacious. The major drawback of oral Bu is
hepatic veno-occlusive-disease (VOD), associated with the unpredictable
intestinal absorption/bioavailability of oral Bu; high plasma concentra-
tions correlate with VOD. To avoid the unpredictable bioavailability, we
evaluated a parenteral Bu formulation for conditioning of CML patients
undergoing allo-BMT. Bu (0.8 mg/kg) was given every 6 hrs x16 doses,
followed by Cy 60 mg/kg daily x2, then allo-BMT. 48 patients (M/F
31/17) with a median age of 39 years (range 19-64) were treated through
November 1999. 16 patients were in chronic phase (CP), 28 in accelerat-
ed phase (AP), and 4 in blastic crisis (BC) (IBMTR criteria). Results:
Follow-up ranges from 3 weeks to >33 months (median 11 mos).
Engraftment to ≥500 neutrophils/mL was at 13 days (range 11-20) and
≥20,000 plt/mL at 15 days (range 8-35). Median time of neutropenia was
8 days (range 6-15). 47/48 patients engrafted and available DNA-RFLP
studies confirm donor chimerism in 41 of 42; 1 CP patient rejected the
graft (recurrent CML), samples from 2 patients were unavailable, and
results from 4 patients are pending. In CP the one-yr over-all (OS) and
progression-free survival (PFS) are 93 % and 84 % respectively. For the
32 patients in the advanced group the 2-yr OS and PFS were 75% and
80%, respectively. The only treatment-related mortality in the first six
months was one patient who died from reactivated HCV at 5* months.
Pharmacokinetic data from 12 patients showed low interpatient variabil-
ity, mean Bu AUC was 1196 mM-min, and mean plasma Bu clearance
was 101 ml/min/m2. This IV Bu formulation (Busulfex®) was very well
tolerated; our patients experienced no serious regimen-related toxicity. It
should be used as a safer alternative to oral Bu in conditioning therapy
for allo-BMT in CML.
5
ACCELERATED,MULTI-CYCLE, FILGRASTIM/PERIPHERAL BLOOD
PROGENITOR SUPPORTED,HIGH-DOSE CHEMOTHERAPY PRODUCES
FREQUENT COMPLETE REMISSIONS IN PATIENTS WITH POORLY-
DEBULKED OR INOPERABLE OVARIAN CARCINOMA
Crown, J.P.; O’Leary, M.; Ballot, J.; Gainford, C.; King, T.; Murphy, J.;
Lenehan, P.; Murphy, J.; McCarthy, D.; Fennelly, D. St. Vincent’s University
Hospital, Dublin, Ireland
Advanced ovarian cancer (OC) is partially chemotherapy sensitive.
Patients(Pts) with poorly debulked(PD) or inoperable(Inop) disease sel-
dom achieve pathological (P) complete remission(CR). Randomised tri-
als (PRCT) indicate a modest, inconsistent relationship between
chemotherapy dose and response. We have reported a high rate of surgi-
cal CR, but with few PCRs using a Filgrastim (G) and peripheral blood
progenitor(PBP)-supported high-dose chemotherapy(AMCHDC) regi-
men consisting of cyclophosphamide (Cyc), carboplatin (J) and paclitaxel
(T). In the current study we included escalating doses of thiotepa (TT)
and melphalan (M). 
Regimen(all doses in mg/m2, J dose area under curve-AUC): Cycles
#1-2: Cyc 3000 + T 300; #3-5: Cyc 1500 + J AUC 12; # 6 Cyc 3000 +
TT (500-700). In Dose Levels (DL) I-II, TT was escalated. In DL 3-4,
M(80-120)is substituted for J. PBP are harvested following #1, for re-
infusion following #3-6. Routine antibiotics and G were administered.
Second surgery (2LL) was routine. 
Results: Accrued 13 (1-ineligible, not OC), 6 cycles- 10, early with-
drawal for progressive OC-1, on-study-1, evaluable for response-11.
Pts/DL: I-2; II-5; III-4, IV-1. Status at entry: Inop-6, PD-5; well
debulked(WD)-1. There were no treatment-related deaths. Grade IV
neutropenia and grade III-IVthrombocytopenia are universal following #
3-6. PCR was seen in 3/5 evaluable Inop, 2/5 PD and 1/1 WD. Four oth-
ers had complete resection of residual OC (1Inop; 3PD). One Inop pt is
in radiological CR pending 2LL. Nine pts are alive, 7 in CR, (at 40+, 30+,
26+, 21+, 4+, 1+, 1+months) 1 alive with OC, 1 pending 2LL, 3 died of
OC. Conclusions: (1) This regimen is feasible, but highly myelosuppres-
sive. (2) Although the numbers are small, it appears to produce a very
high rate of CR in Inop/PD OC pts. Further accrual to the program is
planned to determine the MTD of M, in preparation for a PRCT. 
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PROGNOSTIC FACTORS FOR OS NO OF PTS. HAZARD RATIOS (CIS)
Platelet count ≥100K 31 1.0
Platelet count <100K 38 2.0 (0.9-4.4), P = 0.09
Sclerodermatous or mixed histology 18 1.0
Lichenoid histology 51 2.5 (1.0-5.6), P = 0.03
Single site or no skin involvement 15 1.0
Skin involvement, <50% of BSA 26 2.2 (0.4-10.7), P = 0.34
Skin involvement, >50% of BSA 28 13.7 (3.0-63.0), P < 0.001
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REINFUSION OF INCREASED NUMBERS OF CD34+ PROGENITORS
PRODUCES COMPLETE CHIMERISM IN MATCHED SIBLING TRANS-
PLANTS FOLLOWING A SIGNIFICANTLY REDUCED MYELOABLATIVE
R E G I M E N
Dicke, K.A.; Livingston, D.L.; Mayorga, J.; Richardson, C.; Fulbright, L.K.
Arlington Cancer Center, Arlington, TX
Matched sibling allogeneic stem cell transplants can retain efficacy with
less morbidity by modifying the conditioning and infusion regimens.
Busulphan, at 16 mg/kg, is an effective single agent for acute and chronic
myeloid leukemia. Immunosuppressive agents, i.e. total body irradiation,
are unnecessary if large numbers of peripheral stem cells (PSC) are trans-
planted. We have treated 2 benign phase CML patients (pts) and 2 AML
pts in either 1st or 2nd remission. PSC from G-CSF primed siblings were
infused 48 and 72 hours after busulphan. The median number of cells/kg
infused were 10.1x10*6 PSC, 9.4x10*7 B cells, 2.6x10*8 T4 and 1.2x10*8
T8 cells. G-CSF began 24 hours after infusion. An absolute neutrophil
count >1000 was achieved by day 11 (10-13) and platelets >50,000 by day
14 (12-17). Transfusion support was minimal and only 1 pt was hospital-
ized (6 days) within the first 90 days. Graft vs. host (GVH) prophylaxis
consisted of continuous infusion cyclosporin (1.3 mg/kg/day) to maintain
a serum level of 250-350 for 6-8 months before tapering. Solumedrol, 25-
mg intravenous (IV) q 24 hours was administered for 30 days before taper-
ing. While immunosuppressed, pts received antimicrobial therapy includ-
ing oral Valtrex and IV Levaquin, Fortaz, Vancomycin, Acyclovir and
D i flucan with intermittent Bactrim and Ambisome. There was no VOD,
ARDS or Grade III/IV acute GVHD. At 3-4 weeks post transplant, all pts
demonstrated 100% chimerism as determined by restriction fragment-
length polymorphism. Complete chimerism persisted for 9-19 months.
Late, fatal complications (6-19 months post transplant) included recurrent
leukemia, chronic GVHD, pulmonary aspergillosis and myocardial infarc-
tion related to juvenile diabetes. Increased stem cell dose using a less mor-
bid conditioning regimen results in complete chimerism and permits out-
patient management during and immediately following matched sibling
allogeneic transplant. Long term outcome however is still predicated on
controlling relapse and chronic GVH. 
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REDUCTION IN MORTALITY AND MORBIDITY FOLLOWING AUTOLO-
GOUS HAEMOPOIETIC STEM CELL TRANSPLANTATION
Dodds, A.J.; Presgrave, P.; Milliken, S.T.; Concannon, A.J.; Biggs, J.C.; Ma,
D.D.; Nivison-Smith, I. St. Vincents Hospital, Sydney, Australia
We performed a retrospective analysis of 264 adult patients undergo-
ing first autologous haemopoietic stem cell transplantation (HSCT) over
12 years from Jan 1987 to April 1999. The median age was 43 (13 - 67).
The HSC source was peripheral blood stem cells (PBSC) in 151
patients, bone marrow (BM) in 63 and combined PBSC/BM in 50. Rou-
tine prophylaxis using a combination of norfloxacin, fluconazole and low
dose heparin was introduced in 1992. The use of prophylactic nor-
floxacin was associated with a reduction in the incidence of gram nega-
tive bacteraemia from 30.5% to 7.1%. In a Cox regression analysis, pro-
phylaxis with norfloxacin was the most significant factor in this reduction
( p<0.0005). Prophylaxis with fluconazole reduced overall fungal infec-
tions from 23.7% to 3.4%. Invasive fungal infection was reduced from
10.2% to 0.0%. In a Cox multivariate regression analysis the use of flu-
conazole was the only factor that was associated with a reduced risk of
fungal sepsis (p<0.0005). Duration of neutropenia was not found to be
s i g n i ficant. The use of low dose heparin was associated with a reduction
in veno-occlusive disease of the liver (VOD) from 9.3% to 0.9%.
Heparin was the only factor associated with a reduced risk of VOD in
the treated group.(p = 0.001) 
The overall transplant related mortality (TRM) of the group was
3.4%. The TRM of patients transplanted before June 1992 was 13.2%
compared to 0.5% in the group transplanted after this time (p<0.01). A
single transplant related death has occurred in the last 7 years. The HSC
source was an additional factor in survival but not as significant as the
use of the prophylactic measures. We conclude that appropriate prophy-
laxis with these agents adds to the safety of the procedure and may con-
tribute to the reduced mortality associated with autologous HSCT.
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RELATIONSHIP BETWEEN NUMBER OF CD34+ CELLS PER KG AND
NUMBER OF UNITS RED BLOOD CELLS AND PLATELETS TRANSFUSED
FOLLOWING HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM
CELL RESCUE
Dillman, R.O.; Beutel, L.D.; Chico, S.; German, R.; Schiltz, P.M.; Barth,
N.M.; VanderMolen, L.A.; Mahdavi, K.; O’Connor, A.A.; Nayak, S.K. Hoag
Cancer Center, Newport Beach, CA
Between 1994-1998,105 patients underwent treatment with high-dose
chemotherapy and autologous stem cell rescue at our institution. A ret-
rospective analysis was performed to confirm that the number of CD34+
stem cells was a good predictor of marrow recovery. It was hypothesized
that the number of CD34+ stem cells would have an inverse correlation
with the amount of blood cell products utilized. Patients who had been
transplanted and the number of CD34+ cells x 106 per kg given were
retrieved from records of the Hoag Cell Biology Laboratory. The num-
bers of units of red blood cells (RBC) and numbers of multiunit platelet
packs were retrieved from records of the Hoag Hospital blood bank.
Dates of transplant and survival were confirmed with records compiled
by Cancer Data Services. Patient cohorts were defined based on the
number of CD34+ cells/kg that were given. The numbers of units of
cells given from the date of transplant (or first transplant if patients had
undergone tandem transplants) was determined. For patients who had
two transplants, the number of CD34+ cells/kg were divided by two.
Patients who died within 30 days of transplantation were excluded from
analysis. There were 71 patients with breast cancer, 27 hematologic
malignancies, and 7 with other solid tumors. The results are in the table. 
As suggested by other publications, engraftment was better when at
least 2 x 106 CD34+ cells/kg were given, but the amount of blood cell
support used was even less when larger numbers of stem cells were
given. However, we did not see any significant difference over the range
of 2-4.9 vs 5-9.9 x 106. 
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A “SINGLE” APPLICATION OF G-CSF AFTER AUTOLOGOUS PERIPHER-
AL BLOOD STEM CELL TRANSPLANTATION (APBSCT) - A PILOT
S T U D Y
Faber, E.1; Knotková, R.1; Zapletalová, J.2; Dusková, L.1; Kempná, J.1;
Kujícková, J.2; Pikalová, Z.1; Tauber, Z.1; Indrák, K.1 1. University Hospital,
Olomouc, Czech Republic; 2. Medical Faculty, Palacky University, Olomouc,
Czech Republic
The speed of the recovery after APBSCT could be affected by the
quality of the graft, previous chemo and radiotherapy and growth factors
used either during mobilisation or post-transplant. Growth factors
applied after APBSCT could reduce the duration of neutropenia by 2 - 6
days. However, this did not influence the incidence of complications and
duration of hospitalization in every study. We performed a pilot study to
test the safety and effectiveness of “single” delayed application of growth
factors after APSCT. G-CSF was given subcutaneously after first neu-
trophils appeared in peripheral blood (Neu = 0 . 1 x 1 09/l) in 13 patients
with acute leukaemia, lymphoma and multiple myeloma. In 5 of them a
single vial of G-CSF was sufficient to induce the complete recovery of
neutrophils within 24 hours. We compared these patients with 12 con-
trols with similar diagnosis and conditiong. In control group G-CSF was
given immediately after decline of neutrophils under 0.5x109/l. There
were no differences in the CD 34+ cells in graft, previous chemotherapy
and age of the patients between both groups. First injection of G-CSF in
control group was given on day +3 and the total dose of G-CSF was
3300mg in average (in the study group day +11 and 468mg). Signific a n t
differences (p = 0.006 - 0.0002) between both groups were found in the
duration of neutropenia and the time to achievement of 0.5 and
1.0x109/l neutrophils. In all cases differences were 3 days in favour of
control group. However, no statistical differences were found in dura-
tion of hospitalization, fever and recovery of platelets. We conclude that
the use of the growth factors after APBSCT could be probably safely
delayed to the time when first neutrophils appear in peripheral blood. 
IBMTR/ABMTR: Poster Presentations
RANGE OF # CD34+ NUMBER OF AVERAGE # CD34+ A V E R A G E AVERAGE # UNITS
CELLS PER KG PATIENTS IN COHORT CELLS PER KG # UNITS OF RBC OF PLATELETS
0-1.9 6 1.25 26.5 50.6
2-4.9 15 2.86 11.9 15.1
5-9.9 16 7.96 10.8 17.1
10-19.9 13 12.9 10.6 12.6
20-49.9 26 34.5 8.7 10.5
50-99.9 13 69.2 6.1 6.5
>100 14 199 4.8 6.6
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EX VIVO EXPANSION OF AC133+ SELECTED AUTOLOGOUS PERIPH-
ERAL BLOOD PROGENITOR CELLS IN BREAST CANCER
Filip, N.; Vavrova, J.; Blaha, M.; Vokurkova, D.; Va a sek, J. Charles Uni -
versity Hospital, Czech Republic, Czech Republic
High-dose chemotherapy with hematopoietic rescue appears promising
in the treatment of breast cancer. As compared with rescue by bone mar-
row transplantation, peripheral blood progenitor cells shorten the period
of pancytopenia and reduce the risk of infection and bleeding. However,
the collection of peripheral blood progenitor cells requires processing of
a large volume of blood by leukapheresis. It is useful to minimalize the
contamination of peripheral blood progenitor cells with tumor cells. 
We have developed a method of growing the progenitor cells ex vivo
from a relatively small volume of blood. Over the last few years, tech-
niques have become available that allow the extensive proliferation of
hematopoietic progenitor cells in ex vivo culture systems. The most
commonly used method involves a simple liquid suspension culture sys-
tem supplemented with a range of cytokines. Large increases in total cell
numbers and committed progenitor cells can be readily obtained and,
with some techniques, significant expansion of primitive hematopoietic
cells has been demonstrated. We studied the effect of stem cell factor
(SCF), interleukin 3 (IL-3) and interleukin 11 (IL-11) on the prolifera-
tion of human CD34+/ A C 1 3 3+ progenitors isolated from leukapheresis
products from chemotherapy plus granulocyte-colony-stimulating factor
(G-CSF)-mobilised adult donors. 
MiniMACS AC133+ isolated cells contained a mean of 85% (80-90)
AC133 cells. Enriched AC133 cells coexpressed CD34 80%
C D 7 1l o w36.6% and CD33 6.6%. 
After a seven-day ex vivo expansion in presence of SCF+IL-3+IL11,
the number of cells increased 19 times. These cells expressed
1 2 % C D 3 4+,74% CD71+( 2 3 % C D 7 1h i g h) and 59% CD33+.This means
that the absolute number of CD34+ cells increased slightly, the number
of CD33+ cells increased 100 times, and cells with a high density
C D 7 1h i g h (23%) appeared. These cells represent the cells committed to
erythroid differentiation. The number of CFM-GM in culture after a
seven-day ex vivo expansion in the presence of SCF+IL-3+IL-11
increased 45 times.
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CHEMOTHERAPY WITH G-CSF FOR MOBILIZATION YIELDS IMPROVED
PERIPHERAL COLLECTION, QUICKER RECOVERY AFTER HIGH DOSE
CHEMOTHERAPY AND REDUCES PROGRESSION RISK COMPARED TO
G-CSF ALONE FOR MOBILIZATION
Gajewski, J.L.; Donato, M.; Anderlini, P.; Korbling, M.; Ueno, N.; Saliba, R.;
Rondon, G.; Ippoliti, C.; Champlin, R.; Hortobagyi, G. University of Texas
M.D. Anderson Cancer Center, Houston, TX
Intensive chemotherapy+GCSF or GCSF are used to mobilize PBPC.
121 pts entered a randomized trial comparing cyclophosphamide
( C T X ) 1 . 5 g m / m2/d x 3,VP16200 mg/m2 BID x 3d & cisplatin 45
m g / m2/d x 3(CVP) + GCSF 6mcg/kg BID to GCSF 6mcg/kg BID for
PBPC mobilization with target collection -4 x 106 CD34+ cells/kg in 
< 6 pheresis. HDC was CTX 2mg/m2 /d x 3, thiotepa 250mg/m2/d x 3
& BCNU 150m2/d x 3. 2CVP/GCSF pts failed to attain target CD34
dose compared to 22 GCSF pts, P <.001. CVP/GCSF pts recovered
>ANC 500 (9d vs 10d, P = .001) and PLT 20K (9d vs 11d, P = .001) than
GCSF pts. Disease stage II/III/IV were similar for CVP/GCSF
(13/17/31) & GCSF pts (14/18/28). Treatment related mortality and
survival were similar. Multivariate analysis including ER, dx to HDC,
stage at HDC, and total number of prior chemotherapy showed that
CVP/GCSF mobilization and ER+ were associated with a reduced actu-
arial risk of progression (prog)(P <0.05) and improved actuarial progres-
sion free survival (PFS) and >1 prior chemotherapy regimen (P = 0 . 0 4 ,
0.09) had opposite effects. CVP/GCSF improve pheresis efficiency,
reduced prog risk, and improved pfs.
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SUCCESSFUL SECOND MISMATCHED UNRELATED TRANSPLANT FOR
MAROTEAUX-LAMY SYNDROME USING FLUDARABINE AND MELPHALAN
Friedman, D.J.; Eames, G.M.; Bowman, W.P.; Griffin, T.C.; Murray, J.C.;
Sanders, J.M.; Saez, R.; Corbin, J.; Anderson, J.; Storey, M. Cook Children’s
Medical Center, Fort Worth, TX
Maroteaux-Lamy syndrome is a mucopolysaccharidosis (MPS VI) dis-
order treatable with bone marrow transplantation. This procedure raises
serum and tissue levels of arylsulfatase B (ASB) that degrade the abnor-
mal mucopolysaccharide in cellular lysosomal granules. Systemic organ
dysfunction is often rapidly reversed but skeletal problems are less reme-
diable with this procedure. 
A four-year-old girl with MPS VI, underwent two bone marrow trans-
plantations from different mismatched unrelated donors. The patient was
diagnosed prenatally because of a previously affected brother. The girl’s
first preparative regimen included busulfan 20 mg/kg, cyclophosphamide
120 mg/kg, antithymocyte globulin (ATG) 90 mg/kg, and TBI 1400 cGy
with 50% head and lung shielding. She received a cell dose of 5.4 x 108
nucleated cells/kg and 5.5 x 105 T-cells/kg after T-cell depletion. The
marrow was rejected and only autologous engraftment occurred. 
A second unrelated transplant was performed three years later at age
four. The patient now had significant valvular and cardiac impairment
with an ejection fraction of 38% and a shortening fraction of 21%. The
donor was again mismatched at the B-locus. The second preparative
regimen consisted of fludarabine 150 mg/m2, melphalan 140 mg/m2 a n d
ATG 120 mg/kg. She received 7.5 x 108 total nucleated cells /kg, 1.3 x
1 07 C D 3 4+ cells/kg and 8.3 x 105 T-cells/kg. Post-transplant graft-ver-
sus-host disease, (GVHD) prophylaxis included FK506 and steroids.
The regimen was well tolerated. There was rapid WBC and platelet
recovery without any major toxicity, veno-occlusive disease or GVHD.
The WBC nadir was 300/mm2. RFLP studies at day 33 post-transplant
revealed full donor engraftment and normal blood ASB levels. The
patient is 56 days post-transplant and doing well. 
Fludarabine, melphalan and ATG shows great promise as a non-mye-
loablative protocol that incurs limited toxicity, yet achieves successful
engraftment for some patients with genetic disorders who have both
unrelated and mismatched donors.
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AMIFOSTINE AS A CYTOPROTECTANT DURING CONDITIONING THER-
APY FOR ALLOGENEIC BONE MARROW TRANSPLANTATION
Goh, Y.T.; Hwang, W.Y.; Tan, C.H.; Koh, L.P.; Linn, Y.C.; Tan, H.C. Sin -
gapore General Hospital, Singapore, Singapore
13 patients in our center were randomly assigned to receive (6
patients) or not receive (7 patients) intravenous amifostine 740 mg/m2
per day for each day of conditioning therapy. Amifostine was adminis-
tered within 15 minutes before conditioning therapy and the daily dose
was divided when the conditioning required more than one dose a day
(e.g. when TBI was given twice a day). 
2 of the 6 patients receiving amifostine had grade 4 mucositis while
this occurred in 4 of the 7 patients on the control arm. 1 of the 6 patients
on amifostine developed grade 4 liver toxicity (based on elevations of the
plasma bilirubin) while this was seen in 3 of 7 control patients. Grade 1
renal toxicity was seen in 3 patients of each arm. 
Neutrophil recovery, defined by a recovery of the absolute neutrophil
count to >0.5 x 109/L, occurred at a median of 17.6 days (range 14 to 21
days) for those on amifostine and at a median of 14.6 days (range 5 to 20
days) for the controls. Recovery of the platelet counts to > 20 x 109/ L
was at a median of 17.7 days (range 11 to 25 days) for those on amifos-
tine and at a median of 20.5 days (9 to 36 days) for the controls. Dura-
tion of hospitalization was little different: median 30.5 days, range 11 to
53 days on amifostine and median 29.4 days, range 20 to 42 days for
controls. 
Recruitment is still ongoing but preliminary data suggests that amifos-
tine adds little to the toxicity of allogeneic bone marrow transplantation
and may have some effect in reducing the mucositis and liver toxicity
associated with the conditioning regimens.
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C V P / G C S F G C S F P V A L U E
Days pheresis med. 1 (1-5) 3 (1-7) <0.001
Stage II PFS 75±13%SE 59±18% 0.9
Stage III PFS 75±13% 54±13% 0.2
Stage IV PFS 62±9% 35±10% 0.2
Stage II Prog 11±10% 29±18% 0.5
Stage III Prog 11±10% 46±13% 0.09
Stage IV Prog 36±9% 65±9% 0.1
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ALLOGENEIC BONE MARROW TRANSPLANTATION (BMT) IN CHIL-
DREN AFTER A PRIOR AUTOGRAFT
Hale, G.A.1; Benaim, E.1; Cunningham, J.M.1; Heslop, H.E.2; Horwitz,
E . M .1; Leung, W.1; Rochester, R.J.1; Shearer, P.D.1; Woodard, J.P.1; Bow -
man, L.C.1 1. St. Jude Children’s Research Hospital, Memphis, TN; 2. Baylor
College of Medicine, Houston, TX
Twenty-three children with acute myelogenous leukemia (AML) or
non-Hodgkin’s lymphoma (NHL) underwent allogeneic bone marrow
transplantation for graft failure (n = 1) or recurrent malignancy (n = 2 2 )
between February 1992 and August 1999 following autologous BMT.
The single patient with graft failure had trilineage aplasia with no evi-
dence of disease recurrence over two years post-autograft. The median
time to relapse after autograft was 161 days (range, 48-918). The median
time from autograft to allograft was 291 days (range, 72-1460). Fourteen
patients received induction chemotherapy and 9 patients went directly to
BMT. Five were in remission at time of allogeneic BMT. Five received
marrow from matched siblings (MS), 15 from matched unrelated donors
(MUD) and 3 from mismatched family members (MMFM). Condition-
ing regimens included cyclophosphamide (CY), cytarabine (Ara-C), and
total body irradiation (TBI) to 1200 cGy (MS) or 1400 cGy
(MUD/MMFM). Grafts from MMFM and MUD were depleted of T
cells, while those from MS were not. Twenty-two engrafted at a median
of 19 days post-BMT. One patient died prior to engraftment. Eight
patients developed Grade II-IV acute GVHD; 4 of 17 evaluable devel-
oped chronic GVHD. Nine of the 23 patients (39.1%) are alive disease-
free between 364 and 2222 days post-BMT, all with Karnofsky/Lansky
scores of 90-100. All but one have maintained longer remissions than
following their autograft, resulting in a 3-year DFS of 37%. Eight
patients relapsed at a median of 206 days (range, 35-669 days) post-
BMT and all eventually died. Eight patients died of regimen-related tox-
icity, two of whom had recurrent disease. Of note, six had no grade III-
IV non-hematologic organ toxicities. Although regimen-related toxicity
and recurrent disease remain important problems, a significant percent-
age of pediatric patients may successfully undergo allogeneic BMT after
failing autologous BMT. In the future, nonmyeloablative regimens may
improve the outcome for these patients. 
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ISOLATION OF HUMAN PERIPHERAL BLOOD DENDRITIC CELLS FOR
CLINICAL APPLICATION
Hart, D.N.; Gilleece, M.H.; Muster, D.; Vuckovic, S.; López, J.A. Mater
Medical Research Institute, South Brisbane, Australia
Purpose of the study 
Isolate blood dendritic cells (DC) for potential use in immunotherapy. 
Methods 
Current methods of expansion and enrichment of monocyte derived
DC (Mo-DC) populations, require prolonged in vitro culture in the
presence of exogenous growth factors. Furthermore the resulting Mo-
DC have significant phenotypic (and potentially functional) differences
to circulating DC. We have investigated the feasibility of purifying
blood DC populations by a series of simple enrichment procedures,
including positive selection with the monoclonal antibody CMRF-44,
that do not require extensive culture in vitro. The resulting DC popula-
tion relates closely to the physiological precursor population and may be
functionally superior to Mo-DC. We undertook the isolation of these
cells by sequential steps of enrichment from PBMC, obtained from buffy
coat or pheresis MNC preparations. 
Results 
After a short incubation, the cells were centrifuged over a Nycodenz
gradient, a method previously used to enrich DC from the blood (J.
Immunol. Methods 184:84, 1995). The interface population was labeled
with biotinylated CMFR-44 antibody (B l o o d 89:3708, 1997) followed by
streptavidin coated magnetic beads, and positive selection (Miltenyii
MACS). This procedure enriches CMRF44+ CD19-CD14- DC fif t y
fold to a purity >25%. Further enrichment to 80% purity was achieved
by negative selection using CD14 plus CD19 specific antibodies prior to
the positive selection step. 
Conclusions 
We describe the phenotypic and functional characteristics of these DC
in comparison to conventional preparations. We propose further investi-
gation of the potential of this routine blood DC purification platform as
a basis for controlled trials of DC vaccination as therapy for cancer. 
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ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION IN
J A P A N
Harada, M.1 , 2; Takenka , K.1 , 2; Shinagawa, K.1 , 2; Kawano, F.2; Kasai, M.2;
Sawada, H.2; Nakao, S.2; Aotsuka, N.2; Kodera, Y.2 , 3 1. Okayama University
Medical School, Okayama, Japan; 2. Japan Blood Transplant Study Group,
Japan; 3. Nagoya First Red Cross Hospital, Nagoya, Japan
In 1996, a multicenter phase II study of allogeneic peripheral blood
stem cell transplantation (allo-PBSCT) for standard-risk leukemia was
conducted. After conditioning, 26 patients with AML, ALL and CML
received G-CSF-mobilized PBSC from HLA-identical siblings.
Cyclosporine and short-term methotrexate were given for GVHD pro-
phylaxis. Median days to ANC>5 0 0 /ml and platelets>2 0 , 0 0 0 /ml were 12
(9-20) and 13 (9-27), respectively. Acute GVHD (grade II-IV) and
chronic GVHD were observed in 9/25 (36%) and 19/25(76%), respec-
tively. At a median follow-up of 585 days, their overall survival (OS)
and disease-free survival (DFS) were 77% and 81%, respectively. Day
100 transplant-related mortality (TRM) was 4%(1/26). A nationwide
survey of allo-PBSCT/1997 showed similar results in 103 transplant
patients. Median days to ANC>5 0 0 /ml and platelets>2 0 , 0 0 0 /ml were
13(7-49) and 13(7-40), respectively. Grade II-IV acute GVHD devel-
oped in 37/99 (37%) and chronic GVHD in 59/86 (69%). 100 day
TRM was 10% and 29% for standard-risk and high-risk leukemia. OS
and DFS were 72.5% and 67.5% for standard risk leukemia and 29.4%
and 29.4% for high-risk leukemia. These observations clearly indicate
that allo-PBSCT is characterized by rapid engraftment and increased
risk of chronic GVHD and can be used as an alternative to allogeneic
bone marrow transplantation.
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AN UPDATE ON UNRELATED UMBILICAL CORD BLOOD TRANSPLAN-
TATION FOR CORRECTION OF GENETIC DISEASES
Howrey, R.P.1; Martin, P.L.1; Ciocci, G.1; Driscoll, T.A.1; Szabolcs, P.1; Buck -
ley, R.H.1; Rubinstein, P.2; Kurtzberg, J.1 1. Duke University Medical Center,
Durham, NC; 2. New York Blood Center, New York, NY
We report our experience in 74 patients with genetic disorders trans-
planted with unrelated UCB at DUMC between 1994 and 1999. 
Results: Twenty-one transplants were performed for immunodefic i e n-
cy syndromes, eighteen for bone marrow failure syndromes, and thirty-
five for inherited metabolic or hematologic disorders. The median age at
time of transplantation was 26 months(6 weeks to 26 years), median
weight was 11.1 kg (3.8 to 73). Ninty-seven percent received grafts dis-
parate at 1 (n = 20), 2 (n = 47) or 3 (n = 5) HLA antigens, with a median
nucleated cell dose of 9.3 x107 cells/kg (1.8-33.8). Eighty-eight percent
of evaluable patients engrafted with donor cells. Six were not evaluable
secondary to early infectious (4), cardiac (1), or other treatment related
(1) death. The majority of graft failures occurred in the bone marrow
failure group, where the overall engraftment rate was 56% (9/16), com-
pared with 98% in the other groups. Grade II-IV acute graft versus host
disease occurred in 20 patients (33%), resulting in five deaths (8%).
Twenty-six patients died of regimen-related toxicity (15 infections, 6
pulmonary, 2 cardiomyopathies, 2 CNS bleeds, 1 hyperammonemia),
and one patient with FA died of squameous cell carcinoma 4 years after
successful UCB transplantation. Forty-two patients treated are surviving
(57%), with a median follow-up of 541 days (66-1915). Survival with
i m m u n o d e ficiencies (62%) and inherited hematologic or metabolic dis-
orders (63%) was better than with bone marrow failure syndromes
(39%) in part due to the poor survival of patients with Fanconis anemia
(1/6 16%) and the higher incidence of graft failure. 
Conclusion: UCB is a viable source of stem cells for patients with
genetic disorders who lack a suitable matched related donor, particularly
those with non-bone marrow failure syndromes where the incidence of
graft failure is exceptionally low and transplantation early in the course
of disease may be critical to outcome.
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ADVERSE SIDE EFFECTS ASSOCIATED WITH G-CSF IN PATIENTS WITH
CHRONIC MYELOID LEUKEMIA (CML) UNDERGOING ALLOGENEIC
PERIPHERAL BLOOD STEM CELL TRANSPLANTATION (PBSCT)
Khoury, H.J.; Adkins, D.R.; Brown , R.A.; Vij, R.; Westervelt, P.W.; Good -
nough, L.T.; DiPersio, J.F. Washington University, St. Louis, MO
Transplantation using allogeneic PBSC followed by post-transplant (PT)
myeloid growth factors is associated with rapid hematopoietic engraftment.
G-CSF is well tolerated, medullar bone pain is the most common side effect.
We report a high incidence of side effects associated with PT G-CSF CML
patients undergoing allogeneic HLA-identical sibling donor PBSCT. 
Between 1996 and 1999, 20 CML patients conditioned with cyclophosphamide
(120 mg/kg) and 550 cGy single-dose TBI, received unmanipulated allogeneic
PBSCT followed by G-CSF (10 mcg/kg/d sc) initiated on d+1. CSA alone was
used for GVHD prophylaxis. Ten patients (50%) developed an unexpected, yet
dramatic reaction, 60 minutes (range, 30-300) from the first (n = 7) or second
( n = 3) injection of G-CSF. Reactions consisted of one or more of the following:
dyspnea (8 patients), chest pain (3), nausea (5), hypoxemia (2), diaphoresis (6), ana-
phylaxis (2), syncope (3), and flushing (3). Administration of hydrocortisone (HC)
and antihistamine (AH) resulted in rapid resolution of symptoms. After premed-
ication with HC and AH, 4 patients were rechallenged with G-CSF and symp-
toms recurred in 2. In an attempt to determine predictive factors, this cohort
(Group 1) was compared to CML patients who did not experience a reaction
when G-CSF was administered for mobilization of autologous PBSC (Group 3),
or post-allogeneic PBSCT (Group 2). Patients in all 3 groups were comparable
with regards to age, gender, and presence of splenomegaly at the time of diagno-
sis. No differences were found for the other variables examined (Table). When
compared to patients in Group 2, neutrophil recovery for patients in Group 1 was
comparable(12.8 vs. 11.4 d)despite dicontinuation of G-CSF. 
We conclude that administration of G-CSF post-allogeneic PBSCT for CML
was associated with a high incidence of side effects. The underlying mechanism
for these events is unknown, and these reactions could not be predicted. 
2 2
OPTIMAL UMBILICAL CORD BLOOD PROCESSING: BASIC STUDY FOR
THE DEVELOPMENT OF CORD BLOOD BANK
Kim, H.J.1; Kim, S.W.1; Kim, S.H.1; Suh, C.1; Kim, K.W.2; Cho, H.J.2;
Kim, S.B.1; Kim, A.1; Lee, J.S.1; Kim, W.K.1 1. Asan Medical Center, College
of Medicine, University of Ulsan, Seoul, South Korea; 2. Asan Institute for Life
Science, Seoul, South Korea
E f ficient volume reduction is important to make a cost-effective umbilical
cord blood (UBC) banking system. The aim of this study was to find a
method of red cell depletion of UCB without major losses of the hematopoi-
etic progenitor-CD34+ cells. 
Eighteen cord blood samples were collected in heparinized bottle immedi-
ately after Cesarean section. Five aliquots of each cord blood were stored at
room temperature and processed within 12 hours. We used four types of RBC
depletion methods (Ficoll density gradient separation, gelatin sedimentation,
red cell lysis, starch sedimentation) and compared the results of viability, RBC
reduction rate, WBC and mononuclear cell (MNC) recovery rate, CD34+ c e l l s
and colony forming unit (CFC). 
The mean collected cord blood volume was 81.3mL (42~128mL). There
were no differences of viability and RBC reduction rate among groups. WBC
and MNC recovery rate were significantly higher in gelatin group (59.5 ± 9 . 3 ,
47.7 ± 14.5%) than Ficoll (18.4 ± 7.5, 36.1 ± 14.7%), RBC lysis (46.8 ± 1 1 . 4 ,
30.4 ± 11.1%) (p<0.05). Gelatin group has significantly higher CD34 count
than Ficoll and starch, and higher CFC count than Ficoll and RBC lysis
( p<0.05). But the results of CD34+ cell (65.7 ± 42.1 3 1 03/mL) and CFC
(127.7 ± 66.0 3 1 02/mL) of untreated control group are significantly higher
than those of RBC depletion groups. 
Cord blood processed with gelatin sedimentation has higher recovery rates
of WBC, MNC, CD34+ cells and CFC than other groups. Unlike other
reports, the absoulte numbers of CD34+ cell and CFC count of gelatin sedi-
mentation method are significantly lower than those of untreated control
group. Different processing technique and materials could be the causes of
the diffenrences of our results from other reports but novel volume reduction
methods should be estabilished to make an effective cord blood bank.
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HIGH DOSE STEM CELL TRANSPLANTATION IN HIGH RISK APLASTIC
ANEMIA WITH ADDITIONAL POOR RISK FACTORS
Kim, D.W.; Min, C.K.; Cho, B.; Han, C.W.; Min, W.S.; Kim, H.K.; Kim,
C.C. Catholic Hemopoietic Stem Cell Transplantation Center, The Catholic
University of Korea, Seoul, South Korea
We report our experiences of high dose stem cell transplantation in
high-risk aplastic anemia patients with various poor risk factors. 
Between May 1996 and November 1998, 19 patients (10 male, 9
female) with SAA were transplanted using G-CSF mobilized PBPCs and
bone marrow. The median age was 31 years (20-46 years). The median
time from diagnosis to transplants was 72 months (4-131 months). Eigh-
teen patients had received more than 20 units of red cells or 40 units of
platelet transfusions and 2 patients had familial blood transfusions prior
to transplants. Three patients had infections and one patient had chronic
subdural hematoma. Preparative regimen consisted of cyclophosphamide
(50mg/kg/day, 4 days), antithymocyte globulin (1.25mg/kg/day, 3 days,
rabbit type; Pasteur Merieux), and procarbazine. To get higher stem cell
dose, G-CSF mobilized peripheral blood progenitor cells (PBPCs) were
infused together with bone marrow (BM). CD3+ cells in PBPCs were
partially depleted using an immunoadsorption. Final inoculum contained
9.51 (4.36-19.92) x 108/kg mononuclear cells, 16.75 (5.73-26.5) x 106/ k g
CD34+ cells, and 15.4 (0.9-72.8) x 107/kg CD3+ cells. Neutrophil recov-
ery to 0.5x109/L and platelet to 20x109/L were achieved 12(10-41) and
17(10-90) days following the first dose of PBPCs and bone marrow infu-
sion, respectively. Primary graft failure occurred in one patient, who was
subsequently engrafted with second PBPCs infusion. Grade II-IV acute
GvHD occurred in 3 out of 19 (15.8%) and chronic GvHD in 5 out of 16
(26.3%). The actuarial 3 year disease free survival was 89.5% with a
median follow up of 30(12-41) months. Two patients died with acute and
chronic GvHD respectively. 
These results suggest the high dose stem cell transplants using G-CSF
mobilized PBPCs and BM can lead to lower incidence of graft rejection
and a rapid engraftment without significant differences in the incidence
of GvHD and other complications. 
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THE NEPHROTOXICITY OF HIGH-DOSE IFOSFAMIDE, CARBOPLATIN
AND ETOPOSIDE FOLLOWED BY AUTOLOGOUS PERIPHERAL BLOOD
STEM CELL TRANSPLANTATION
Kinalp, C.; Arpaci, F.; Ozet, A.; Ozturk, B.; Komurcu, S.; Turan, M.; Yenice -
su, M.; Caglar, K.; Pak, Y.; Yalcin, A. Gulhane Military Medical Academy,
Ankara, Turkey
Nephrotoxicity is one of the most frequent dose limiting toxicity of
high dose ifosfamide, carboplatin and etoposide (ICE) regimen followed
by autologous peripheral blood stem cell transplantation (PBSCT). The
factors affecting nephrotoxicity in the early period of high dose ICE and
autologous PBSCT (between -8th and +30th days) in 47 patients were
investigated in this study. Nephrotoxicity was defined as an absolute
increase in the serum creatinine level of 0.5 mg/dl or more than baseline
level. The patients were evaluated by dividing into two groups as having
nephrotoxicity (23.4%) or not (76.6%). The transplant related overall
mortality rate was 17%. Prognosis was poorer in patients who experi-
enced nephrotoxicity during early periods of transplantation. The trans-
plant-related mortality was higher in patients with nephrotoxicity than
patients without (54.5% vs. 5.5%, p = 0.001) and there was a positive
correlation between nephrotoxicity and death (rs = 0.55, p = 0 . 0 0 1 ) .
Forty-five percent of patients with nephrotoxicity (10.6% of overall
patients) required hemodialysis and the mortality rate was the highest in
this subgroup (80%). The frequency of cisplatin administration before
high dose ICE in patients with nephrotoxicity (54%) was not higher
than those without nephrotoxicity (61.12%). However, the previous
cumulative dose of cisplatin (470 mg/m2 vs. 227 mg/m2, p = 0.02), and
median age (37 years vs. 26 years, p = 0.019) were higher in the group
with nephrotoxicity. The elderly patients and the ones who received pre-
viously cisplatin over the cumulative dose of 282.5 mg/m2 were under a
much greater risk of nephrotoxicity. In conclusion, the major cause of
mortality due to high dose ICE was nephrotoxicity. Nephrotoxicity was
seen even with the much lower doses than the maximum tolerable dose.
Especially the risk of nephrotoxicity was greatest in the elderly patients
who received high cumulative dose of cisplatin.
GROUP 1 GROUP 2 GROUP 3
( N = 1 0 ) ( N = 1 0 ) ( N = 1 4 ) p
Pre-existing cardio-pulmonary condition 3/10 3/10 7/14 0.49
Median DLCOc (range) 72 (56-100) 86 (74-100) 88.5 (62-96) 0.36
Median CD34+ cells transplanted(range) 6.0x106 (3.1-46.5) 6.2x106(2.8-16.2) N/A 0.63
Median G-CSF dose in mcg(range) 780 (560-925) 776 (620-1000) 915 (425-1150) 0.45
Median WBC pre-GCSF (range) 13.5 (2-39) 11.6 (4.4-55) 12.3 (6-46) 0.48
Median WBC day 1 G-CSF (range) 40.9 (9.7-70) 30.5 (3.2-89) 55.9 (27-90) 0.09
Median WBC day 2 G-CSF (range) 31.4 (6.8-71) 24 (8.3-86) 85 (30.4-177) 0.02*
Median WBC day 3 G-CSF (range) 11.3 (1-24) 7 (3-33) 56.3 (40-115) 0.0002*
* compares Group 3 to Groups 1&2
F I C O L L G E L A T I N RBC LYSIS S T A R C H
CD34+ cell/mL (3 103) 15.0 ± 13.2 36.1 ± 20.4 28.4 ± 20.3 20.7 ± 12.7
CFC/mL (3 102) 35.8 ± 19.7 56.1 ± 29.0 41.2 ± 25.7 46.2 ± 22.6
CD34+ recovery rate(%) 28.9 ± 22.6 71.4 ± 38.1 57.7 ± 44.0 50.7 ± 55.2
CFC recovery rate(%) 31.1 ± 18.8 49.2 ± 26.8 33.4 ± 14.3 33.6 ± 19.3
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INFECTIONS IN AUTOLOGOUS STEM CELL TRANSPLANT RECIPIENTS
Kumar, L.; Parida, S.; Kochupillai, V.; Raju, G.M.; Kapil, A. All India Insti -
tute of Medical Sciences, New Delhi, India
In a prospective study, 50 consecutive patients were evaluated to deter-
mine the spectrum of infections over 58 months. Patients age ranged
from 13 to 65 years (median 43); 34 were males and 16 females. Indica-
tions for transplant were: multiple myeloma-20, NHL-5, Hodgkin’s dis-
ease-4, CML-4, AML-3, ALL-3, Breast cancer-5, Ovary-2, GCT testis-
2, small cell lung cancer-1, & PNET-1. A total of 92 neutropenic febrile
episodes (mean 1.8) were recorded within first 30 days. Infection could be
documented in 60 episodes; clinically alone in 8.7%; Clinical + radiologi-
cally - 5.4%; Clinical + microbiologically - 15.2%; Clinical + radiological
& microbiologically in 15.2%. 12% of patients had bacterimia alone.
34.8% of episodes were defined as isolated febrile episodes. Chest was the
most common site of infection (36%), followed by GIT (24%), catheter-
8.7%, skin and soft tissue-10%, sinusitis/URTI-4% and UTI in 2% of
patients. 8 (16%) patients had infection at multiple sites. Microbiological-
ly, gram negative organisms (73%)(Ecoli, acinetobacter, enterobacter)
and gram +ve (27%)(staph aureus, coag neg staph aureus) were most
common isolates. Catheter infections were primarily due to gram +ve
organisms. 27 patients received amphotericin-B, however, fungal infec-
tion could be documented only in 3 (6%) patients due to aspergillus,
mucormycosis and candida in one each. One patient had infection due to
Myco Tuberculosis. Post-transplant(30-100 days) 2 patients developed
hepatitis B and 2 had Herpes Zoster(HZ). Another 3 patients developed
HZ in late post BMT period (D>100). 4(8%) patients died of infectious
complications, 2 of resistant E. coli, 1 due to resistant enterobacter sep-
ticemia and one due to bilateral pulmonary mucormycosis. 
Conclusion: There is need for improved diagnostic tests to detect infec-
tions early as well as new therapies to overcome antimicrobial resistance. 
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A COMPARISON OF NON-TBI AND TBI CONDITIONING REGIMENS IN
BONE MARROW RECIPIENTS UNDERGOING MATCHED-UNRELATED
TRANSPLANTATION IN HONG KONG
Lie, A.K.; Leung, A.Y.; Liang, R.H. HKU, HK, China
The present study investigated the effects of non-Total Body Irradia-
tion (TBI) conditioning on the outcome of 8 patients (CML = 5 ;
A M L = 3; Mean age 32.8 ± 3.3) undergoing Matched-Unrelated Bone
Marrow Transplantation (MUD BMT) using busulfan (16 mg/kg) and
cyclophosphamide (150 mg/kg). The outcome of 28 patients
( C M L = 16; AML = 7; Biphenotypic acute leukaemia = 2; ALL = 2 ;
M D S = 1) using TBI (12Gy) containing regimen (Mean age 29.3 ± 1.7 )
were also analyzed. The number of days requiring TPN (due to oral
mucositis) was significantly lower in the Bu-Cy group (18 ± 3.6 days)
compared with the control (31.9 ± 4.1 days, p<0.05). There were no dif-
ferences in neutrophil (ANC > 0.5 x 10 9/L) and platelet (>25 x 109/ L
without transfusion) engraftments. The Bu-Cy group had less veno-
occlusive disease (VOD) (2/8 vs 11/28 in control) but more haemorrhag-
ic cystitis (HC) (3/8 vs 5/28 in control) though the differences were not
s i g n i ficant (p>0.05). Patients in the Bu-Cy group also had a signific a n t l y
lower occurrence (1/8) of severe GVHD (Overall grade ≥2) than the
control group (18/28) (p<0.05). Transplant-related mortality (TRM)
within 100 days after BMT was 0 in the Bu-Cy group but was 7 (out of
28) in the control (GVHD related = 4; Regimen-related toxicity = 2 ;
Graft failure = 1). The difference, however, did not reach statistical sig-
n i ficance (p>0.05). There was no difference in the occurrence of early
graft failure in both groups of patients (1/8 in the Bu-Cy group vs 3/28
in the control). In conclusion, we have shown that the use of Bu-Cy dur-
ing conditioning in MUD BMT had no adverse effect on neutrophil and
platelet engraftments and did not increase the occurrence of graft failure.
TBI based conditioning was associated with increased severity of oral
mucositis and increased risk of VOD and severe GVHD and a higher
transplant-related mortality.
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PROSPECTIVE STUDY OF PROGNOSTIC VALUE OF HEMATOPOIETIC
CHIMERISM IN PATIENTS WITH ACUTE LEUKEMIA AFTER ALLOGENE-
IC BONE MARROW TRANSPLANTATION
Lee, K.H.; Choi, S.J.; Lee, J.H.; Kim, S.; Lee , J.S.; Kim , S.H.; Park, C.J.;
Chi , H.S.; Kim , W.K. Asan Medical Center, Seoul, South Korea
The value of hematopoietic chimerism as a predictive marker for the
relapse of acute leukemia after allogeneic BMT was evaluated in a
prospective study. Monthly assays of hematopoietic chimerism were per-
formed from peripheral blood samples through PCR amplification of
short tandem repeats or amelogenin loci. Between December 1997 and
June 1999, 31 patients were enrolled. Two patients died within 1 month
of BMT before evaluation of chimerism status. One patient/donor pair
did not have informative bands for chimerism evaluation. Among 28
evaluable patients, there were 14 male and 14 female (14 AML and 14
ALL) with mean age of 29.3 years (range, 18-46). Mixed chimerism
(MC) was observed at least once in 13 of 28 patients. Among 15 patients
of complete donor chimerism (CC) group, four patients relapsed at 17,
6, 12.5 and 12 months post-BMT respectively. All four patients main-
tained CC up to 1 month prior to clinically documented relapses. Seven
patients in CC group were alive in CR at 3 to 17 months post-BMT.
The remaining 4 patients in CC group expired at 1 to 5 months due to
treatment-related toxicities. Among 13 patients in MC group, two
patients relapsed with acute leukemia. Nine patients who showed MC
early after BMT eventually converted to CC and remain CR at 3 to 20
months. Two patients in MC group died of treatment related toxicities.
In conclusion, when sensitive PCR-based assays for hematopoietic
chimerism were applied on a monthly basis to patients with acute
leukemia after allogeneic BMT, the relapse of leukemia could not be
predicted reliably. Majority of patients relapsed without showing prior
evidence of increasing MC. CC could not rule out the risk of relapse.
Further prospective studies involving larger number of patients are nec-
essary to clarify dynamic relation between post transplant hematopoietic
chimerism and leukemia relapse. 
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A TRIAL OF HIGH DOSE CHEMOTHERAPY (HDC) AND AUTOLOGOUS
PERIPHERAL BLOOD STEM CELL (APBSC) SUPPORT FOLLOWED BY
LOW DOSE INTERLEUKIN-2 (IL-2) IN PATIENTS (PTS) WITH MULTI-
PLE MYELOMA (MM)
Magalhaes-Silverman, M.C.1; Burgunder , M.3; Rybka, W.T.4; Donnenberg,
A .3; Ball, E.D.2 1. University of Iowa, Iowa City, IA; 2. University of Califor -
nia, San Diego, CA; 3. University of Pittsburgh, Pittsburgh, PA; 4. Pennsyl -
vania State University, Hershey, PA
Relapse after HDC and APBSC support is the main cause of therapeu-
tic failure in MM. We sought to determine if IL-2 posttransplant would
affect engraftment and toxicity associated with transplantation. 
Eleven consecutive pts with MM underwent PBSC harvest followed
by conditioning with BUCY2 or melphalan/TBI. Granulocyte colony-
stimulating factor was started on day 0 and intravenous IL-2 at 2x105
I U / m2/day was started on day+2 for 4 days followed by Il-2 at 3x105
I U / m2/day for a total course of 90 days. 
There were 5 males and 6 females. Median age was 49 years ( range
44-60). At diagnosis 4 pts had stage II and 7 stage III. Five pts had sensi-
tive disease and 6 resistant. One pt failed to proceed to transplant due to
prolongued pancytopeia after mobilization. The remaining 10 pts
received a median of 9x106 CD34+ cells/Kg (range 2-30). Nine pts start-
ed IL-2 on day+2. For these 9 pts the median time to ANC of at least
0 . 5 x 1 09/L was 10 days (range 8-13). The median time to a platelet
c o u n t> 2 0 x 1 09/L was 34 days (range 10-244). Five pts completed the 90
day course of IL-2. In the remaining 4 pts the duration of IL-2 therapy
ranged from 15 to 74 days. In one pt Il-2 therapy had to be interruped
due to development of pneumonia. Side effects associated with the infu-
sion of Il-2 include: rash in 2 pts, anorexia and fatigue in 3 pts, edema in
2pts. Four pts developed infectious process while on Il-2(pneumonia in 1
pt, Pseudomonas bacteremia in 2 pts and herpetic esophagitis in 1pt).
Reasons for early termination of IL-2 infusion include intolerance to
side effects in 2 pts and infection in other 2. 
We conclude that while engraftment is not adversely affected by the
infusion with IL-2 postransplantation infectious complications are a con-
cern in this pt population.
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FLUDARABINE/CYCLOPHOSPHAMIDE FOLLOWED BY ALLOGENEIC
PERIPHERAL BLOOD STEM CELL TRANSPLANTATION (PBSCT) FOR
OLDER PATIENTS WITH MALIGNANT HEMATOLOGICAL DISORDERS
Magalhaes-Silverman, M.C.; Choon, C.K.; Schlueter, A.; Hohl, R.J.; Field,
E.; Gingrich, R.D. University of Iowa, Iowa city, IA
The use of allogeneic stem cell transplantation is usually restricted to
patients (pts) younger than 55 years of age due to the excessive trans-
plant related mortality (TRM) observed in older pts.The low risk of
TRM from non-myeloablative transplants makes the procedure applica-
ble to older pts. 
Here we report 4 pts with a median age of 61 years (range 57 to 62)
who underwent conditioning with fludarabine at 25mg/m2x5 days and
cyclophosphamide at 750mg/m2x3 days followed by PBSCT from a G-
CSF stimulated HLA identical sibling donor. Cyclosporin and mini-
dose methotrexate were used as GVHD prophylaxis. Cycloporin was
given until day 60 then tapered off if no GVHD occured. Diagnosis
include secondary AML in 1pt, multiple myeloma in another, CML in
accelerated phase in 1 pt and secondary MDS in another. There were 3
females and 1 male. Two pts had previous transplants (1 allogeneic and 1
autologous). Median transplant dose was 5.2x106 CD34+ cells/kg and
0 . 9 x 1 08 CD3+ cells/Kg. Severe mucositis and VOD did not occur.
Hematologic nadirs were brief with a median time to a ANC >0 . 5 x 1 09/ L
of 8 days (range 7 to 11) and a platelet count of >2 0 x 1 09/L of 11 days
(range 8 to 12). At day 15 chimerism analysis of peripheral blood T cells
showed donor engraftment in all pts (50-90%). By day 60 chimerism
analysis showed 100% donor cells in all the 4 pts. All pts experience
acute GVHD. In 2 pts acute GVHD was severe (grade IV) and con-
tributed to the death of one pt. One pt has chronic GVHD. Three pts
are alive at +233,+213 and +103 days. Two pts are in CR while one pt
with multiple myeloma has active disease. 
We conclude that this approach seems feasible in an older population.
GVHD is still a problem in these pts. Accrual continues. 
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UNRELATED UMBILICAL CORD BLOOD TRANSPLANTS FOR HIGH-RISK
AND RELAPSED ACUTE LEUKEMIAS IN CHILDREN
Martin, P.L.; Howrey, R.; Driscoll, T.A.; Szabolcs, P.; Rubinstein, P.;
Kurtzberg, J. 1. Duke University Medical Center, Durham, NC; 2. New
York Blood Center, New York, NY
We report the use of unrelated cord blood cells (UUCB) transplanta-
tion for patients with high risk or relapsed leukemia. Methods: Charts
from 86 consecutive UUCB transplants for the diagnosis of acute lym-
phoblastic leukemia (ALL), acute nonlymphocytic leukemia (ANLL) or
infant ALL were reviewed to identify degree of HLA match of the graft
and the patient, mononuclear cell dose per kg of the UUCB graft,
occurrence of graft vs host disease (GvHD), transplant related mortality,
relapse and the patient’s current status. Data: Demographic date: Medi-
an age 9.33 years (range 0.33-21.83 years); 53-males, 33-females; 13-
patients who had prior high dose chemotherapy with stem cell rescue (6-
auto; 3-UUCB; 2-matched sib; 1-MUD; 1-Haplo). Median nucleated
cell dose/kg was 4.23x107(range-0.67-to17.5). The median follow up on
survivors is 925 days (range 148-2271). 
Occurance of acute GvHD grade II-IV and III-IV was 35% and 10%
respectively. Four of 29 long-term survivors developed limited chronic
GvHD and 1 developed extensive chronic GvHD. Conclusions: Use of
UUCB for high risk or relapsed acute leukemia carries significant mor-
bidity (45% in this very heavily pre-treated population). Nevertheless, in
a carefully chosen population it is an effective therapy that carries an
acceptable risk of acute and chronic GvHD. Factors associated with a
favorable outcome included diagnosis of infant ALL and referral to
transplant in CR1 or CR2.
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RESPIRATORY SYNCITIAL VIRUS (RSV) INFECTION IN PATIENTS (PTS)
UNDERGOING STEM CELL TRANSPLANTATION: EARLY INSTITUTION
OF THERAPY IS ASSOCIATED WITH LOW MORTALITY 
Magalhaes-Silverman, M.C.; Lee, C.K.; Hohl, R.J.; Gingrich, R.D. Universi -
ty of Iowa, Iowa city, IA
RSV is a cause of upper and lower respiratory infections in immuno-
compromised pts undergoing stem cell transplantation and is often asso-
ciated with a high mortality. Here we report 26 pts who experience 28
episodes of RSV infection and their outcome. Upper respiratory infec-
tion (URI) was defined as the presence of signs or symptoms of respira-
tory illness without a new infiltrate on chest radiograph in a pt with RSV
in a respiratory specimen. Lower respiratory infection (LRI) was defin e d
as a presence of an infiltrate on chest radiograph with a positive test for
RSV in a respiratory specimen. 
Twenty eight cases of RSV infection were diagnosed among the pts
transplanted in our institution between 1990 and 1998. There were 16
females and 10 males with a median age of 41 years ( range 18-57).
Eleven pts underwent autologous transplantation while 15 allogeneic (9
related and 6 unrelated). The median time from transplant to RSV
infection was 272 days(range 7 to 1640). There were 21 episodes of URI
and 7 of LRI. RSV was identified by rapid antigen testing or culture. It
was identified in a nasopharyngeal washing in 21 episodes and in a BAL
specimen in 7. Two of the 7 pts who developped LRI required mechani-
cal ventilation. Ten pts required oxygen therapy. Pts were treated with
aerosolized ribavirin+/- intravenous immunoglobulin. One of the pts
who required mechanical ventilation died. All other pts survived. Overall
mortality was 4%. 
Conclusion: The prompt use of ribavirin in pts with RSV infection is
associated with low mortality. 
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SECONDARY HEMATOLOGICAL MALIGNANCIES AFTER AUTOLOGOUS
PROGENITOR STEM CELL TRANSPLANTATION IN PATIENTS WITH
MULTIPLE MYELOMA
Milone, G.A.; Fernandez, I.I.; Corrado, C.S.; Martinez Rolón, J.; Juni, M.;
Pavlovsky, S. Fundaleu, Capital Federal, Argentina
Between April 1992 and April 1999, 77 patients with diagnosis of mul-
tiple myeloma received autografts. Four (5.2%) patients developed sec-
ondary hematological malignancies: 3 (3.9%) MDS/AML and 1 (1.3%)
NHL EBv (+). 
Patients’ characteristics are detailed in the table. 
Previous therapy with alkylant agents and the use of high-dose mel-
phalan or cyclophosphamide induce a considerable number of secondary
hematological malignancies (5.2%)in patients with multiple myeloma
and autotransplantation. We are analyzing our population of patients
periodically with bone marrow aspiration and cytogenetics in order to
find chromosomal abnormalities and use them as predictor of these
m a l i g n a n c i e s .
IBMTR/ABMTR: Poster Presentations
C H A R A C T E R I S T I C S PATIENT 1 PATIENT 2 PATIENT 3 PATIENT 4
Type/Stage/Age IgG; III, 44 BJ; I; 52 IgG; I; 53 IgG; II; 65
Previous CT Mel x 12 Mel x 6 Mel x 5 / VAD x 9
VAD + CSP x 3
Mobilization regimen CPM 3 g/m2 CPM 3 g/m2 CPM 3 g/m2 CPM 4.5 g/m2
Ablative regimen Mel 200 mg/m2 Mel 200 mg/m2 BUCY BUCY
Cells infused Bone Marrow + Peripheral Peripheral Peripheral 
Peripheral blood blood blood blood
Status pre-post Tx PR / PR PR/CR PR/PR NR/PR
Time from Dx to 2d malignancy 21 months 53 months 122 months 20 months
Time from Tx to 2d malignancy 6 months 47 months 58 months 4 months
2d malignancy AML M2 MDS/AML M1 MDS/AREBT NHL EBv+
S U R V I V O R S / FAILURES DUE TO:
D I A G N O S I S T O T A L T R M R E L A P S E
Infant ALL 7/9 (78%) 2 0
ALL-CR1/CR2 8/21 (38%) 11 2
Relapse/≥CR3 4/24 (17%) 13 7
AML CR1/CR2 3/6 (50%) 3 0
In-relapse 6/25 (24%) 11 8
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QUALITY OF LIFE AMONG LONG TERM SURVIVORS OF AUTOLOGOUS
STEM CELL TRANSPLANTATION FOR LYMPHOMA
Morris, M.E.; Lynch, J.C.; Byar, K.L.; Eilers, J.G.; Vose, J.M. University of
Nebraska Medical Center, Omaha, NE
Autologous stem cell transplantation (ASCT) is a widely used treat-
ment modality for lymphoma, but its impact on the quality of life (QOL)
of long term survivors has not been well described. We conducted a
cross-sectional mail survey, using three well-established quality of life
instruments (MOS SF-36, FACT-BMT, City of Hope-BMT), of 5 year
or greater survivors of ASCT for lymphoma. Eighty-two patients (53%)
completed the MOS SF-36 and are the basis of this report. Respondents
were transplanted between June 1984 and June 1992 and were a median
of 7.7 (range 5.7 to 13.7) years after transplantation at the time of survey.
Thirteen patients (16%) had relapsed after ASCT, but prior to survey.
The median age at transplant was 41 years (range 19 to 59), 43% are
female, and 96% are white, non-Hispanic. Forty-seven (57%) were
transplanted for non-Hodgkin’s lymphoma (NHL) and 26% received a
TBI-containing conditioning regimen. Thirty-one (38%) received bone
marrow as the stem cell source and 3 (4%) received both bone marrow
and peripheral blood stem cells. The majority (76%) had received two or
more chemotherapy regimens prior to transplant and 37% had received
previous radiotherapy (RT). Most patients reported their general health
as good (26%) or fair (45%). NHL diagnosis, relapse after ASCT, RT
prior to ASCT, and older age were significantly related to decreased
general health, as measured by the MOS SF-36, in multivariate analysis.
NHL diagnosis was also significantly associated with decreased physical
functioning, role-physical functioning, bodily pain, and vitality scores.
Stem cell source, use of TBI, time since transplant and year of transplant
were not significantly related to QOL. Survivors of transplantation for
Hodgkin’s Disease appear to have superior long term QOL than sur-
vivors of transplantation for NHL, although diagnosis may be a surro-
gate for conditioning regimen or other aspect of treatment.
3 6
IDENTIFICATION OF HEMATOPOIETIC PROGENITOR CELLS BY THE
AUTOMATED HEMATOLOGY ANALYZER (SE-9000T M) IN AUTOLOGOUS
STEM CELL HARVEST PRODUCTS
Park, K.; Suh, C.; Kim, S.; Kim, S.; Park, J.; Lee, K.; Kim, H.; Park, C.;
Chi, H.; Kim, W. Asan Medical Center, Seoul, South Korea
Purpose: The yield of stem cell collection after mobilization is crucial
for autologous stem cell transplantation. A quantitative determination of
CD34+ cells using flow cytometry or stem cell culture has been used.
But these methods require much time, technical experience and expen-
sive reagents. The automated hematology analyzer (Sysmex SE-9000T M,
TOA, Japan) equipped with special detection unit for immature myeloid
cells can detect hematopoietic progenitor cell (HPC) within 90 seconds.
Detection is made possible by the combiantion of a special reagent sys-
tem and direct current/radiofrequency biosensors. We studied the rela-
tion of HPC and variable parameters with CD34+ cell yield in autolo-
gous stem cell harvest products. 
Method: In a series of 32 patients (median age:44, M:F = 11:21), 184
leukaphereses were performed after mobilization regimens with
chemotherapy and G-CSF or G-CSF only. Full blood cell counts were
enumerated on peripheral blood (PB) samples taken prior to each leuka-
pheresis. Mononuclear cell (MNC) and HPC counts by automated
hematology analyzer and flow cytometry based CD34+ cell yield were
measured on the harvest product. The relationship among PB white
blood cell (WBC), PB monocyte, HPC, MNC and CD34+ cell yield in a
single leukapheresis was estimated by Pearson correlation analysis. 
Results: PB WBC count showed no correlation with CD34+ cell yield
in a single leukapheresis (r = 0.02, p = 0.81). PB monocyte count showed
a weak correlation (r = 0.21, p = 0.01) and MNC in harvest also showed a
weak correlation (r = 0.36, p = 0.0001) with CD34+ cell yield. In con-
trast, HPC count correlated well with CD34+ cell yield (r = 0 . 6 8 ,
p = 0.0001) and data could be fitted by a linear regression equation
y = 0.330+0.974 x. 
Conclusion: HPC assay by the automated hematology analyzer corre-
lated well with the CD34+ cell yield in a mobilized autologous stem cell
harvest. HPC might be used as a simple and efficient indicator of blood
stem cell mobilization and collection. 
3 5
ANALYSIS OF PROGNOSTIC FACTORS PREDICTIVE OF EVENT-FREE
SURVIVAL (EFS) FOLLOWING UNRELATED DONOR (UD) BONE MAR-
ROW TRANSPLANTATION (BMT) FOR CHRONIC MYELOID LEUKEMIA
(CML): A 10-YEAR EXPERIENCE
Nobile, L.M.; Nevill, T.J.; Brockington, D.A.; Nantel, S.H.; Sutherland,
H.J.; Hogge, D.E.; Toze, C.L.; Conneally, E.A.; Shepherd, J.D.; Barnett,
M.J. Vancouver General Hospital, Vancouver, BC, Canada
Between 06/88 and 07/98, 60 pts with CML underwent UD-BMT for
CML at VGH. There were 40 males and 20 females with median age
33.5 (range 20-53) years. Disease status was 1SP in 38 pts, AP in 20 pts
and BP in 2 pts. Prior therapy included hydroxyurea (HU) (40 pts),
alpha-interferon (IFN) ± HU (10 pts), busulfan ± HU/IFN (4 pts), com-
bination chemotherapy (4 pts) and none (2 pts). HLA-A, B and DR typ-
ing were done serologically until 06/93 after which DR DNA typing was
utilized. Forty-four donor/recipient pairs were HLA-matched. Thirteen
pairs were 1-Ag mismatched (A locus 3 pts; B locus 3 pts; DR locus 7
pts) and 3 pairs 2-Ag mismatched. Conditioning was cyclophos-
phamide/total body irradiation with (8 pts) or without (52 pts) etoposide.
GVHD prophylaxis was CsA/MTX with (12 pts) or without (38 pts)
XomaZyme; T cell depletion (TCD) and CsA (8 pts); or other (2 pts).
Actuarial risk of grade II-IV acute and chronic GHVD was 69% and
77%, respectively. Six pts died of regimen-related toxicity, 9 pts died of
acute GVHD, 14 pts died of chronic GVHD and 2 pts died of infection;
three patients experienced graft failure and 5 pts have relapsed. The
cumulative probabilities of relapse and non-relapse mortality are 12%
and 58%, respectively. Twenty-one pts are alive without relapse with
median followup 89 (range 23-134) months. The EFS for all, 1SP, AP
and BP pts are 35%, 42%, 21%, and 0%, respectively. Multivariate
analysis showed advanced disease status (p = .007), TCD (p = . 0 0 9 ) ,
higher nucleated cell dose (p = .04) and female donor (p = .05) adversely
i n fluenced EFS. Pts with CML in 1SP receiving a T-replete matched or
1-Ag mismatched UD-BMT had an EFS of 52%. These results support
the appropriateness of UD-BMT for CML while in 1SP. 
3 7
HYPERBARIC OXYGEN THERAPY IN THE TREATMENT OF
CYCLOPHOSPHAMIDE INDUCED HEMORRHAGIC CYSTYTIS
Paton, E.A.1; Simões, B.P.1; Stracieri, A.L.1; Coutinho, M.A.1; Tabak, D.G.2;
Voltarelli, J.C.1 1. BMT Unit - Hospital das Clínicas - FMRPUSP, Ribeirão
Preto, Brazil; 2. CEMO - INCA, Rio de Janeiro, Brazil
Several reports suggest the therapeutic effects of a hyperbaric oxygen
regimen (HO) in the treatment of radiation induced hemorrhagic
cystytis. HO induces a hyperoxaemic state that produces vasoconstric-
tion in the bladder mucosa with neovascularization and secondary gran-
ulation tissue growth. 
We present a 28 y.o. male patient who underwent an allogeneic BMT
from an HLA identical sibling for AML M2 in CR1, conditioned with
BUCY2 (Busulfan 16 mg/Kg and Cyclophosphamide 120 mg/Kg). He
received Mesna 180 mg/Kg and GVHD prophylaxis with CsA+Mtx.
Engraftment ocurred on D+ 19 and on D+23 he started with microscop-
ic haematuria that evolved to urinary bleeding on D+34. Cystoscopy
showed mucosal diffuse bleeding and histology revealed Cyclophos-
phamide toxicity signs. Urinary bleeding showed no response to hyper-
hydration, bladder irrigation, massive platelet transfusions and intravesi-
cal Prostaglandin E1 infusion. On D+44 patient started hyperbaric
oxygen therapy in a hyperbaric chamber at 2.0 atm pressure of 100% O2
for 60-90 minutes/session. After 26 sessions patient had a complete
remission of urinary bleeding and at the moment he is on D+ 410 in CR
with a complete chimerism. 
The case above prove the efficacy of hyperbaric oxygen therapy in the
treatment of severe and refractory Cyclophosphamide induced hemor-
rhagic cystytis. 
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ADOPTIVE IMMUNOTHERAPY IN THE TREATMENT OF ACUTE
LEUKAEMIAS IN ADVANCED PHASES
Paton, E.A.; Simões, B.P.; Stracieri, A.L.; Coutinho, M.A.; Voltarelli, J.C.
BMT Unit - Hospital das Clínicas - FMRPUSP, Ribeirão Preto, Brazil
There are several evidences that the main factor responsible for cure of
haematologic malignancies in allogeneic BMT is the “graft versus
leukaemia” (GVL) effect and many strategies were developed in order to
enhance this mechanism in BMT patients. At this moment the major
role of GVL is in post BMT chronic and acute leukaemias relapses
through donor lymphocyte infusions (DLI) associated or not to
cytokines (IL-2, IFN, G-CSF, p.e.). 
We present in the table bellow three cases of post BMT acute
leukaemias relapses responsive to DLI. 
The remission rate obtained with adoptive immunotherapy in these
cases evidences the efficacy of this approach in advanced stages of acute
leukaemias. New strategies that explore the GVL effect in earlier phases
of the diseases are in development. 
4 0
PRECLINICAL PHARMACOLOGY OF ANTINEOPLASTIC AGENTS USED
IN HIGH DOSE CHEMOTHERAPY WITH HEMATOPOIETIC STEM CELL
SUPPORT FOR SOLID TUMORS
Porrata, L.F.; Adjei, A.A. Mayo Clinic, Rochester, MN
Clinical trials evaluating high-dose chemotherapy (HDT) for solid
tumors are based on the principle that antineoplastic agents exhibit a lin-
ear relationship between drug doses and tumor cell kill. We reviewed
the experimental evidence supporting a linear, steep dose-response rela-
tionship for HDT conditioning agents used in hematopoietic stem cell
transplantation for solid tumors. Preclinical pharmacologic studies eval-
uating dose-response relationships for different chemotherapeutic agents
in solid tumor cell lines and xenografts were identified through a MED-
LINE and CANCER-LIT search. Linear, steep dose-response relation-
ships over a 2 to 5-log range of tumor-cell kill were identified for
BCNU in breast cancer and sarcoma, melphalan in breast cancer, head
& neck, and sarcoma, and nitrogen mustard in breast cancer. A linear
dose-response relationship was reported for only a 2-log range of tumor-
cell kill for cisplatin (breast cancer), cyclophosphamide (breast cancer),
doxorubicin (testicular cancer), and paclitaxel (astrocytoma, breast, ovar-
ian, and lung cancer). One study demonstrated a synergistic, steep dose-
response relationship with the combination of thiotepa and cyclophos-
phamide in a breast cancer cell line. No preclinical studies were
i d e n t i fied for busulfan, carmustine, carboplatin, chlorambucil, dacar-
bazine, epirubicin, hydroxyurea, and ifosfamide, which are all agents uti-
lized in HDT in a variety of solid tumors. In conclusion, only BCNU,
melphalan, nitrogen mustard and the combination of thiotepa with
cyclophosphamide demonstrated preclinical evidence supporting their
use in HDT conditioning regimens for solid tumors. The pharmacolog-
ic evidence for the use of other antineoplastic agents for HDT in solid
tumors is non-existent. More preclinical studies are needed for a rational
development of this therapeutic approach for solid tumors. 
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HIGH DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM CELL TRANS-
PLANTATION (ASCT) IN NON-HODGKIN´S LYMPHOMA (NHL): THE
ROLE OF HISTOLOGY AND STATUS PRE-TRANSPLANT IN 148
PATIENTS FROM A SINGLE INSTITUTION
Pavlovsky, S.; Milone, G.; Corrado, C.; Fernández, I.; Martinez Rolón, J.;
Juni, M. FUNDALEU, Capital Federal, Argentina
Purpose: To evaluate the treatment-related mortality (TRM), event
free survival (EFS) and overall survival (OS) after ASCT according to
histology and status pre-transplant in NHL. 
Materials and methods : A total of 148 patients (pts), 36 with low-
grade (LG) and 112 with intermediate-high grade (I-HG) NHL, were
autografted between July 1991 and August 1999 and evaluated in
November 1999. The median age was 45 years old (range 7-68), and
there were 82 male and 66 female pts. CBV was the ablative regimen
used in the majority of pts (141), ICE was used in 4 pts, and BUCy in 3.
One pt received bone marrow (BM), 19 pts BM and peripheral progeni-
tor cells (PPC) and 128 pts, PPC alone. A total of 53 pts were in fir s t
complete remission (CR1), 50 in ≥CR2, and 45 in ≤PR (27 PR1, 12
≥PR2, 6 PD) at transplant.The median follow-up was 41 months (range
2-101). 
Results: According to pre-transplant status and histology, the actuarial
EFS and OS at 60 months are detailed in the table. Statistical analysis:
* P = NS; ψP = 0.0000; ψP = 0.0002. Only 4 relapse were observed after
36 months; 2LG and 2IHG. Only 2 pts (1.3%) died of TRM, both of
sepsis in CR2 with I-HG NHL. 
Conclusion: The TRM was very low (1.3%) and the status pre-trans-
plant was more important in I-HG NHL, with a statistically higher rate
of EFS and OS in those transplanted in CR1. In LG NHL the number
of patients is low and the follow-up is not yet sufficient for a conclusive
evaluation of the value of ASCT in this entity. 
4 1
BONE MARROW AND PERIPHERAL BLOOD STEM CELLS ASSESSE-
MENT AFTER LONG TERM CRYOPRESERVATION
Robinson, A.J.1; Sorrentino , M.A.1; Di Risio - Bianchi, C.2; Longoni , H.1;
Luchetta , G.P.1; Dufour, C.1; Merlo, C.1; Bascoy, M.1; Pastorino Aubry, E.1
1. Navy Hospital Pedro Mallo, Buenos Aires, Argentina; 2. Academia
Nacional de Medicina, Buenos Aires , Argentina
Purpose: to evaluate the effects of long term cryopreservation periph-
eral blood and bone marrow stem cells 
Methods: C r y o p r e s e r v a t i o n. 23 samples from patients were placed in
cryotubes 2 ml each. System Cryomed, microcomputer 1010, Storage
Model 2700 Taylor Warthon 27 K liquid nitrogen (LN), printer 6100
programed curves cryopreservation were used. 
T h a w i n g. Cryotubes were removed from LN, thawed in water bath
37ºC, shaking gently. Five times dilution, foetal calf serum + heparine 10
IU to 1500 rpm centrifugation, cells washed twice. 
Semisolid Culture Media: after thawing, washed cells were cultured 
Petri s´ boxes + Pixy (donation Dr. Messner Toronto Canada) + 2 U
rhuEPO (Sidus Argentina)+ IMDM (Iscove Modified Dulbecco´s Medi-
um)+ 30% Foetal calf + 0.3% Bacto agar(Difco). Heater 37ºC humidity
saturated + 5% CO2. 
Long Term Cultures: Eagle´s modified Medium. CFU-GM, BFU-
E,Stromal cells cultures were used to test their functionality. 23 patients
were studied 5 AML,7 MM,6 NHL,3 ALL, 2 HD. Nine patients
received BMSCT and 14 PBSCT. Cells were frozen during a period of
24 to 33 days before infusion, and 16 to 40 months before cultures. 40%
of both AML, MM colonies have grown in vitro. The remaining dis-
eases showed colony growth almost 100%. A good correlation between
CD 34 + cells and colonies in lymphoid diseases was observed. There
was no correlation when ALL and MM were tested, suggesting that
underlying disease may affect growth in culture. Stromal Layer fully
developed from BM, while PBSC only generated macrophages and
fibroblasts. Four patients underwent BMSCT (one) and PBSCT (three)
from cells cryopreserved 4 years before: all of them engrafted. 
Summary: Our results suggests that the efficacy of hemopoietics cells
after cryopreservation can be measured by CFU-GM, BFU-E, long
term cultures. Long term cryopreservation did not affect the growth
capability of cells, but perhaps the underlying disease, instead of cryo-
preservation itself. 
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C O N D . / G V H D R E L A P S E D L I /
S E X / A G E D I A G P R O P H . D A Y T CELLS/KG C Y T O K Y N E G V H D F / U
M/14y Ac. Leuk. BUCY2/CsA +537 1st: D+1,1x10e8 1st: IFN Chronic CR w/complete
Biphen. CR1 +Mtx 2nd: D+639 2nd: IL-2 limited chimerism for 3y.
2,7x10e8 Relapse +
extensive GVHD.
Death on D+1500.
F/32y AML M4 BUCY2/CsA + 357 D+372 No Chronic CR D+600
2nd relapse +Mtx 3x10e8 limited
F/38y AML M4 BUCY2/CsA +304 D+323 No No CR w/75%
CR2 +Mtx >2x10e8 chimerism for 3 m.
Relapse and death
on D +430.
H I S T O L O G Y LOW GRADE NHL INTERMED. HIGH GRADE NHL
STATUS PRE-T C R 1 > = C R 2 < = P R C R 1 > = C R 2 < = P R
# Pts 13 11 12 40 39 33
% EFS 62* 51 30 57ψ 32 29
% OS 63* 91 42 74ψ 36 35
128
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AUTOLOGUS HEMATOPOIETIC PROGENITOR CELLS TRANSPLANT
(HPCT) IN LYMPHOMA
Rossi, R.; Canepa, C.; Saba, S.; Orlando, S.; Klein, G.; Perez, M. UTMO, La
Plata, Argentina
Purpose: To describe characteristics and clinical outcome of patients
(pts) with Hodgkin Lymphoma (HL) and non-Hodgkins (NHL) and
HPCT in our center. 
Patients and Methods: From June 1994 to October 1999, 128 proce-
dures had been done to 125 pts; 3 pts received double procedures.
HPCT had been done in 36 pts, 18 pts of them had HL and the other
18 had NHL (one pt received double procedure). Middle age was 36 (r:
19-59) and relation male/female was 1.57 (22/14). Peripheral HPCT
had been used in 18 procedures, bone marrow HPCT in one procedure
and both in 18 procedures. Histological subtypes in HL were LP 2 cases,
NE 6 cases, MC 8 cases and LD 2 cases. Clinical staging was I in 12.5%,
II in 44%, III in 12.5% and IV in 31%. Four pts had bulky disease. His-
tological subtypes in NHL were HG/IG 15 pts, LG 3 pts. Clinical stag-
ing was II in 24%, III 29% and IV 47%. Myeloablative regimens were
CBV 16, BACT 12, BEAM 8, ICE 1. 
Results: The median granulocyte engraftment was day+15 (r 10-27)
and median platelet engraftment was day+18 (r 8-42). Median days of
hospitalization were 31.5 (r:21-73).Fever was present in 35 pts,median
4.2 days(r:0-18), antibiotics were used median days 15(0-47).Red cells
transfusion was performed, using media of 4.2 units (r:0-12), and
platelets media 9.2 (2-30 U). Mortality associated with procedure was
6 % during the first 30 days posttransplant. Overall survival was 78%,
and 73 % , 24 to 36 month posttransplant. 
Conclusion: the best results can be possible in a public
institution.This is our first experience with bone marrow transplant in
patient with Lymphoma. 
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HIGH YIELDS OF CD34+ AND CD3+ CELLS AFTER DEPLETION OF
CD19+ CD20+ B CELLS FROM MOBILIZED PBSC USING ANTI-CD19
AND ANTI-CD20 MONOCLONAL ANTIBODIES COUPLED TO HIGH
DENSITY MICROPARTICLES (BCELL-HDM)
Schmittling, R.; Houde, H.; Lu, T.; Graney, M.; DeLucia, D.; Goddard, J.;
Jarpe, M.; Atkinson, K.; Monroy, R. Eligix, Inc, Medford, MA
Effective purging of tumor cells from autologous peripheral blood
stem cell (PBSC) transplants of patients with non-Hodgkins lymphoma
(NHL) may improve long term outcome. Current methods for purging
tumor cells result in a loss of desirable stem cells and inappropriately
deplete T cells. Several studies have documented a pronounced immun-
o d e ficiency in patients that were infused with CD34-selected autologous
PBSC. An alternative approach to CD34 selection is the depletion of
tumor cells from PBSC before autologous transplantation. We previous-
ly demonstrated an ability to purge >4 logs of B cells and recover ~90%
CD34+ and CD3+ cells from GCSF mobilized PBSC of normal donors
using CD19 and CD20 monoclonal antibodies conjugated to high densi-
ty microparticles (BCell-HDM)and a manual system. A semi-automated
cell processing system has been developed and we demonstrate purging
B cells from mobilized normal donor PBSC using this system. The
apheresis product without extensive pretreatment is transferred asepti-
cally into a sterile depletion chamber containing BCell-HDM. After
combining cells and BCell-HDM, the chamber is rotated end over end
for 10 minutes, and the BCell-HDM are allowed to settle by gravity for
5 minutes. Cells in the supernatant are aseptically transferred to the next
chamber and this process is repeated for a total of 3 cycles. Mobilized
PBSC from normal donors (n = 8) with a mean cell count of 3.2 ±0.2 x
1 01 0nucleated cells were processed in a 220mL volume using the semi-
automated system. B cells were purged to >4 logs in all samples as deter-
mined by immunocytochemistry. Mean percent CD34+ cell recovery
was 87.0%±3.7% with a range of 71.3% - 98.4%. Mean percent CD3+
T cells recovery was 87.4% ±2.8% with a range 77.8% - 99.2%. This
optimized cell processing system will be implemented in a pivotal trial to
test the safety and efficacy of purging B cells from NHL patients.
4 3
ABSENCE OF B CELL LYMPHOPROLIFERATIVE DISORDER (BLPD)
FOLLOWING T-CELL DEPLETED BONE MARROW TRANSPLANTS
Rowlings, P.A.1; Greenstein, V.1; Waldstein, D.1; Oswald, C.2; Ford, D.1;
Argyle, J.1; Zeigler, J.2; Russell, S.2; Vowels, M.2 1. Prince Of Wales Hospital,
Randwick, Australia; 2. Sydney Childrens Hospital, Ranswick, Australia
B cell lymphoproliferative disorder (BLPD) is a complication follow-
ing allogeneic bone marrow transplantation. Its prevalence is increased
among patients receiving T-lymphocyte depleted grafts from non-iden-
tical donors, anti-T cell therapy to prevent or treat graft-versus-host dis-
ease (GVHD) and transplanted for immunodeficiency (ID). The report-
ed incidence of BLPD ranges from 5 – 30% and peaks at 3-5 months
post transplant, progressing very rapidly (1). 
Forty eight patients aged 1 month to 18 years received TCD bone
marrow transplants, 20 from unrelated donors and 28 from HLA mis-
matched parents. The majority of these patients received ATG as part of
their conditioning regime prior to transplant. Median follow-up is 11.5
months, with 74% of patients being studied for greater than 3 months.
To date there have been no reported cases of BLPD in any of these
patients despite the presence of multiple risk factors (P = 0.01). 
These patients benefited from reduced incidence and severity of
GVHD without the expected high incidence of BLPD reported by oth-
ers following the use of T cell depletion and ATG in unrelated and
HLA disparate bone marrow transplants. 
1. Bhatia, S., Ramsay, N., Steinbuch, M., Dusenbery, K., Shapiro, R.,
Weisdorf, D., Robison, L., Miller, J. & Neglia, J. (1996) B l o o d
87,3633-3640 
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SIMPLE AND EFFICIENT DEPLETION OF CD8+ T CELLS FROM DONOR
APHERESES USING ANTI-CD8 MONOCLONAL ANTIBODY COUPLED TO
HIGH DENSITY MICROPARTICLES (TCELL-HDM) AND A SEMI-AUTO-
MATED CELL PROCESSING SYSTEM
Schmittling, R.J.; Graney, M.; Houde, H.; Goddard, J.; Jones, N.; Atkinson,
K.; Monroy, R. Eligix, Inc, Medford, MA
Donor leukocyte infusions (DLI) are effective in treating relapse in
leukemia patients who have received allogeneic hematopoietic stem cell
transplants and may also be effective in preventing relapse post-trans-
plantation. However, unmanipulated DLI leads to a significant incidence
(60-80%)of grade II-IV acute GvHD. Depletion of CD8+ T cells from
the DLI product maintains GvL while reducing the incidence of GvHD
from 60-80% to 22%. Early methods to deplete CD8+ T cells used a
cumbersome procedure involving antibody and complement.To facili-
tate the adoption of CD8-depleted DLI, we have developed a simple
depletion system using anti-CD8 monoclonal antibody conjugated to
high density microparticles (TCell-HDM).This study shows the use of
our semi-automated cell processing system to deplete CD8+ T cells
from apheresis products.The apheresis product without extensive pre-
treatment is transferred aseptically into a sterile depletion chamber con-
taining TCell-HDM. After combining cells and TCell-HDM, the
chamber is rotated end over end for 10 minutes, and the TCell-HDM
are allowed to settle by gravity for 5 minutes. Cells in the supernatant
are aseptically transferred to the next chamber and this process is repeat-
ed for a total of 3 cycles. A final magnetic capture step insures that no
TCell-HDM remain in the cell product. Apheresis units from normal
donors (n = 8) with a mean cell count of 9.9±0.2 x 109 nucleated cells
were processed. Mean percent CD4+ T cell recovery was 92.8%±1 . 3 %
with a range of 88.6% - 98.2% and a mean of 3.4 ±0.5 x 109 CD4+ T
cells were recovered. Mean value for CD8+ T cell depletion was
9 9 . 0 %±0.2% with a range of 98%-99.7%. This optimized cell process-
ing system will be implemented in a pivotal trial to test the safety and
e f ficacy of CD8-depleted DLI.
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PROGNOSTIC FACTOR ANALYSIS OF HIGH RISK BREAST CANCER
TREATED WITH HIGH DOSE CYCLOPHOSPHAMIDE, CARBOPLATIN
AND THIOTEPA (CTCB) AND PERIPHERAL BLOOD STEM CELLS
( P B S C )
Schwartzberg, L.S.; Birch, R.; West, W.H. Response Oncology Inc., Memphis,
T N
Between 1991 and 1996, 540 patients with high risk breast cancer
d e fined as stage II disease with greater than 4 positive lymph nodes
( n = 308) or node positive stage III adjuvant breast cancer (n = 232) were
entered on protocols utilizing cyclophosphamide (2gm/m2 over 2-3
hours days 1-3 ), Thiotepa (167 mg/m2 over 1 hour day 1-3) and carbo-
platin (167 mg/m2 over 1 hour day 1-3). Median number of positive
nodes was 10 (range 1-41). 467 patients are alive and 359 patients survive
event free at a Median Follow up of 46 months (range 6 - 93 months).
The Kaplan-Meier estimates of overall and event free survival at 5 years
were 84% and 61%. Univariate analyses show the following factors to be
s i g n i ficantly associated with event free survival: stage of disease (II vs III,
p = 0.0035), Number of positive nodes (<10 vs ≥10 p = 0.0118), hormone
receptor status (ER or PR positive vs ER and PR negative p = 0 . 0 0 0 1 ) ,
histologic grade (moderate or well differentiated vs poorly differentiated
p = 0.0026). S-phase (n = 301) and ploidy analysis (n = 397) were avail-
able in subsets of patients and were of marginal signific a n c e ( p = 0.09 and
p = 0.08 respectively). In multivariate analyses hormone receptor status
( p = 0.0028), histology (p = 0.0277) and stage of disease (p = 0.0179) but
not the number of lymph nodes (p = 0.19) were significant. If the popu-
lation is divided according to the number of multivariate adverse risk
factors the Kaplan-Meier estimates of 5 year event free survival were
89%, 57%, 55% and 43% for 0, 1, 2 and 3 risk factors respectively. We
conclude known prognostic factors for breast cancer relapses retain their
s i g n i ficance even after CTCB and PBSC. Very poor risk subgroups (3
adverse risk factors) should be considered for alternative therapy.
4 9
CANCER CELL-MEDIATED ADOPTIVE IMMUNOTHERAPY IN CONJUNC-
TION WITH NON-MYELOABLATIVE STEM CELL TRANSPLANTATION
( N S T )
Slavin, S.; Nagler, A.; Morecki, S.; Ackerstein, A.; Weiss, L.; Or, R. Hadassah
University Hospital, Jerusalem, Israel
Donor lymphocyte infusion (DLI), following allogeneic BMT intro-
duced at Hadassah in Jerusalem in early 1987, was already shown to be
effective for treatment and prevention of relapse. Starting more than 5
years ago, these observations led to developing the concept of NST as a
new modality for the treatment of hematologic malignancies and more
recently, also metastatic solid tumors. Optimal use of NST depends on
induction of tolerance to donor alloantigens, which can be accomplished
using well tolerated immunosuppressive rather than myeloablative con-
ditioning, followed by donor stem cell infusion (step 1). Following
induction of host vs graft tolerance by donor stem cells, donor T-cells
present in the graft can induce effective graft vs tumor effects (step 2),
which can eliminate residual host tumor or stem cells. Graft versus host
haematopoietic stem cell effects could be further amplified with DLI
given on an outpatient basis, preferably graded increments, for better
control of GVHD, step 3. Several versions of NST regimen are current-
ly under investigation in murine models of leukemia/lymphoma and
metastatic breast cancer, using naive and specifically immune donor lym-
phocytes to amplify the anti-cancer potential of DLI, while trying to
minimize anti-host responses. 
NST protocols based on the use of fludarabine with either busulfan,
cytoxan or single low dose TBI seem effective for stable engraftment,
while minimizing procedure-related toxicity and mortality and late com-
plications. The use of NST may open new horizons for a broader spec-
trum of indications for stem cell transplantation for treatment of malig-
nant and non-malignant diseases and for organ transplantation. In
addition, the use of alloreactive and tumor reactive lymphocytes may
provide a platform for improved immunotherapeutic procedures in an
attempt to maximize desirable anti-cancer effects while minimizing
untowards anti-host responses, thus opening the road for more effective
cost effective and safer anti-cancer immunotherapy. 
4 8
SYNGENEIC STEM CELL TRANSPLANT (SCT) FOR SPENT PHASE POLY-
CYTHEMIA VERA (S-PV): SPLENIC INFLUENCE ON ENGRAFTMENT
Shambavi, R.; Isola, L.M.; Gilbert, H.; Scigliano, E.; Wienberg, R.S.; Frucht -
man, S.M. Mount Sinai Medical Center, New York, NY
Medical management of S-PV is ineffective. Allogeneic SCT may be
curative. The effect of splenectomy on engraftment, the role of SCT and
the concept of graft versus disease to explain regression of myelofib r o s i s
(MF) are debatable. We report on a patient with S-PV who underwent a
syngeneic SCT. A 56 year old male with PV developed S-PV, massive
splenomegaly and transfusion dependence. A bone marrow (BM) biopsy
showed dense MF. The patient underwent a syngeneic SCT with GCSF
primed PBSC, CD34+ count 8x106/kg. without splenectomy, at another
institution. He failed to engraft by D+40 with WBC 200/1 and
p l a t e l e t s<10,000/1, and underwent a splenectomy followed by a BM
boost from his syngeneic donor on D+41. On D+43 he engrafted with
Hb 8.9g/dl, WBC 1,100/ul and platelets 16,000/ul and on D+134 had a
normal CBC. BM Biopsies after transplant showed regression of MF.
Endogenous BFU-E, indicative of PV, are now absent from BM cultures.
Serum cholesterol pre-transplant was low at 120mg/dl, compatible with
PV; post-transplant cholesterol is 208 mg/dl. Initially, the patient had
graft failure despite an adequate cell dose; after splenectomy and a boost
of BM cells, he had trilineage reconstitution. In conclusion,1) normal
hematopoiesis can be restored after syngeneic SCT despite extensive MF
2) fibrosis can regress following a TBI containing regimen and syngeneic
SCT 3) it is possible to cure S-PV by syngeneic SCT as evidenced by
normalization of CBC, regression of MF, absense of endogenous BFU-E
in BM and restoration of normal cholesterol metabolism. A graft vs. BM
stroma effect has been used to explain regression of MF after allogeneic
transplantation, but in a syngeneic transplant this phenomenon is non-
existent, suggesting that there may be a role for autologous SCT in S-PV
to obliterate MF. A case may, therefore, be made for autologous stem cell
collection for patients in early proliferative phase of PV.
5 0
LOW CD34+ CELL DOSE IS ADVERSELY ASSOCIATED WITH RELAPSE-
FREE (RFS) AND OVERALL SURVIVAL (OAS) FOLLOWING AUTOLO-
GOUS BLOOD STEM CELL TRANSPLANTATION (ASCT)
Stewart, D.A.1 , 2; Guo, D.1; Gluck, S.1 , 2; Morris, D.1 , 2; Chaudhry, A.1 , 2; Klassen,
J .2; Luider, J.2; Auer, I.2; Brown, C.1 , 2; Russell, J.A.1 , 2 1. Tom Baker Cancer
Centre, Calgary, AB, Canada; 2. Foothills Hospital, Calgary, AB, Canada
Purpose: To determine if the infused CD34+ cell dose is independently
associated with RFS and OAS following ASCT. 
Methods: Data were analyzed on 277 consecutive patients who received ASCT
from 1993-1999. Univariate and multivariate analyses were performed for both
relapse and death considering the following factors: age, gender, diagnosis, disease
status (first remission, relapse, refractory), number of prior chemotherapy regi-
mens, prior radiotherapy (RT), mobilization regimen (G-CSF only, chemo plus
G-CSF, or dose-intensive cyclophosphamide, etoposide, cisplatin (DICEP) plus
G-CSF), conditioning regimen (TBI or no TBI), and CD34+ cell dose. 
Results: The 158 women (57%) and 119 men (43%) ranged in age from 14-
69 years (median 44). Diagnoses included: stage 2/3 breast cancer (n = 6 5 ,
24%), metastatic breast cancer (n = 33, 12%), aggressive non-Hodgkin’s lym-
phoma (NHL, n = 80, 29%), low grade NHL (n = 21, 8%), Hodgkin’s disease
( n = 31, 11%), and other (n = 47, 17%). Disease status at ASCT was fir s t
remission (n = 123, 44%), relapse (n = 112, 40%), or refractory (n = 42, 15%).
Sixty-six patients (24%) had prior RT, 85 had > 1 chemotherapy regimen, and
52 (19%) received TBI. The median CD34+ cell dose (x106/kg) was 7.29
(range 0.26-127). Patients were grouped into quartiles according to the
CD34+ cell dose (<4, 4-7, 7-14, and >1 4 x 1 06 CD34 cells/kg). By univariate
analysis, the most discriminating cut-point of CD34+ dose for RFS (p<0 . 0 0 0 1 ,
r2 = 0.064) and OAS (p<0.0001, r2 = 0.066) was 4x106/kg. There was no differ-
ence in RFS or OAS for patients in the three quartiles above 4x106/kg. Sixty-
five (23%) patients received <4 x 1 06 CD34+ cells/kg. Results of the multivariate
analysis are tabulated below. Even when insignificant factors such as diagnosis,
number of prior chemotherapy regimens, and mobilization regimen are
included in the model, the CD34+ cell dose remains associated with RFS
( R R = 1.80, p = 0.012) and OAS (RR = 1.97, p = 0.010). 
Conclusions: The CD34+ cell dose <4 x 1 06/kg was independently associated
with lower RFS and OAS rates following ASCT.
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R E L A P S E D E A T H
F A C T O R R R 95%CI RR p V A L U E R R 95%CI RR p V A L U E
Refractory Status 6.03 3.57-10.20 <0.0001 5.35 2.96-9.67 <0.0001
Relapsed Status 2.04 1.30-3.21 0.0020 2.23 1.31-3.82 0.0033
Age > 50 years 1.91 1.27-2.87 0.0020 1.81 1.14-2.88 0.0120
CD34+ Cell Dose <4x106/kg 2.21 1.49-3.33 <0.0001 2.14 1.38-3.33 0.0007
130
5 1
KINETIC EVALUATION OF PLASMA CYTOKINES IN FEBRILE EPISODES
AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION
Stracieri, A.B.; Paton, E.J.; Simıes, B.P.; Covas, D.T.; Coutinho, M.A.;
Voltarelli, J.C. School of Medicine Hemocentro Foundation of Ribeirão Preto
Brazil, Ribeirão Preto, Brazil
Patients submitted to hematopoeitic stem cell transplantation (HSCT)
display extensive and profound immunodeficiency, including prolonged
neutropenia, which predisposes severe and frequent infections. These
and other complications of HSCT are usually associated with fever for
which the biochemical mechanism is not completely understood. 
In the present study we evaluated the production of proinfla m m a t o r y
(IL-1-beta, TNF-alpha, IL-6, IFN-gamma, IL-8) and antiinfla m m a t o r y
(IL-10) cytokines in patients submitted to HSCT during febrile episodes
of various etiologies. Kinetic variation of cytokine plasma levels was
measured by an immunoenzymatic assay (ELISA) at different intervals
(0, 2, 4, 6, 12, 24 hours) following fever initiation. We evaluated 39
febrile episodes in 16 patients with four types of transplantation compli-
cations: 1) presumed infection with negative blood cultures, 2) infections
caused by Gram-negative bacteria, 3) infections caused by Gram-posi-
tive bacteria, 4) drug reactions to amphotericin-B. 
The production of both pro and antiinflammatory cytokines was
increased during bacterial infections specially those caused by Gram-
negative bacteria. In febrile reactions caused by amphotericin-B the only
cytokine showing increased levels was IL-1-beta and no cytokine was
augmented during fever of unknown origin with negative blood cultures.
There was no difference in cytokine levels between neutropenic and
non-neutropenic patients or between patients receiving dipirone or
acetaminophen as antithermic agent. 
Elevated levels of cytokines in Gram-negative and Gram-positive bac-
teremias may be used as a diagnostic marker even before blood cultures
are positive. On the other hand, if cytokine levels are uniformly low dur-
ing the first 24 hours of the febrile period it is likely that the blood cul-
tures remain negative. Thus, the analysis of cytokine kinetics after
HSCT may have important pathophysiologic and clinical implications. 
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SUPPORTIVE GROUP FOR RELATIVES OF BONE MARROW TRANS-
PLANTATION RECIPIENTS: A PSYCHOLOGICAL INTERVENTION
Torrano-masetti, L.M.1 , 4; Oliveira, E.A.2 , 4; Santos, M.A.4; Voltarelli, J.C.3;
Simões, B.P.3 1. Fundação Hemocentro de Ribeirão Preto, Ribeirão Preto,
Brazil; 2. Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto,
Ribeirão Preto, Brazil; 3. Faculdade de Medicina de Ribeirão Preto USP,
Ribeirão Preto, Brazil; 4. Universidade de São Paulo Faculdade de Filosofia
Ciências e Letras de Ribeirão Preto, Ribeirão Preto, Brazil
Introduction: Although the cancer diagnosis within a family starts a
process of emotional suffering, the relatives need to cooperate with the
treatment and encourage the patient. The decision to carry out the
BMT can be complex and often painful process. In order to minimize
the family anxiety during the transplantation period two psychologists
created a weekly supportive group. Objective: Verify the effects of this
procedure in the relatives and describe how they deal with the immi-
nence of death, the protective isolation of the patient, the pain, and
many physical and emotional suffering frequently associated with the
BMT. Procedure: The qualitative data was collected and transcribed
from 40 group sessions in a period of ten months, and a thematic analy-
sis was then applied. The data and analysis was submitted to two inde-
pendent judges. Results: The most difficult moment for the families was
the diagnosis. The disease changes many important thoughts, and the
m o d i fications may be either positive (e.g.: empowerment of the family
unit) or negative (e.g.: economic problems, physical and emotional suf-
fering). The decision of carrying out the BMT is painful, because of the
high risk of death. In the situations where the patient has severe compli-
cations, the relatives may regret having accepted the procedure. Conclu-
sion: The development of awareness of suffering is a gradual process for
family caregivers. Uncertainty and anguish characterize such process.
Several factors contribute to this uncertainty and the questions they
make will be answered through their personal experiences. In this way,
the group makes feasible the construction of their own histories, con-
tributing to help and relieve their emotional suffering. 
5 3
EARLY IMMUNE RECOVERY AFTER ALLOGENEIC TRANSPLANTATION
FOR ACUTE MYELOID LEUKEMIA AS MEASURED BY DAY 29 LYMPHO-
CYTE COUNT AND NON-NEUTROPHIL FRACTION IS OF PROGNOSTIC
I M P O R T A N C E
Thomé, S.D.; Anderson, P.M.; Tefferi, A.A.; Gastineau, D.A. Mayo Clinic,
Rochester, MN
Purpose: To corroborate or refute a prior study demonstrating prog-
nostic importance of early immune recovery after allogeneic BMT for
AML (B l o o d 91:3481-3486,1998; Ray Powles et al). 
Methods: Early immune recovery was assessed by day 29 lymphocyte
counts as per Powles and colleagues. In addition, the non-neutrophil
white cell fraction (mainly lymphocytes plus monocytes) was calculated
(total WBC-neutrophil) on day 29. Kaplan-Meier analysis was per-
formed using different cut-offs for absolute lymphocyte counts and non-
neutrophil fraction counts. Patients entered in this pilot study were
treated at a single institution between 6/1993 and 10/1999 with allo-
geneic transplantation for AML. 
Results: 41 patients had sufficient data for analysis. 12 received periph-
eral blood stem cells, 29 received bone marrow. Using a cut-off of 0.4
for absolute lymphocyte count or a cut-off of 0.8 for non-neutrophil
white cells produced statistically highly significant dichotomous survival
curves on Kaplan-Meier analysis. Higher immune cell fractions predict-
ed for better survival. 
Conclusions: The results of this pilot study confirm the findings of
Powles et al. Higher levels of circulating lymphocytes or higher levels of
non-neutrophil white cells are correlated with better post-transplant sur-
vival. The postulated graft versus leukemia effect may therefore be indi-
rectly measurable and predictable early after transplant. We propose to
study this relationship in a larger data set, such as the IBMTR/ABMTR
in order to confirm or refute these interesting fin d i n g s .
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A REFLEXIVE GROUP FOR HEALTHCARE PROFESSIONALS OF ONCO-
HEMATOLOGY: STRATEGY TO DISTRESS RELIEF
Torrano-masetti, L.M.2 , 3; Simões, B.P.4; Oliveira, E.A.1 , 3; Santos, M.A.3 1 .
Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto, Ribeirão
Preto, Brazil; 2. Fundação Hemocentro de Ribeirão Preto, Ribeirão Preto,
Brazil; 3. Universidade de São Paulo Faculdade de Filosofia Ciências e Letras
de Ribeirão Preto, Ribeirão Preto, Brazil; 4. Faculdade de Medicina de Ribeirão
Preto, RibeirãoPreto, Brazil
Introduction: A healthcare professional works for the reestablishment
of health. The onco-hematological patient cannot always be cured. In
these cases of poor prognosis the healthcare professionals are given the
task of providing the patient with supportive care. In such circumstance,
the patient needs more and more care to survive, and nurses need to be
very close to them and to their family. The nurses, as well as other
healthcare professionals, may suffer from an impotence feeling and with
the imminence of death, which brings prejudice to their quality of work.
A weekly reflexive group coordinated by a psychologist and a hematolo-
gist, aiming at optimizing the quality of nursing care and at relieving the
staff stress. Objectives: Describe the meeting process carried out in a
period of 12 months, looking for the psychological impact in the health-
care professionals after the intervention. Subjects: Fourteen healthcare
professionals, 10 female and 4 male. Procedure: The qualitative data was
collected and transcribed from 40 group sessions. The data and analysis
were submitted to two independent judges. Results: The members of the
group verbalize questions regarding the life and death, the disease and
their choices of life including the professional and affective dimension
involved in taking care of the patient. The group seems to represent a
possibility of elaboration and growth in opposite to the distress to which
they are daily submitted in their work. The sessions may improve the
nurses’ capacity to care for patients preserving their emotional integrity.
Conclusion: By giving emotional support, the reflexive sessions seem to
optimize nursing care and to promote some distress relief in the staff.
The patients also benefit from a safety feeling, which can finally offer
them the chance to cooperate in their own treatment.
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COUNSELING GROUP FOR CANDIDATES WAITING FOR HEMATOPOI-
ETIC CELL TRANSPLANTATION: A PSYCHOLOGICAL INTERVENTION
Torrano-masetti, L.M.2 , 4; Santos, M.A.2; Oliveira, E.A.1 , 2; Simões, B.P.3 1 .
Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto, Ribeirão
Preto, Brazil; 2. Universidade de São Paulo Faculdade de Filosofia Ciências e
Letras de Ribeirão Preto, Ribeirão Preto, Brazil; 3. Faculdade de Medicina de
Ribeirão Preto USP, Ribeirão Preto, Brazil; 4. Fundação Hemocentro de
Ribeirão Preto, Ribeirão Preto, Brazil
Introduction: The patient who awaits Bone Marrow Transplantation
(BMT) needs information about: chemotherapy, reverse isolation, food
restriction, social isolation and the risk of life. During the time that pre-
cedes BMT, the patients were invited to take part in a psychological
group, two times a month. The intention was to provide them with infor-
mation about BMT, and to give them opportunity to express and listen to
each other’s emotional experiences. Objectives: Verify the effects and
psychological benefits of this procedure at the initial phase of adaptation
(until 6 months after BMT), as well as psychosocial adjustment in BMT
recipients. Subjects: A sample of 9 patients, four of female, with ages
varying between 22 and 46 years old. Procedure: The patients were dis-
tributed in two groups at random: experimental sample (ES)– four
patients participated in the psychological group; and the control sample
(CS) – five patients that didn’t participate in such meetings. The qualita-
tive data was collected by individual semi-directive interview. All the
interviews were recorded and transcribed. Results: Four pre-BMT coun-
seling patterns emerged from the analysis of the interview data: (a) self-
perception as a participant in the group, (b) information and counseling
provided by the healthcare team, (c) increase of their hope of success, (d)
self-perception of the psychosocial adjustment and adaptation after BMT.
Conclusions: The patients of ES highlighted the importance of emotion-
al support to ameliorate their cooperation through the different phases of
BMT. The patients of CS emphasized external factors that contribute to
well being during and after BMT. The evaluation of ES shows that shar-
ing the difficulties and emotional suffering with people who face the same
situation may bring intense relief. The psychological intervention seems
to give patients conditions to trust and work along with the BMT team,
facilitating decision-making and finally improving their quality of life.
5 9
PHARMACOECONOMIC ANALYSIS OF IV ONDANSETRON VS ORAL
GRANISETRON IN CONDITIONING REGIMENS
Wong, S.1 , 2; Law, A.2; Chau, H.V.1; Keuroghelian, S.1; Lim, S.1; Ho, W.1 1 .
University of California, Irvine, Orange, CA; 2. Western University of Health
Sciences, Pomona, CA
The purpose of this study was to conduct a pharmacoeconomic analy-
sis to compare the cost and effectiveness of oral (PO) granisetron (Gr)
and intravenous (IV) ondansetron (Ond) as prophylactic antiemetic for
stem cell transplantation conditioning regimens. Sequentially, 17
patients (pts) who were undergoing allogeneic or autologous stem cell
transplantation were placed on daily IV Ond 30 mg IVPB plus 30 mg
continuous infusion, and another 17 pts were placed on PO Gr 1 mg q
12 hours from day #1 until 24 hours post chemotherapy. All pts
received combinations of the following treatments at standard condi-
tioning regimen doses: Total body irradiation, busulfan, cyclophos-
phamide, thiotepa, carboplatin, ifosfamide, and etoposide or
etopophos.Except etopophos (4-hour infusion), all the intravenous
chemotherapies were administered as continuous infusions over 24
hours. Data were evaluated retrospectively from the pts’ medical
records. The male:female ratios for Ond (7:10) and Gr (12:5) were not
s i g n i ficantly different, but the average age for the 2 groups; Ond (30.5
years) vs Gr (42.0 years)were significantly different. All pts studied
experienced acute and/or delayed nausea (N) and/or vomiting (V). Data
were analyzed using SPSS™ version 9.0. Comparison between the 2
groups using independent T-tests for interval data showed that there
were no statistically significant differences (α = 0.05) between the 2
groups on the incidence of acute N, acute V, delayed N, and delayed V
at all severity gradings. There were no differences between the number
of pts who developed headache and constipation, or who needed rescue
medications. A cost comparison between Ond and Gr indicated signifi-
cant savings with Gr at $69.96/pt/day over Ond at $288.33/pt/day. In
conclusion, the effectiveness data between the 2 treatment groups were
not significantly different. The cost minimization analysis showed sig-
n i ficant cost savings with PO Gr over IV Ond. Future research could
extend this study to larger samples. 
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HIGH-DOSE CHEMOTHERAPY (HDCT) FOR PRIMARY BREAST CANCER
REFRACTORY TO NEOADJUVANT CHEMOTHERAPY (NAC)
Ueno, N.T.; Rondon, G.; Donato, M.L.; Mehra, R.C.; Anderlini, P.; Giralt,
S.A.; Gajewski, J.L.; Braunschweig, I.; Rahman, Z.; Buzdar, A.U. 1. The
University of Texas, Houston, TX; 2. Anderson Cancer Center, Houston, TX
We investigated the effect of HDCT on disease-free survival (DFS)
and overall survival (OS) in patients (pts) with primary breast cancer
(stages II 5,IIIa 5, and IIIb 6) refractory to NAC, a pt subset known to
have low PFS and OS (Cancer Chemother Pharmacol 1997;40:321, S u r g
Clin North Am 1997;76:393). A total of 16 pts.(median age 46 yr, range
36-58 yr) were evaluated. After NAC, all pts underwent mastectomy,
HDCT with autologous PBPC transplantation (ABMT), and radiation
therapy. If tumor was unresectable after NAC, HDCT with ABMT was
administered before mastectomy. For ABMT, filgrastim-mobilized
progenitor cells were collected after CVP (cyclophosphamide, VP-16,
cisplatin) chemotherapy and infused after HDCT. The conditioning
regimen was cyclophosphamide(6 gm/m2 ), BCNU(450 mg/m 2), and
thiotepa (720 mg/m 2 ). 
MR; minor response, SD; stable disease, PD; Progressive disease.
Tumor remained unresectable. After a median follow-up of 381 d
(range, 165-682 d from the day of transplant, 14 pts remained disease-
free. DFS at one year is 80%. One patient died of multiorgan failure at
344 d without disease. Median DFS was 381 d (165-682) from day of
transplant and 655 d (296-905) from the day of NAC initiation. Com-
pared with our historical experience in pts with locally advanced breast
cancer refractory to NAC, the DFS and OS of those who underwent
HDCT was significantly improved. This warrants further study involv-
ing long-term follow-up.
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NON-MYELOCYTIC IMMUNE RESPONSE TO INVASIVE ASPERGILLOSIS
FOLLOWING LETHAL IRRADIATION AND HEMATOPOIETIC STEM CELL
T R A N S P L A N T A T I O N
BitMansour, A.A.; Weissman, I.L.; Brown, J.M. Stanford University School
of Medicine, Stanford, CA
The leading single risk for the development of invasive aspergillosis is
neutropenia. However, up to two thirds of patients who develop
aspergillosis following hematopoietic cell transplantation are not neu-
tropenic at the time of diagnosis. The mortality rate of this infection
approaches 100%— a rate far greater than is seen following chemother-
apy or treatment with corticosteroids. Previous murine models of inva-
sive aspergillosis have relied upon chemotherapy-induced neutropenia
or treatment with corticosteroids to render the animal susceptible to
infection. In our model, mice received lethal irradiation (950 Gy, split-
dose), followed by transplantation of hematopoietic stem cell (HSC)
(200 double-sorted cells, Thy1.1lolin-Sca-1+c-kithi). The mice were
divided into two groups which received unfractionated splenocytes
either from mice naive to aspergillus infection or from mice who had
been immunized with an intravenous inoculation of 1x106 conidia of a
clinical isolate of Aspergillus fumigatus two weeks prior to transplantation.
Two days following transplantation, mice were challenged with 100
conidia the same clinical isolate of A. fumigatus injected into the lateral
tail vein. Mice were weighed daily, then killed at specific time points to
determine fungal load in the kidneys, lungs, liver, spleen, and brain.
Mice who were challenged with A. fumigatus and had received a graft of
only HSC had a survival rate of 15% in contrast to a 32% survival rate in
mice who received naïve splenocytes co-transplanted with the HSC.
However, the highest survival rate (75%) was observed in animals who
had received splenocyte co-transplantation from immunized mice.
These findings confirm the presence of a non-myelocytic splenocyte
population that is able to protect against lethal infection due to
Aspergillus spp. following hematopoietic cell transplantation. Using this
model of invasive infection and a companion model of inhaled conidial
inoculation, the non-myelocytic immune response to and contributing
risks for invasive aspergillosis may be systematically analyzed
2 3
MEASUREMENT OF THYMIC OUTPUT USING T CELL RECEPTOR EXCI-
SION CIRCLES (TRECS) FOLLOWING ALLOGENEIC HEMATOPOIETIC
STEM CELL TRANSPLANTATION: ADULT VS. PEDIATRIC PATIENTS
Chao, N.J.; Chen, B.J.; Smith, C.A.; Cui, X.; Szabolcs, P.; Kurtzberg, J.;
Haynes, B.F.; Patel, D.D. Duke University, Durham, NC
T cells can arise from new precursors arising from the donor graft,
through peripheral expansion of donor mature T cells carried in the
graft, or through proliferation and expansion of recipient peripheral
blood (PB) T cells. T cell precursors rearrange the T cell receptor
(TCR) delta (D) locus to form the α chain of the TCR during which the
T C R∆ chain is excised and forms a circular episome. These signal joint
(sj) TRECs are detected in T cells that are recent thymic emigrants,
whereas T cells that have divided repeatedly in the periphery contain
fewer TRECs. We sought to determine the modes of T cell reconstitu-
tion, and analyze whether the recovery following SCT occurs exclusively
from the peripheral expansion of mature T cells (TREC -) or rather
occurs in part from renewed thymogenesis (TREC+). We found 6 of 8
pediatric patients had normal peripheral blood mononuclear cell
(PBMC) TREC levels (median 7,394 TRECs/mg PBMC [range 6,690-
22,833] vs. 2,000-8,000 range of TRECs/mg PBMC in age matched
normal controls) one to three years post SCT, suggesting that immune
reconstitution was at least in part due to thymogenesis. In contrast, in
adult patients, we found that only 3/16 patients had evidence of minimal
post-SCT thymic function compared with normals (191, 244, 308
TRECs/mg peripheral blood mononuclear cells [PBMC] vs. 800-2000
TRECS/mg PBMC in age matched normal controls). These latter data
demonstrated that reconstitution in adult SCT was near exclusively from
PB T cell expansion. In the three patients with low levels of TRECs post
SCT,chronic graft-vs. -host disease was associated with reduced TREC
levels. Thus in children, the thymus is able to continue to reconstitute
the PB T cell pool post SCT, whereas in the adults studied, T cell
reconstitution post SCT was primarily due to expansion of PB T cells.
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HOST B CELLS PROMOTE GRAFT-VERSUS-HOST DISEASE AFTER
ALLOGENEIC BONE MARROW TRANSPLANTATION: EFFECT OF FLU-
DARABINE CONDITIONING
Fuchs, E.J.; Engstrom, L.W.; Couzi, R.J.; Iannone, R.; Luznik, L. Johns
Hopkins University School of Medicine, Baltimore, MD
Acute graft-versus-host disease (GVHD) after allogeneic blood or
marrow transplantation (alloBMT) is dependent upon donor T cells
that recognize distinct histocompatibility antigens on the surface of host
antigen-presenting cells (APCs). Efforts to reduce GVHD following
alloBMT have focused on administering non-specific immunosuppres-
sion after transplantation or depleting T cells from the donor graft.
However, the effect of modulating host APCs is relatively unexplored.
Here, the influence of host B cells on acute GVHD after alloBMT was
examined. Compared to normal F1 hybrid mice, B cell-deficient F1
recipients were relatively resistant to the induction of acute GVHD by
the infusion of parental spleen cells. The absence of GVHD in the B
c e l l - d e ficient recipients was associated with nearly undetectable donor T
cell chimerism. A short course of fludarabine, a purine analogue with
activity in B cell malignancies, transiently reduced normal B cell num-
bers and rendered normal F1 recipients resistant to the induction of
GVHD by parental spleen cell infusion. These results demonstrate that
host B cells promote acute GVHD, presumably by acting as stimulatory
APCs for alloreactive donor T cells, and suggest that GVHD may be
modulated by pharmacologic manipulation of host APC populations.
PURIFIED ALLOGENEIC HEMATOPOIETIC STEM CELL (HSC) TRANS-
PLANTATION PREVENTS AUTOIMMUNE DIABETES AND INDUCES TOL-
ERANCE TO DONOR MATCHED ISLETS
Scheffold, Y.C.1; Edwards, C.2; Jerabek, L.3; Burge, M.J.1; Beilhack, G.1;
Weissman, I.L.3; Shizuru, J.A.1 1. Department of Medicine, Stanford Univer -
sity, Stanford, CA; 2. Department of Immunology, Stanford University, Stan -
ford, CA; 3. Department of Pathology, Stanford University, Stanford, CA
P u r i fied allogeneic HSCs were transplanted into autoimmune dia-
betic (NOD) mice to determine if (1) HSC grafts will block the dia-
betes pathogenesis, and (2) tolerize to donor and auto-antigens and
allow the diabetic host to accept an HSC donor-matched islet graft.
T h y - 1l oL i n- / l oS c a - 1+ HSCs were isolated from MHC mismatched
donor AKR mice (H-2K). Prediabetic NOD mice (H-2g 7) received
either 950 or 700 rads, plus antibodies directed against NK and CD4+
T cells, and transplantation of 3000-10,000 HSCs. Recipient mice
became either near complete chimeras (950 rads) or partial chimeras
(700 rads). Both groups retained recipient T cells. 0/34 mice treated
with the 950 rad regimen and 0/7 mice treated with the 700 rad regi-
men progressed to hyperglycemia. In contrast, all mice that received
syngeneic NOD BM developed frank hyperglycemia. To study how
HSC grafts modify recipient immune responses, peripheral blood of
chimeric mice was analyzed for donor vs host Vβ T cells. We found
that the HSC graft can mediate negative selection of donor and recip-
ient T cells by central deletion. We then tested if NODs that were
already diabetic could be cured by simultaneous allogeneic HSC plus
donor-matched islet transplatations. Diabetic NODs received AKR
HSCs using the regimens described above and one day later isolated
islets from AKR donors were infused into the portal vein. Both groups
demonstrated significantly prolonged islet graft survival as compared
to non-HSC transplanted NOD mice, however, only mice treated
with the myeloablative regimen retained their islet grafts long-term.
We conclude that transplantation of HSCs blocks the pathogenesis of
diabetes, even though the mice retain their own endogenous T cells;
thymic deletion of T cells is one mechanism by which HSCs alter
recipient immune responses; and tolerance induction to HSC donor
matched islets in diabetic mice requires a high level of donor
hematopoietic cell chimerism.
THE ROLE OF THE FAS LIGAND AND PERFORIN CYTOTOXIC PATH-
WAYS IN GRAFT-VERSUS-HOST-DISEASE, GRAFT-VERSUS-LEUKEMIA
AND DONOR LEUKOCYTE INFUSION
Kappel, B.J.1; Muriglan, S.J.1; Horndasch, K.J.3; Teshima, T.2; Ferrara,
J . L .2; Burakoff, S.J.3; van den Brink, M.R.1 1. Memorial Sloan-Kettering
Cancer Center, New York, NY; 2. University of Michigan, Ann Arbor, MI; 3.
Dana Farber Cancer Institute, Boston, MA
BACKGROUND: In allogeneic bone marrow transplantation (BMT)
donor T cells are primarily responsible for anti-host activity (resulting in
graft-versus-host disease (GVHD)) and anti-leukemia activity (graft-ver-
sus-leukemia (GVL)). We studied the relative contribution of the Fas
ligand (FasL) and perforin cytotoxic pathways in GVHD, GVL and
donor leukocyte infusion (DLI). 
METHODS: We used well-established murine parent into F1 models
for allogeneic bone marrow transplantation with a full mismatch for
MHC class I and II (B6 into C3FeB6F1 and B6 into B6D2F1). In these
models GVL activity (against the C3H/HeJ leukemia 32Dp210 and
DBA/2 mastocytoma P815) has been well defined and donor T cells
from FasL-defective and perforin-deficient B6 mice were used to study
the role of cytotoxic effector pathways in GVHD, GVL and DLI. 
RESULTS: In experiments with varying numbers of donor T cells and
leukemic cells, we found that FasL-defective B6.gld donor T cells display
diminished GVHD activity (GVHD mortality: 6%) compared to normal
B6 donor T cells (GVHD mortality: 100%) but have intact GVL activity
(leukemia mortality: 0%). In contrast, perforin-deficient B6.pfp-/- donor
T cells have intact GVHD activity (GVHD mortality: 94%) but display
diminished GVL activity (leukemia mortality: 50%). Splenic T cells from
recipients of B6.gld or B6.pfp-/- T cells had an identical proliferative
response to host antigens in a MLR, however splenic T cells from recipi-
ents of B6.pfp-/- T cells had no cytolytic activity against leukemia cells in
a cytotoxicity assay. In addition, we found that GVL activity during DLI
was also dependent on an intact perforin cytotoxic pathway. 
CONCLUSIONS: Our data demonstrate that donor T cells mediate
GVHD activity primarily through the FasL effector pathway and GVL
activity through the perforin pathway. This suggest that the specific
blockade of a cytotoxic pathway could be used to prevent GVHD with-
out interfering with GVL activity. 
RESULTS OF A PHASE II MULTICENTER STUDY OF ABX-CBL MONO-
CLONAL ANTIBODY (ANTI-CD147) IN PATIENTS WITH STEROID
RESISTANT GRAFT VERSUS HOST DISEASE (GVHD)
Blazar, B.R.1; Degg, H.J.2; Rifkin, R.3; Bolwell, B.4; Long, G.5; Scheuning,
F .6; Cunningham, J.M.7; Abhyankar, S.8; Havrilla, N.9; Schwab, G.9 1. Uni -
versity of Minnesota, Minneapolis, MN; 2. Fred Hutchinson Cancer Research
Center, Seattle, WA; 3. Rocky Mountain Cancer Center, Denver, CO; 4. The
Cleveland Clinic Foundation, Cleveland, OH; 5. Duke University, Durham,
NC; 6. University of Wisconsin, Madison, WI; 7. St. Jude Children’s Research
Hospital, Memphis, TN; 8. Richland Palmetto Hospital, Columbia, SC; 9.
Abgenix Inc., Fremont, CA
Steroid resistant acute GVHD remains a major cause of morbidity and
mortality following allogeneic stem cell transplant. Standard salvage
therapy has consisted of increasing steroid dosage and/or adding anti-
thymocyte globulin. Although salvage therapy can rescue a portion of
these patients, the majority succumb to either GVHD-associated or
therapy-related complications. ABX-CBL is a murine IgM monoclonal
antibody that recognizes CD147, an antigen present on activated T, B
and NK cells. A Phase I study using CBL-1 (the previous formulation of
ABX-CBL) provided encouraging results which led to a multicenter
phase II study. Fifty-nine patients (age range 1-59: 30 median) with
steroid resistant GVHD were treated. Thirty patients received related
donor transplants (and 29 received unrelated donor transplants. Stem
cell source consisted of BM (n = 51), PBSC (n = 6) or cord blood (n = 2 ) .
Patients with steroid resistant GVHD and IBMTR Stage B, C or D
were eligible. Part 1 (n = 27) of this study was a dose escalation study and
part 2 (n = 32) provided additional safety data as well as further dose
exploration. The dose limiting toxicity was severe myalgia occurring in 2
of 3 patients treated at the highest dose (0.3 mg/kg) which necessitated
decreasing the dose of the last cohort to 0.2 mg kg. No HAMA respons-
es were detectable. Overall, 26 of the 51 (52%) evaluable (received > 4
infusions of ABX-CBL) patients including 23 of 43 (53%) treated at
doses > 0.1mg/kg improved their grade of acute GVHD. Twenty-six of
50 (52%) patients treated at doses > 0.1mg/kg survived at least 100 days
after the first dose of ABX-CBL compared to 2 of 9 (22%) patients who
received ABX-CBL at a dose of 0.01 mg/kg. Therefore future studies
with ABX-CBL are warranted. 
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CD4+ T CELL RECOVERY FOLLOWING CYTOREDUCTIVE THERAPY IN
ADULTS IS CORRELATED WITH REPOPULATION BY NAIVE
CD45RA+CD45RO- CD4 CELLS, THYMIC ENLARGEMENT AND
INCREASED TCR Vβ REPERTOIRE DIVERSITY
Hakim, F.1; Memon, S.1; Cepeda, R.1; Jones, E.2; Chow, C.2; Gress, R.1 1 .
National Cancer Institute, NIH, Bethesda, MD; 2. Clinical Center, NIH,
Bethesda, MD
During the protracted reconstitution of the immune system following
adult cytoreductive therapies, the mechanism of T cell repopulation
affects both the numerical recovery and the functional repertoire diversi-
ty. In adults treated for breast cancer with cytoreductive therapies, the
limited recovery of CD4 cells occurring during the first year has been
shown to be primarily associated with peripheral expansion of CD4 cells
expressing the phenotype of activated/memory cells (CD45RA-
CD45RO+), rather than by recovery of naive CD4 populations
(CD45RA+CD45RO-)(Hakim et al, B l o o d ’97), as occurs in pediatric
patients. In our current studies of long term immune reconstitution, in
contrast, recovery of normal levels of CD4+ T cells after 3 years was
determined to be highly correlated with recovery of naive phenotype
CD45RA+CD45RO- CD4 cells (r = 0.849, p = 0.0002). Furthermore,
retrospective analysis of thoracic CT scans has demonstrated a correla-
tion between CD45RA+ CD4 cell levels at 3 years and an increased
thymic size index during the first 1.5 years post therapy (r = 0 . 9 2 7 ,
p = 0.0001). Finally, spectratype analysis of T cell receptor (TcR) V β
repertoire diversity in CD4 cells demonstrated that the recovery of diver-
sity (measured as CDR3 length heterogeneity) was similarly associated
with recovery of CD45RA+ CD4 cells. Furthermore this increase in
repertoire diversity occurred in the CD45RO+ memory population as
well as in the naive CD45RA+ CD4 cells, consistent with functional uti-
lization of the expanded repertoire. These data suggest that the long term
recovery of CD4 T cell numbers and TcR repertoire diversity in adults is
dependent upon recovery of thymically matured, naive CD4 cells.
A RANDOMIZED TRIAL OF CD8 DEPLETED VS UNSELECTED DONOR
LYMPHOCYTES ADMINISTERED TO PREVENT RELAPSE FOLLOWING T
CELL DEPLETED ALLOGENEIC BMT
Soiffer, R.J.; Canning, C.M.; Alyea, E.P.; Webb, I.; Ritz, J. Dana Farber
Cancer Institute, Boston, MA
T cell depletion (TCD) of donor marrow reduces the morbidity and
mortality of allogeneic BMT but is associated with an increased risk of
disease recurrence. Attempts to safely reduce the risk of relapse after
TCD-BMT are actively being pursued. Donor lymphocyte infusions
(DLI) can induce durable remissions in some patients who have
relapsed after BMT but can cause significant graft-versus-host disease
(GVHD). Studies have been performed which suggest that CD8 deple-
tion of donor lymphocytes may reduce the risk of GVHD without com-
promising efficacy. We are conducting a clinical trial in which patients
are randomized to receive either CD8 depleted or unselected donor
lymphocytes prophylactically following CD6+ BMT. 11 patients
(9F,2M,49 yrs, range 22-66) with hematologic malignancies (3 AML, 3
MDS, 2 ALL, 2 CLL, 1 NHL) have been enrolled. By design, DLI was
administered 6 months after CD6+ TCD-BMT. No patients had
GVHD or were taking immune suppressive medications at time of
DLI. Infusions were adjusted so that both groups of patients (CD8
depleted, n = 6) and unselected, n = 5) received 1.0 x 107 CD4+ cells/kg.
The unselected group received a median of 2.51 x 107 compared with
2.09 x 107 total cells/kg in those receiving CD8 depleted DLI. Two
patients developed fevers with infusion.GVHD developed in 5/5
(100%) patients receiving unselected DLI compared with 0/6 patients
receiving CD8 depleted DLI. GVHD (1 Gr. 1, 2 Gr 2, 2 Gr 3) devel-
oped a median of 12 weeks (7-18) post-DLI. All 5 patients with GVHD
have developed chronic GVHD. All 11 patients are alive a median of 16
months post BMT, 10 months post DLI. One patient (ALL, CD8
depelted relapsed at 10 months). Our preliminary results strongly sug-
gest that CD8 depletion of DLI reduces the risk of acute and chronic
GVHD. Impact on relapse remains to be determined.
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LASTING “CURE” FOR PATIENTS WITH ACUTE MYELOID LEUKEMIA
AFTER AUTOLOGOUS BONE MARROW TRANSPLANTATION
Abdallah, A.1; Egerer, G.1; Goldschmidt, H.1; Körbling, M.2; Ho, A.D.1 1 .
University of Heidelberg, Heidelberg, Germany; 2. MD Anderson Cancer
Center, University of Texas, Houston
There are few reports on the long-term outcome for high-risk AML
patients more than 6 years after autologous bone marrow transplantation
(ABMT). From 1983 to 1993, 94 patients with AML were treated at our
single institution in Heidelberg with high-dose cyclophosphamide (200
mg/kg body weight) preceded by total body irradiation (TBI) with 14.4
Gy followed by ABMT. Bone marrow was purged with 4 hydroxypericy-
clophosphamide (4-HC). A retrospective analysis in November 1999
showed that 20 of 94 patients were alive and in continuous complete
remission for a median of 136 months (range 72 - 182 months) after
ABMT and could be considered as “cured.” At 180 months, the overall
survival and PFS rate was 21.0% (see figure). We have analyzed the
characteristics of such long-term survivors. Among these, 68.8% were
transplanted in first CR, 18.8% in second CR and 12.5% in third CR.
There was no significant difference in gender, age or time to hematopoi-
etic reconstitution between long-term responders versus those who have
deceased. Our retrospective analysis showed that a significant number of
patients with acute myeloid leukemia derived long-term benefit from
HDCT and ABMT with 4-HC purged preparation. 
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EFFECTS OF THE CD4 NON-PEPTICIC INHIBITOR TJU-103 ON
ALLOREACTIVE CD4+ T CELL PRECURSORS
An, J.; Korngold, R.; Huang, Z.; Brunner, J.; Grosso, D.; Filicko, J.; Flomen -
berg, N. Thomas Jefferson University, Philadelphia, PA
Graft-versus-host disease (GVHD) is a major obstacle to successful
human allogeneic bone marrow transplantation (BMT). CD4 T lympho-
cytes play a critical role in the initiation of GvHD, particularly in unrelat-
ed donor BMT. A heptapeptide analog of the CC’ loop of the CD4 D1
domain, the 802-2 peptide has been shown to suppress the development
of GvHD in mice, and to inhibit the response of human alloreactive
helper T lymphocytes to the alloantigen in vitro. Using computer model-
ing to identify small organic molecules which might bind to the pocket
formed by the FG and CC’ loops of the CD4 D1 domain, several organic
inhibitors of CD4 lymphocyte activation have been identified. This study
examined the effects of one such inhibitor, TJU-103, on the alloactiva-
tion of CD4 lympohocytes in mixed lymphocyte cultures (MLC) using
cells from fully HLA mismatched healthy individuals and from hap-
loidentical allogeneic bone marrow donor/recipient pairs. Immunomag-
netic beads coated with anti-CD4 or anti-CD8 monoclonal antibody
were used to examine the phenotype of the growth wells obtained from
limiting dilution microMLCs. The alloreactive T lymphocyte precursors
were decreased by 60% in the group of microcultures treated with TJU-
103 versus vehicle in the HLA fully mismatched (f = 1/8,197 vs 1/2,943)
and in the HLA haploidentical (f = 1/50,176 vs 1/18,975) groups. Most
important, among these alloantigen stimulated microcultures, the clonal
growth of CD4+ cells was inhibited approximately 3 fold in the cells
treated with TJU-103 compared with control. However, the clonal
growth of CD8+ cells was not affected by the same concentration of
TJU-103. This data demonstrates that the inhibition of alloresponses in
these mixed lymphocyte microcultures by TJU-103 is specific for the
CD4 and not CD8 subset of lymphocytes. TJU-103 and its derivatives
thus warrant further study regarding their effects on GVHD, graft rejec-
tion, and autoimmune disorders.
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LONG-TERM REMISSION FOR ADULT PATIENTS WITH ACUTE LYM-
PHOID LEUKEMIA AFTER AUTOLOGOUS BONE MARROW TRANSPLAN-
T A T I O N
Abdallah, A.1; Egerer, G.1; Goldschmidt, H.1; Körbling, M.2; Ho, A.D.1 U n i -
versity of Heidelberg, Heidelberg, Germany; 2. MD Anderson Cancer Center,
University of Texas, Houston
Patients with high-risk acute lymphoblastic leukemia (ALL) might
derive benefit from high-dose chemotherapy (HDCT) and autologous
bone marrow transplantation (ABMT). There are few reports on the
long-term disease-free survival after more than 6 years. From 1983 to
April 1994, 32 patients with ALL at high-risk for relapse were treated
with high-dose cyclophosphamide (200 mg/kg body weight) preceded by
total body irradiation (TBI) with 14.4 Gy followed by ABMT. Bone
marrow was purged with 4 hydroxy-pericyclophosphamide (4-HC). A
retrospective analysis in November 1999 demonstrated that 12 of the 32
patients were alive and in continuous complete remission for a median of
156 months (range 66 - 181 months) after ABMT. At 180 months, the
overall survival and disease-free survival was 37.5% (see figure). Prog-
nostic factors were analyzed but thus far, no significant difference in age
(23.3 years for the long-term survivors and 29.7 years for those who
died), gender, or remission status before ABMT could be identified. Our
retrospective analysis showed that a significant number of adult patients
with acute lymphoid leukemia derived long-term benefit from ABMT
with purged marrow. 
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TRANSJUGULAR LIVER BIOPSY AND APPROACH TO HEPATIC DYS-
FUNCTION IN ALLOGENEIC BONE MARROW TRANSPLANT
Arai, S.; Lee, L.; Margolis, J.; Boitnott, J.; Lund, G.; Lee, J.; Johnson, C.;
Vogelsang, G. Johns Hopkins Oncology Center, Baltimore, MD
The cause of hepatic dysfunction in marrow transplant patients is
often hard to make on clinical grounds alone. The treatment of each of
these causes is different and therefore, establishing the diagnosis is
important. A systematic approach toward patients with liver dysfunction
has not been taken, but clearly would be of benefit. In this study, we
reviewed the incidence and etiology of post-transplant hepatic dysfunc-
tion, and report on the utility of transjugular liver biopsy in situations of
uncertain clinical diagnosis. Of 2,564 patients undergoing bone marrow
transplant between 1988 and 1998, 12 patients (0.47%) developed acute
cholecystitis. Seven of the 12 patients (58%) developed cholecystitis in
1998 alone, after employing a dedicated gastrointestinal consultation
service for post-transplant patients. The true incidence of acute chole-
cystitis may therefore be higher than previously reported and diagnosis
may warrant subspecialist input. In addition, from 1998 to 1999, we uti-
lized transjugular liver biopsy routinely to evaluate patients with post-
transplant hepatic dysfunction of unclear etiology to try to better char-
acterize the causes of hepatic dysfunction. Of 72 patients undergoing
allogeneic transplant, 18 patients underwent transjugular liver biopsies.
Complication rate was 5%. Liver histology aided in management of the
patients in 65% of cases by providing a new diagnosis. The timing of
the liver biopsy post-transplant may be critical. Most notable is the high
frequency of nonspecific findings after day 80. We conclude that tran-
sjugular liver biopsy is safe and provides adequate histology for diagno-
sis which aided in management of 65% of patients by providing a new
diagnosis. We would propose early intervention with transjugular liver
biopsy which may yield more meaningful results for management. At
our institution, we have begun a multispecialty systematic approach to
the evaluation of post-transplant liver dysfunction utilizing early tran-
sjugular liver biopsy and dedicated gastroenterology, surgical, and inter-
ventional radiology services. 
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RANDOMIZED CLINICAL TRIAL OF THALIDOMIDE, CYCLOSPORIN
(CSA) AND PREDNISONE VERSUS CSA AND PREDNISONE AS INITIAL
THERAPY FOR CHRONIC GRAFT VERSUS HOST DISEASE (CGVHD)
Arora, M.; Wagner, J.; Blazar, B.; Davies, S.; Defor, T.; Enright, H.; Weis -
dorf, D. University of Minnesota, Minneapolis, MN
CGVHD is a major cause of morbidity following allogeneic BMT.
Thalidomide (Thal) is an immunosuppressive agent active in therapy of
CGVHD; mostly as salvage for patients (pts) with high risk or resistant
CGVHD. We tested the efficacy of initial therapy with Thal. Fifty four
pts who underwent allogeneic BMT at the U of MN and had extensive
CGVHD were randomized to receive either CSA and Prednisone
( n = 27, control group) or CSA, Prednisone and Thal (n = 27, Thal
group). Pts. were stratified as related and unrelated donor (URD). Pts.
were evaluated for response at 2mo., 6mo. and 1yr. of therapy. The
response rates were 89% (control group) vs 83% (Thal group) at 2mo.
( p = 0.7), 84% vs 83% at 6mo. (p>0.8) and 73% vs 85% at 1yr. (p = 0 . 5 ) .
Multivariate analysis revealed (URD) transplant (OR = 11.3, p = 0 . 0 3 )
and progressive onset (OR = 7.7, p = 0.06) to be significant predictors of
poor early response while platelets <100,000 was a significant predictor
of poor response (OR = 10.4, p = 0.04) at 1yr. Skin involvement was a
s i g n i ficant predictor of good response (OR = 0.04, p<0.01). Both treat-
ment groups had similar 1yr survival (68% vs 72%, p = 0.8). Multivariate
analysis revealed grade III-IV acute GVHD (RR = 4.7, p<0.01), URD
( R R = 6.8, p<0.01), sex mismatch (RR = 9.6, p<0.01), and platelets
< 100,000 (RR = 4.06, p<0.01) to be independently significant predictors
of mortality. There was more frequent constipation (52%, p<0 . 0 1 ) ,
sleepiness (63%, p<0.01) and neuropathy (48%, p<0.01) in the Thal
group. There were significantly more bacterial infections in the control
group. (3.1/1000person-years vs 1.6/1000 person-years, p = 0.04). 
Conclusion- Thal did not alter the response rate or survival when
added to CSA/prednisone as initial therapy for CGVHD. Overall a high
response rate ( 79% response with 52% CR ) and a high survival rate
(70% at 1yr and 60% at 2yrs) was observed. Randomized controlled
evaluation of Thal as salvage therapy is still needed. 
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DENDRITIC CELL/TUMOR FUSIONS AS A NOVEL TUMOR VACCINE
Avigan, D.E.1; Gong, J.2; Wu, Z.2; Smith, T.1; Chen, D.2; Joyce, R.M.1; Uhl,
L .1; Kufe, D.2 1. Beth Israel Deaconess Med Ctr, Boston, MA; 2. Dana-Farber
Cancer Institute, Boston, MA
Dendritic cells (DC) are potent antigen presenting cells that promi-
nently express costimulatory and adhesion molecules necessary for the
initiation of primary immune responses. We have recently reported that
the fusion of DC with murine carcinoma cells results in the generation
of heterokaryons that co-express tumor specific antigens and costimula-
tory molecules. Vaccination with fusion cells protected animals from an
otherwise lethal challenge of tumor cells and induced the rejection of
established metastases. In the present study, fusions were generated with
human DC and human breast carcinoma cell lines, patient-derived DC
and autologous primary breast carcinoma cells and patient derived DC
and autologous melanoma cells. Fusion cells co-expressed tumor anti-
gens and DC-derived co-stimulatory molecules. The fusion cells also
retained the functional potency of DC and stimulated allogeneic T cell
proliferation. Fusion cells generated from patient-derived tumor cells
and DC stimulated proliferation of autologous cytotoxic T lymphocytes
which lysed autologous tumor cells in vitro by a MHC-restricted mecha-
nism. Minimal lysis was observed of autologous monocytes or allogeneic
tumor cell lines. Cocultured DC and tumor cells that had not been fused
were ineffective in generating autologous T cell responses. These fin d-
ings demonstrate that fusions of human DC and breast cancer cells acti-
vate T cell responses against autologous tumor. We have initiated a
phase I clinical trial in which patients with metastatic breast cancer
undergo serial vaccination with autologous DC/tumor fusions as well as
receive a control vaccine consisting of DC pulsed with KLH. Tumor
cells are harvested from accessible tissue and fused with DC generated
from adherent mononuclear cells cultured with GM-CSF and IL-4.
Successive cohorts of patients are treated with escalating doses of fusion
cells and toxicity is being monitored. T cell proliferative response to
autologous tumor cells and tumor specific CTL precursor frequency are
being determined at serial time points. 
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PURGING OF AUTOLOGOUS HSC TRANSPLANTS FOR NHL USING
HIGH-DENSITY MICROPARTICLES COATED WITH ANTI-CD19/20 MON-
OCLONAL ANTIBODIES: ELIMINATION OF B CELLS, HIGH CD34+
CELL YIELD AND RAPID ENGRAFTMENT
Atkinson, K.; Freedman, A.2; Gribben, J.2; Kuhlman, C.2; Jallow, H.2; Houde,
H .1; Jarpe, M.1; Letizia, C.1; Monroy, R.1; Schmittling, R.1 1. Eligix, Inc.,
Medford, MA; 2. Dana Farber Cancer Institute, Boston, MA
Contamination of stem cells with residual tumor has been associated
with a high incidence of relapse in patients with NHL following autolo-
gous HSC transplantation. Effective purging of tumor cells may
improve the results of HSC transplantation, but current methods of
purging are technically difficult to perform with large numbers of cells
and do not consistently remove all detectable cells. We report a phase I
clinical trial in which 6 patients with relapsed B cell NHL received high
dose chemotherapy followed by infusion of autologous HSC depleted of
B cells using High-Density Microparticles coated with anti-CD19 and
anti-CD20 monoclonal antibodies in a manual system. HSC were mobi-
lized with cyclophosphamide and G-CSF. No B cells were detected by
immunocytochemistry in any of the 11 aphereses from the 6 patients
post-depletion at a sensitivity of less than 1 in 106, representing a medi-
an log depletion of B cells of greater than 2.0 (range greater than 2.0 to
greater than 2.3) logs. The median yield of non-target cells post–deple-
tion was as follows: CD34+ 80%; CD3+ 81%. All patients received high
dose cyclophosphamide, BCNU, and etoposide prior to reinfusion of
their B cell depleted autologous HSC. The median number of CD34+
cells cryopreserved was 3.61 (range 2.49 to 10.16) x 106/kg. Engraftment
post-transplant was rapid in all cases with a median day to achieve an
absolute neutrophil count of 500 per microliter of 10 (range 8 to 13).
The median day to achieve a platelet count of 20,000 per microliter
unsupported by platelet transfusions was 12. 5 (range 9 to 17). This non-
magnetic, negative depletion technology is simple, quick to perform,
effective in depleting target cells below the levels of detection, with
excellent yield of non-target cells, and it can be applied to the cell popu-
lations. Future clinical studies are in progress.
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IL-12 THERAPY FOLLOWING HIGH DOSE CHEMOTHERAPY WITH
STEM CELL RESCUE FOR METASTATIC BREAST CANCER
Avigan, D.E.1; Wu, Z.2; Joyce, R.1; Richardson, P.2; Elias, A.2; McDermott,
D .1; Levine, J.1; Gong, J.2; Kufe, D.2 1. Beth Israel Deaconess Med Ctr,
Boston, MA; 2. Dana Farber Cancer Institute, Boston, MA
In effort to augment cell mediated immunity post-transplant, we are
conducting a phase I study of the use of IL-12 in patients with metastatic
breast cancer who have undergone high dose chemotherapy. IL-12 was
administered as a SQ injection given TIW for 12 weeks. Successive
cohorts were treated at 30ng/kg, 100 ng/kg and 300 ng/kg. 10 patients
have been enrolled of which two patients withdrew prior to receiving
IL-12 due to patient preference and progressive disease, respectively.
The median follow up is 7 months post-transplant with a median inter-
val of 2 months between transplant and initiation of IL-12. One dose
limiting toxicity was observed at 300ng/kg in which a patient developed
grade IV neutropenia requiring the transient interruption of therapy. All
other patients demonstrated a mild depression in WBC and neutrophil
counts. No episodes of infection or sustained fevers occurred. 6/8
patients developed minimal elevations in liver transaminases without
clinical symptoms and one patient developed 3 fold elevation in transam-
inases associated with progression of disease after 9 weeks of IL-12 ther-
apy. The impact of IL-12 on T and B cell function is being assessed via
in vitro and in vivo studies. 5/6 patients demonstrated an increased
DTH response to candida antigen after 3 weeks of IL-12 therapy. 5/7
patients demonstrated an inversion of the CD4/CD8 ratio post-trans-
plant that was unaffected by the administration of IL-12. The impact of
IL-12 on NK cell mediated cytotoxicity was assessed. Mean lysis of the
K562 cell line by IL-2 stimulated PBMC was increased post-transplant,
transiently suppressed after 3 weeks of IL-12, and recovered to post-
transplant levels after 6-9 weeks of ongoing IL-12 therapy. The impact
of IL-12 therapy on mitogen induced T cell proliferation, serum
immunglobulin levels, and TH1/TH2 cytokine profiles are currently
being analyzed. 
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INTERLEUKIN-2 (IL-2) AND GRANULOCYTE-MACROPHAGE COLONY
STIMULATING FACTOR (GM-CSF) FOR POST AUTOLOGOUS STEM CELL
TRANSPLANT (ASCT) IMMUNE MODULATION
Bachier, C.; Lanzkron, S.; Hougham, M.; LeMaistre, C.F. Texas Transplant
Institute, San Antonio, TX
GM-CSF is synergistic with IL-2 in generating activated T-cells in-
vitro. Objectives are to determine safety and immune activation of IL-2
and GM-CSF after ASCT. At 4-8 weeks after ASCT patients (pts)
received 2 cycles of concurrent (GM-CSF days = 1-12,IL-2 days = 7 - 1 2 )
or sequential (IL-2 days = 1-6, GM-CSF days = 6-17) subcutaneous
GM-CSF at 250 µg / m2/day. A 1-week rest was allowed between cycles.
We have treated 12 pts (NHL = 5, multiple myeloma = 4, breast
c a n c e r = 3). Two pts had declines in their M-spike following IL-2/GM-
CSF. IL-2/GM-CSF toxicities intended: flu-like symptoms (Gr 2 = 6 ,
Gr 3 = 4) and gastrointestinal (Gr 2 = 6, Gr 3 = 1). Flow cytometric
analysis appears in the graph below. The graph values are fold increase
from day 1 of each cycle/*p<0.05 vs. day 1IL-2/GM-CSF given post
transplant is safe. IL-2/GM-CSF concurrently or sequentially increase
lymphocyte subsets when compared to either drug alone. IL-2/GM-
CSF could augment the activation obtained with the infusion of T-lym-
phocytes and dendritic cells.
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SIROLIMUS (RAPAMYCIN) FOR THE TREATMENT OF STEROID REFAC-
TORY ACUTE GRAFT-VERSUS-HOST DISEASE (GVHD)
Benito, A.I.1 , 3; Furlong, T.1; Anasetti, C.1; Appelbaum, F.1; Doney, K.1;
Maida, B.2; Martin, P.1; Milner, L.1; Nash, R.1; Storb, R.1 1. Fred Hutchin -
son Cancer Research Center, Seattle, WA; 2. Wyeth-Ayerst Research, Philadel -
phia, PA; 3. Instituto de Salud Carlos III, FIS, Spain
The safety, toxicity and efficacy of oral sirolimus as salvage therapy for
patients with acute GVHD failing first line therapy after allogeneic stem cell
transplantation was evaluated. Between 8/96 and 3/99, 21 patients (12 males, 9
females) 1-46 years of age were enrolled. Primary diagnoses included CML (8),
acute leukemia (7) and others (6). Conditioning therapy consisted of cyclophos-
phamide (CY) 120 mg/kg and fractionated TBI 12-14,4 Gy (n = 15), Cy 120
mg/kg plus busulfan (BU) 16 mg/kg (n = 3) or BU 7 mg/kg plus TBI 12 Gy
( n = 2). The donor was related in 6 (2 HLA identical and 4 HLA non-identical)
and unrelated in 15 patients and peripheral blood in 1. All the patients received
cyclosporine plus methotrexate for GVHD porphylaxis. Onset of acute GVHD
was 5-31 (median 12) days after transplant. GVHD grade II developed in 4
patients (19%), grade II in 15 (71%) and grade IV in 2 (9%). All patients failed
first line therapy with methylprednisolone (2 mg/kg/day). Sirolimus was given
as second line therapy starting 19-78 (median 38) days after transplant. The fir s t
4 patients received a loading dose (8 mg/m2) of oral sirolimus followed by f
m g / m2/day for 13 days. The next 17 patients received 5 (n = 7) or 4
( n = 1 0 ) m g / m2/day for 14 days without loading dose. Eleven patients completed
the 14 days course. Five patients were treated for 9-13 days and 5 for 1-6 days.
Reasons for early discontinuation of sirolimus were lack of improvement in
GVHD (4), myelospuppression (2), seizures (2), infection (1) and others (1).
The most common adverse effects were thrombocytopenia (12) and neutrope-
nia (6). Other side effects included increased triclyceride (n = 9) and cholesterol
( n = 6) serum levels. Eight patients had some evidence of hemolytic uremic syn-
drome, and 12 had infections. Among 16 patients who received 9 or more doses
of sirolimus, 13 responded (81%), 5 (31%) with a complete response and 8
(50%) with a partial response. Six of the 13 responders (46%) are currently alive
(270-780 days after transplant) and 4 have developed chronic GVHD. Seven of
the 13 responders (54%) and all 3 non-responders have died 16-171 days after
transplant from infection (5), multiorgan failure and GVHD (3) and other caus-
es (2). Four of the patients who received less than 9 days of treatment expired at
53-92 days after the transplant and one relasped at 10 months; he is currently in
complete remission, with chronic GVHD after donor lymphocyte infusion.
These data suggest that sirolimus is an effective immunosuppresive agent for
the treament of acute GVHD. Earlier administration during the course of acute
GVHD and longer maintenance at lower doses may reduce toxicity while
increasing the rate of response.
1 0
HELPER T-CELL RECONSTITUTION IN MUD BMT AFTER CONDITION-
ING WITH ATG
Baurmann, H.1; Baumann, P.1; Bräuninger, S.1; Krings, M.1; Georgi, A.1;
Prumbaum, M.1; Kreissig, C.1; Bonnefoy-Berard, N.2; Revillard, J.P.2; Schw -
erdtfeger, R.1 1. BMT-Center, Deutsche Klinik fuer Diagnostik, Wiesbaden,
Germany; 2. Institute of Immunology, Hopital E. Herriot, Lyon, France
We have shown that in adults after MUD BMT and ATG condition-
ing CD4+ T-cell reconstitution is slow and resembles that after T-cell
depleted BMT. To better understand T helper cell recovery in this set-
ting we determined absolute CD4+ T-cell counts and CD45 isomer
expression in 32 adult MUD BMT recipients after conditioning includ-
ing rabbit ATG. 
Seven patients were monitored once, 25 in biweekly intervals. 19
males and 13 females, median age 39 (16 - 57) years, received unmanipu-
lated BM for CMLcP (11), AML (11), ALL (6) and MDS (4) after stan-
dard conditioning including 4 x 2.5 mg/kg Thymoglobulin(R)
(IMTIX/SangStat) on days - 5 to -2. CD4, CD45RA and CD45RO
lymphocyte expression was determined by triple color FACS analysis
with a median observation time of 308 (77 - 1407) days. 
At day 100 a median of 78 CD4+ cells/ml were present with a slow but
steady increase over the next months. Values at the lower end of normal
were only reached during the third year after BMT. CD4+CD45RA+
cells started to increase after one year and peaked at a median of 184/ml
6 months later. The CD4+CD45RA/CD4+CD45RO ratio was below
normal (0.5) already before conditioning. It further decreased to 0
around month 8 and increased thereafter to a relative maximum of 1.1 at
15 months after BMT. 
CD4+ T-cell reconstitution is clearly impaired in adult recipients of
MUD BMT after in vivo T-cell depletion with rabbit ATG.
CD4+CD45RO+ cells predominate and start to increase around day
100, consistent with a first wave of peripheral T-cell expansion. A limit-
ed thymic rebound with release of naive CD4+CD45RA+ cells can be
detected at one year after BMT. Comparative analyses of sibling versus
MUD BMT with and without ATG are warranted to determine the
contribution of different factors to CD4+ T-cell reconstitution. 
1 2
RITUXAN IN VIVO PURGING PRIOR TO COLLECTION OF STEM CELLS
FOR AUTOLOGOUS TRANSPLANTATION IN CHRONIC LYMPHOCYTIC
LEUKEMIA (CLL)
Berkahn, L.C.1; Simpson, D.R.1; Raptis, A.1; Klunkel, L.2; Klingemann,
H . G .1 1. Rush Presbyterian S. Luke’s Medical Center, Chicago, IL; 2. Genen -
tech, Inc, San Franscisco, CA
Autologous transplantation for CLL is hampered by persistent bone
marrow involvement in the majority of cases. METHODS: We have
used Rituxan 375 mg/m2 as an in vivo purging step following cyclophos-
phamide 3 gm/m2 and G-CSF/ GM-CSF mobilization therapy for
patients with advanced stage CLL undergoing autologous stem cell
transplantation. All patients had 0-20% marrow involvement prior to
mobilization. A single pre-Rituxan leukapheresis product (LP) obtained
after the WBC reached 1000/µl served as a control and was not rein-
fused. Rituxan was administered the following day and subsequent leuka-
phereses were drawn 48 hours later to reach a total of 2 x 106 C D 3 4 +
cells/kg. Dual color flow cytometry CD5/CD19 and consensus PCR
using primers to the joining region and FR3 of the variable region of the
immunoglobulin heavy chain (IgH) were used to evaluate the degree of
contaminating CLL cells in the leukapheresis product and to monitor
disease status post transplant. RESULTS: Four of five patients mobi-
lized greater than 2 x 106 CD34+ cells/kg and were able to proceed to
CY/TBI with stem cell transplant. Comparing the pre and post-Rituxan
LP a reduction in the percentage of CD5/CD19 positive cells was seen
in 3 of 5 patients. All LP were PCR positive by PCR for the IgH
rearrangement. At day 100 follow-up 3 of 4 patients had a PCR nega-
tive, CD5/CD19 FACS negative bone marrow analysis. Both patients
evaluable at one year have no molecular evidence of disease. CONCLU-
SION: Rituxan was able to reduce the percentage of CLL cells in the
LP. Despite the infusion of a small percentage of PCR positive and
CD5/CD19 positive cells patients were able to obtain durable complete
molecular remissions. This implies that the PCR positive cells in the LP
may not have long term clonogenic potential. Further follow-up and
c o n firmation in larger numbers is required.
ASBMT: Poster Presentations
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PROPHYLACTIC ADMINISTRATION OF LIPOSOMAL AMPHOTERICIN
PREVENTS DEATH IN A MURINE MODEL OF INVASIVE ASPERGILLOSIS
FOLLOWING HEMATOPOIETIC CELL TRANSPLANTATION
BitMansour, A.A.; Weissman, I.L.; Brown, J.M. Stanford University School
of Medicine, Stanford, CA
Invasive fungal infections are currently the leading infectious cause of
mortality following allogeneic hematopoietic cell transplantation. 
Invasive infection due to Aspergillus spp. carries a mortality rate of near-
ly 100% despite appropriate antifungal therapy. Pharmacologic strategies
including Amphotericin B, inhaled or intravenous, or itraconazole have
not proven to be successful due to toxicities of therapy. Empiric therapy in
febrile neutropenia using liposomal ampohotericin and studies using low
doses of Amphotericin preparations suggest a trend toward decreased inci-
dence of fungal infection. Murine models of invasive aspergillosis have
relied upon chemotherapy-induced neutropenia or corticosteroids to ren-
der the mice susceptible to infection. We present a model of invasive
aspergillosis following lethal irradiation and transplantation of whole bone
marrow. 3-4 month old C57Bl/6 mice were stratified based on weight and
divided into three treatment groups as follows: (1) 5% dextrose in water
(D5W) throughout the study period; (2) liposomal amphotericin (AmBi-
some), 5 mg/kg, every other day starting 4 days prior to transplantation
(D0) then every day starting D+5; and (3) D5W from D-4 through D+2
then liposomal amphotericin, 5 mg/kg, every day from D+5. All treat-
ments were administered intravenously via the lateral tail veins. AmBi-
some or D5W was administered every other day starting on the fourth day
prior to transplantation (D-4). On the day of transplantation, the mice
received 950Gy in split doses followed by retro-orbital injection of 1x106
unfractionated whole bone marrow cells. On D+3, animals were each
challenged with 200 conidia of Aspergillus fumigatus injected via the lateral
tail vein. Appropriate uninfected controls of irradiation and transplanta-
tion were included. Early survival following transplantation is as follows: 
D5W only 0% 
AmBisome pre- and post-challenge 71.4% 
AmBisome post-challenge 10.0% 
Administration of liposomal amphotericin prior to an otherwise lethal
challenge with Aspergillus spp. increased early survival when compared
to placebo or therapy initiated after infection. 
1 6
PHASE I STUDY OF HIGH-DOSE RADIOIMMUNOTHERAPY WITH 90-Y-
HU-BRE-3 FOLLOWED BY AUTOLOGOUS HEMATOPOIETIC STEM CELL
SUPPORT (AHSCS) IN PATIENTS WITH REFRACTORY METASTATIC
BREAST CANCER
Cagnoni, P.J.1; Cook, B.1; Ceriani , R.L.2; Cole, W.C.1; Johnson, T.K.1;
Quaife, R.1; Shpall, E.J.1; Bearman, S.I.1; Nieto, Y.1; Jones, R.B.1 1. Univer -
sity of Colorado, Denver, CO; 2. Cancer Research Institute of Contra Costa,
Walnut Creek, CA
We have previously demonstrated the feasibility of using the murine
version of the monoclonal antibody BrE-3 for high-dose radioim-
munotherapy in patients with breast cancer (Ca Res 55:5921s, 1995). We
have now initiated a Phase I study of a single injection of 90-Y-labeled
MX-DTPA-humanized-BrE-3 followed by G-CSF-mobilized AHSCS
in patients with refractory metastatic breast cancer followed by systemic
G-CSF. 111-In-labeled hu-BrE was co-injected for imaging and
dosimetry purposes. To date, 15 patients have been treated in the fir s t
five cohorts. 8/15 had failed prior high-dose chemotherapy with
AHSCS. Patients received a dose of 90-Y of 10 mCi/m2 ( n = 3), 20
m C i / m2 ( n = 3), 33 mCi/m2, 50 mCi/m2 ( n = 3) or 70 mCi/m2 ( n = 3 )
followed 14 days later by AHSCS. No severe non-hematologic toxicities
were seen in any of the patients. One patient developed uncomplicated
febrile neutropenia and one additional patient had febrile neutropenia
requiring empiric antifungal therapy. Ten patients had a platelet nadir
below 20,000 and required a median of 4 platelet transfusions (1-10). To
date, all the patients recovered multi lineage hematopoiesis except for
one patient in the last cohort (day +28 after AHSCS). Known metastatic
lesions were detected in all patients imaged including: lung, bone, subcu-
taneous tissue, lymph nodes and liver. Mean half-life of 90-Y was 77.9 hs
(74.7-82.2). Responses were: 3 partial responses, 6 stable disease, 2 pro-
gressive disease, 2 clinical improvement (no measurable disease), 1 nor-
malization of tumor marker (no measurable disease), 1 too early to
determine. Detailed dosimetry will be presented. Dose escalation con-
tinues until the maximum tolerated dose is reached. 
Supported in part by grant 1RO3 CA77131-01 from the NCI (PJC)
and by Amgen. 
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DOCETAXEL AND FILGRASTIM PROVIDES A SAFE AND EFFECTIVE
MOBILIZATION REGIMEN PRIOR TO HIGH-DOSE CHEMOTHERAPY
FOR BREAST CANCER
Borges, V.F.1 , 2; Joyce, R.M.1 , 2; Uhl, L.1 , 2; Smith, T.1; Kennedy, L.E.1; Avigan,
D .1 , 2 1. Beth Israel Deaconess Medical Center, Boston, MA; 2. Harvard Med -
ical School, Boston, MA
Docetaxel (D) is a potent chemotherapeutic agent for the treatment of
breast cancer. Current regimens for stem cell mobilization often utilize
cyclophosphamide at 3gm/m2 (Cy) in combination with either fil g r a s t i m
(G-CSF) alone or with granulocyte-macrophage stimulating factor
(GM-CSF). This regimen requires mesna support, intravenous hydra-
tion and frequently an inpatient stay. We performed a sequential cohort
study of 79 patients with locally advanced or metastatic breast cancer
undergoing stem cell mobilization prior to high-dose chemotherapy.
Nineteen patients were treated on an outpatient regimen with D at
1 0 0 m g / m2 followed by G-CSF 5µg/kg/d sq days 1-7 and then
1 0µg/kg/d sq day 8 until completion of leukapheresis. Leukapheresis was
begun on day 8 and continued until goal CD34 count was obtained or
for 8 days. These patients were compared with 60 patients mobilized at
our institution on the two described Cy-based regimens used in prior
sequential studies. Endpoints of interest included the mean total CD34
cell/kg and the mean total CD34 cell/kg per circulatory volume (CV) as
a standardized measure of effort. The need for subsequent hospitiliza-
tion due to febrile neutropenia was monitored. The results presented in
the table below. 
The difference in rate of hospital admission between D and the Cy-
based regimens was statistically significant at p = 0.0021. Therefore,
Docetaxel in combination with G-CSF is an equally effective stem cell
mobilization regimen that avoids the need for an upfront inpatient stay,
reduces the rate of subsequent readmission, and permits the use of a
potent breast cancer drug during mobilization.
1 7
ETOPOSIDE, CYCLOPHOSPHAMIDE AND MELPHALAN (ECM): A
NOVEL HIGH DOSE THERAPY (HDT) REGIMEN FOR PEDIATRIC
PATIENTS WITH POOR PROGNOSIS SARCOMA
Calderwood, S.1; Brille, H.2; Rolland, M.2; Greenberg, M.2; Doyle, J.J.2;
Freedman, M.H.2; Lau, W.2; Saunders, E.F.2 1. The City Of Hope/ Good
Samaritan BMT Program, Phoenix, AZ; 2. The Hospital For Sick Children,
Toronto, ON, Canada
Purpose: To evaluate the efficacy and toxicity of a novel HDT regi-
men in pediatric patients with poor prognosis sarcoma. 
Methods: Patients with poor prognosis sarcoma, (mets. at presentation
n = 6, relapse or progression after front line therapy, n = 5) were treated
with Etoposide (800 mg/m2 infusion over 72 hours, day -5 to day -3),
Cyclophosphamide (60 mg/kg/dose, day -5 and day -4), and Melphalan
( 1 8 0 m g / m2, day -3) followed by autologous HSC rescue. 
Results: Between 03/28/96 and 08/31/98, 11 pts (median age 10.8
years, M: F = 7:4) with rhabdo (n = 4), undifferentiated sarcoma (n = 1 )
or Ewing sarcoma/PNET (n = 6) were treated with ECM. HSC source
was PB (n = 8), PB+BM (n = 2) or BM (n = 1). Grafts were CD34 select-
ed in 9 cases. Median CD34 cell dose was 1.7 x 106/kg (range 0.63 to
4.06). All pts. engrafted. ANC recovered to >0.5 x 109/l at a median of
13 days(range 10 to 18) and platelets recovered to >20 x 109/l at a medi-
an of 28 days (range 16-61). There were no treatment related deaths,
and no grade III or IV toxicity (CALGB transplant toxicity scale).
Anorexia (n = 11), mucocitis (n = 5), VOD of the liver (n = 1) hemor-
rhagic cystitis (n = 1) and renal tubulopathy (n = 1) were noted. Eight
pts. are alive in CR, 3 to 36 mos. post HDT. Three pts. died with pro-
gressive disease. 
Conclusion: These data suggest that this regimen is safe and may be
e f ficacious. Our next cohort of pts. will receive etoposide at a dose of
2400 mg/ m2 infused over 24 hrs. 
ASBMT: Poster Presentations 
R E G I M E N MEAN TOTAL CD34/KG MEAN TOTAL CD34/KG/CV HOSPITAL ADMISSIONS
D + G-CSF 8.59 x 106 2.12 x 106 1 of 19 pts
Cy/G-CSF 6.98 x 106 1.62 x 106 5 of 23 pts
Cy/G-CSF/GM-CSF 5.98 x 106 1.46 x 106 18 of 37 pts
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PEDIATRIC ALLOGENEIC TRANSPLANTATION USING RELATED, HLA
NON-IDENTICAL DONORS
Calderwood, S.2; Rolland, M.1; Doyle, J.J.1; Lau, W.1; Saunders, E.F.1; Freed -
man, M.H.1 1. The Hospital for Sick Children, Toronto, ON, Canada; 2. City
of Hope/ Good Samaritian BMT Program, Phoenix, AZ
Purpose: To evaluate the role of allogeneic bone marrow transplanta-
tion from HLA non-identical related donors in the management of
patients with high-risk leukemia, immunodeficiency or marrow failure
syndromes, for whom no matched related or unrelated donor can be
found. 
Patient Characteristics: Between 11/16/95 and 03/12/98, 16 patients
(median age 6.5 years, range 1 to 13 years, M:F = 12:4) with acute
leukemia (n = 12), SCID (n = 2), SAA (n = 1) or thalassemia major (n = 1 )
underwent allogeneic transplantation with stem cells obtained from
HLA mismatched relatives. 
Methods: Donors were parents (n = 12), a grandparent (n = 1), a
cousin (n = 1) and siblings (n = 2). Standard serological and molecular
methods were used to type HLA A, B and DR antigens. Eight donors
were mismatched at one HLA locus, and 4 were mismatched at 2 or
more loci. Stem cell source was peripheral blood (n = 7), bone marrow
( n = 8), or cord blood (n = 1). Grafts were CD34 selected as a de facto T-
cell depletion in five patients. Conditioning for transplant was BU/CY
( n = 6), CY/TBI (n = 5), VP 16/CY/TBI (n = 2) or VP 16/TBI (n = 3 ) .
All 16 patients received Cyclosporin and Methotrexate as GVHD pro-
phylaxis, and 4 patients received ATG as well. 
Results: Thirteen (81%) pts have stable engraftment. One pt experi-
enced primary graft failure and a 2 pts had late graft failure. Eight (50%)
pts experienced aGVHD (grade I = 1, II = 3, III = 3, IV = 1). One hun-
dred day mortality rate was 0%, and overall survival as of last follow up is
74 +/- 13%. 
Conclusions: Data from this pilot study support the further evaluation
of allogeneic transplantation using mismatched family members as stem
cell donors. 
2 0
RAPID ENGRAFTMENT AFTER ALLOGENEIC TRANSPLANTATION OF
DENSITY ENRICHED PERIPHERAL BLOOD CD34+ CELLS IN PATIENTS
WITH ADVANCED HEMATOLOGICAL MALIGNANCIES
Cao, T.M.1; Kusnierz-Glaz, C.1; Valone, F.2; Stockerl-Goldstein, K.1; Hu,
W . W .1; Johnston, L.J.1; Blume, K.G.1; Negrin, R.S.1 1. Stanford University,
Stanford, CA; 2. Activated Cell Therapy, Mountain View, CA
Preclinical studies have suggested that a T cell subset with a
CD4/CD8-double negative phenotype, termed a natural suppressor
(NS) cell, is capable of suppressing GVHD and can be mobilized into
the peripheral blood with G-CSF , then enriched by density fractiona-
tion. The current study was performed to investigate the feasibility of
applying a density gradient separation technique for enrichment of
CD34+ and NS cells from peripheral blood progenitor cells (PBPCs) for
allogeneic transplantation. Twenty-five patients with advanced hemato-
logical malignancies were treated with FTBI (1200 cGy), etoposide (60
mg/kg), and cyclophosphamide (60 mg/kg). PBPCs were harvested by
apheresis from HLA-identical sibling donors following mobilization
with G-CSF, then applied to a single-step density gradient and the low
density cell population collected following centrifugation. The low den-
sity cell population was infused as the sole source of allogeneic cells fol-
lowing myeloablative therapy. GVHD prophylaxis consisted of
cyclosporine with or without prednisone. CD34 enrichment was effi-
cient with a median CD34+ cell dose of 6.5 x 106/kg (range, 1.0 – 13.9 x
1 06/kg). Conventional CD3+CD4+ or CD3+CD8+ T cells were deplet-
ed by 94.4% (range, 58.8% to 99.2%). Enrichment for T cells with a NS
phenotype was observed but was disparate between donors, and was
achieved for 48% of donor-patient pairs. There were no occurrences of
graft failure in evaluable patients. Median time to ANC > 0.5 x 109/ L
and platelet count > 20 x 109/L was 10.5 and 12 days, respectively. The
incidence of Grade II-IV acute GVHD was 24%. This analysis suggests:
(1) T cell subset manipulaton via density gradient separation is a safe
procedure and allowed rapid hematopoietic recovery; (2) Selective
enrichment of a donor T cell subset with putative GVHD suppressing
activity by this method, however, was not associated with a reduced inci-
dence of acute GVHD in this group of patients. 
1 9
STORAGE OF BLOOD FOR IN VITRO GENERATION OF DENDRITIC
C E L L S
Callaghan, D.H.; Syme, R.M.; Bitner, S.; Wolff, J.E.; Gluck, S. University of
Calgary, Calgary, AB, Canada
Dendritic cells (DC) are professional antigen presenting cells which
can elicit potent antigen specific responses. In vitro cultivation of these
cells from peripheral blood mononuclear cells (PBMC), is of great
importance in the development of immunotherapy strategies against a
variety of diseases including malignancies. Sometimes, timing from
obtaining the sample to processing can be delayed. Therefore, we inves-
tigated the yield and feasibility of culturing DC from peripheral blood of
healthy volunteers. We processed blood either immediately, or after 24
hours storage at either room temperature or 4°C. Once the sample is
received, the white cells were isolated by centrifugation on a Ficoll-
hypaque density gradient. PBMC were resuspended in RPMI and cul-
tured in a flask. Two hours later nonadherent cells were removed and
the remaining adherent cells cultured for 7 days with RPMI and
cytokines (IL-4 and GM-CSF), that encourage DC growth. The cells
are then harvested, counted, and characterized using flow cytometry.
Samples left overnight at room temperature yielded results indistin-
guishable from those of the sample processed fresh. The layers of the
different cells were easily distinguishable after the Ficoll spin and the
PBMC were easily harvested. When these PBMC were cultured with
cytokines, they yielded DC, as determined by flow cytometry and light
microscopy. The samples that were refrigerated overnight; separated
poorly after the Ficoll spin and the PBMC were difficult to harvest. The
maturation into the desired DC showed a nearly 10 fold reduction in
MHC II expression. From our data we conclude that if storage is neces-
sary prior to processing blood for in vitro generation of DC, the samples
should not be stored at 4°C but at room temperature (~20°C).
2 1
HIGH DOSE CHEMOTHERAPY AND AUTOLOGOUS TRANSPLANTATION
FOR FOLLICULAR LYMPHOMA: A REPORT FROM THE STANFORD
E X P E R I E N C E
Cao, T.M.; Negrin, R.S.; Hu, W.W.; Johnston, L.J.; Horning, S.J.; Blume,
K.G.; Stockerl-Goldstein, K. Stanford University, Stanford, CA
A review was performed to investigate high dose chemotherapy
(HDC) and autologous transplantation in patients with follicular lym-
phomas. Seventy-five patients with relapsed follicular low grade lym-
phoma (FLGL) and high risk follicular large cell lymphoma (FLCL)
were treated with etoposide (60 mg/kg), cyclophosphamide (100 mg/kg),
and either BCNU (15 mg/kg) or fractionated total body irradiation
(FTBI) 1200 cGy, followed by purged autologous bone marrow or
peripheral blood progenitor cell transplantation. A review of the clinical
data from these patients was performed for analysis using Cox propor-
tional hazards regression. For the 49 patients with FLGL, the median
age was 49 (range; 32-59) and 67% had stage IV disease at initial presen-
tation. The 4 year estimate of overall survival (OS) is 60% (95% CI, 45-
75%) and progression-free survival (PFS) is 44% (95% CI, 29-59%).
S i g n i ficant prognostic factors for OS by univariate analysis were pre-
HDC exposure to < 3 chemotherapy regimens (p = 0.003) and treatment
with the FTBI-containing HDC regimen (p = 0.04). Both factors main-
tained significance by multivariate analysis. For the 26 FLCL patients,
the median age was 51 (range; 32-66) and in 31% the indication for
HDC was primary induction failure. The 4 year estimate of OS is 58%
(95% CI, 37-79%) and PFS is 51% (95% CI, 30-72%). Composite his-
tology (follicular and diffuse large cell) was significantly associated with
poorer OS (p = 0.02). This analysis suggests: (1) Relapsed FLGL
patients more heavily pre-treated with ≥ 3 different chemotherapy regi-
mens may not benefit from HDC, and the HDC regimen containing
FTBI appears to be superior to the BCNU-based regimen in this cohort
of patients; (2) High risk FLCL without a composite histology can
achieve OS and DFS rates comparable to those widely observed with the
more common large cell lymphomas having exclusively diffuse involve-
ment. 
ASBMT: Poster Presentations
STORAGE METHOD FICOLL SEPARATION YIELD OF DC X106 MHC II EXPRESSION (%)
0 good 8.6 (2.8-14.8) 83.9 (69.7-95.7)
24h/20oC good 11.5 (7.0-18.6) 78.2 (69.5-90.2)
24h/4oC poor 4.9 (3.2-7.4) 20.5 (8.2-32.8)
24h/4oC -> 20oC poor 6.8 (3.0-9.3) 19.7 (15.0-24.5)
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PULMONARY TOXICITY SYNDROME IN BREAST CANCER PATIENTS
UNDERGOING A BCNU-CONTAINING HIGH DOSE CHEMOTHERAPY
REGIMEN WITH AUTOGRAFTING
Cao, T.M.; Negrin, R.S.; Stockerl-Goldstein, K.; Johnston, L.J.; Shizuru,
J.A.; Taylor, T.L.; Wong, R.M.; Blume, K.G.; Hu, W.W. Stanford Universi -
ty, Stanford, CA
The syndrome of non-infectious diffuse lung injury following high
dose chemotherapy (HDC) and autologous transplantation for breast
cancer, referred to as the pulmonary toxicity syndrome (PTS), has been
associated with a remarkably high incidence but has been previously
described primarily in series limited by small patient number. A retro-
spective review was performed to investigate PTS in a cohort of 152
patients with stage II, III, or metastatic breast cancer uniformly treated
with cyclophosphamide 5625 mg/m2, cisplatin 165 mg/m2, and BCNU
600 mg/m2, followed by autologous blood progenitor cell transplanta-
tion. During followup, PTS was diagnosed when the following criteria
were met: (1) an absolute DLCO decline ≥ 10%, and (2) no clinical evi-
dence of an active pulmonary infection. With a median followup of 29
months, the incidence of PTS was 59%, with a median onset at 45 days
(range, 21 – 149 days) post-HDC. Ninety-one percent of PTS patients
treated with oral prednisone therapy for a median of 105.5 days (range,
44 – 300 days) achieved resolution of their PTS without sequelae. For
stage II/III patients who developed PTS the overall survival (OS) at 3
years is 84% (CI, 73% – 95%), and for metastatic breast cancer patients
with PTS the OS is 58% (CI, 38% – 78%). These values are not signifi-
cantly different when compared with the OS for the patients who did
not develop PTS, which are 91% (CI, 81% - 100%) and 53% (CI, 32 –
74%), respectively. This analysis suggests: (1) The incidence of PTS for
breast cancer patients treated with a BCNU-containing HDC regimen
can be remarkably high; (2) Treatment with a course of cortisteroid
therapy is effective in the vast majority; (3) Success with therapy for
patients with PTS is reflected by a comparable OS when compared with
patients who did not develop PTS. 
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GRANULOCYTE COLONY-STIMULATING FACTOR (G-CSF) MOBILIZA-
TION: WHAT HAPPENS IN THE BONE MARROW COMPARTMENT?
Chiang, K.; Lamb, L.; Worthington-White, D.; Rich, I.; Henslee-Downey,
P.J. Palmetto Richland Memorial Hospital, South Carolina Cancer Center,
Columbia, SC
The clinical use of G-CSF has recently been expanded to include
mobilization of stem cells for both autologous and allogeneic transplan-
tation (SCT). Most of the published studies have focused on stem cells
released into the peripheral blood (PB) after G-CSF stimulation. How-
ever, little is known about the effects of G-CSF on BM and the mecha-
nisms involved in stem cell mobilization. The aim of this work was to
evaluate the concurrent effects in normal individuals of G-CSF on BM
and PB stem and progenitor cells, sub-populations, and their cytokine
p r o files. Volunteers received 5 or 10 mcg/kg of G-CSF for 5 consecutive
days (day 1 to day 5). On days 0, 3, 6, 9, and 15, both BM and PB were
examined. Total nucleated cells and the absolute numbers of CD34+ per
ml in both BM and PB showed a similar response pattern with a peak
around day 6. This was followed by a return to baseline levels by day 15.
However, there was a reciprocal change in the proportion of CD34+
cells such that on day 6, CD34+ cells in PB were at a maximum, but at a
minimum in BM. Long-term culture initiating cell (LTC-IC) in the PB
peaked at day 6, while the numbers in BM were consistently higher than
those in PB did and showed an upward trend towards day 15. Cytokine
p r o file measured intracellularly by flow cytometry and in the plasma
ELISA showed an increase in interleukin-2, 4 levels in G-CSF-stimulat-
ed BM. The parallel characterization of stem cell function in both PB
and BM may prove crucial in understanding how stem cells become
mobilized. A further clinical examination at engraftment, graft-versus-
host disease and immune reconstitution using G-CSF-mobilized BM
may thereby provide an alternative stem cell source and improve the
outcomes of SCT.
2 4
MYELOABLATIVE CHEMOTHERAPY FOR ALLOGENEIC TRANSPLANTA-
TION WITH A FLUDARABINE/BUSULFAN PROTOCOL (FLUBUP): COM-
PARISON WITH BUCY
Chaudhry, M.A.; Duggan, P.; Brown, C.B.; Stewart, D.; Ruether, J.D.;
Gluck, S.; Morris , D.; Russell, J.A. Alberta BMT Program, Calgary, AB,
C a n a d a
We have assessed the early toxicity of fludarabine(FLU) 50mg/m2 o n
days -6 to -2 plus busulfan (BU) on days -5 to -2 inclusive (FLUBUP).
Forty-six adults were treated, 23 received BU 1mg/kg po qid. Intra-
venous BU (Busulfex, Orphan Medical) was given at 0.8 mg/kg qid to 2
pts and at 3.2 mg/kg daily to the remaining 21. Early outcomes were
compared with a retrospective group of 50 adult patients (pts) given
BUCY (BU) 1mg/kg po x 16 doses, cyclophosphamide (CY) 60mg/kg x
2. FLUBUP and BUCY groups respectively included comparable num-
bers of pts with high risk malignancy (66% vs. 64%), unrelated (UD) or
genotypically mismatched related donors (MMRD) (36% vs 28%) and
stem cell source (blood cells 63% vs 46%). All pts received acute GVHD
prophylaxis with cyclosporin A plus “short” methotrexate and folinic
acid. All UD and MMRD recipients plus 22 matched related recipients
in the FLUBUP group also received antithymocyte globulin (ATG,
Thymoglobulin) 4.5mg/kg over 3 days pretransplant. 
There were no significant differences in hepatic toxicity or stomatitis
between regimens. The incidence of hemorrhagic cystitis was similar
(FLUBUP 13%, BUCY 22%, p = 0.3). There were three cases of initial
graft failure (2 FLUBUP, 1 BUCY), all in UD BMT recipients. One
non-relapse death occurred before day 100 in the FLUBUP pts, from
aGVHD. In the BUCY group 6 early deaths were related to aGVHD
and one to graft failure. Actuarial 100 day transplant-related mortality
(TRM) was 3% for FLUBUP vs 15% for BUCY (p = 0.049). 
We conclude that FLUBUP is as well tolerated in the short term but
notably accompanied by cystitis. No early deaths were due to regimen
related toxicity in either group and the difference in early TRM may be
related to the use of ATG. More complete evaluation of this regimen
requires longer followup. 
2 6
ECONOMIC ANALYSIS OF PROVIDING HEMATOPOIETIC STEM CELL
TRANSPLANT [HSCT]SERVICES IN AN INTEGRATED PROGRAM
Cloud, R.S.1; Bachier, C.R.1; Grimert, T.R.2; Donnell, M.C.3; LeMaistre, C.F.1 1 .
Texas Transplant Institute, San Antonio, TX; 2. Southwest Texas Methodist Hospi -
tal, San Antonio, TX; 3. Nexell Therapeutics, Inc., Irvine, CA
Little data is available to guide HSCT programs in evaluating relative
costs by transplant type. Multiple providers, multiple points of service
and a variety of methodologies used in evaluating or estimating cost
complicate analysis of such data. In order to better ascertain costs of dif-
ferent types of HSCT and to provide more efficient patient care, we
integrated the continuum of transplant care [inpatient, outpatient, tech-
nical and professional] into a single business unit. This study compared
costs for adult and pediatric patients [pts] receiving autologous [auto]
and allogeneic [allo] HSCT. All transplant-related costs from the pts ini-
tial evaluation through day 100 were evaluated. Cost drivers include
transplant type, degree of match and adult or pediatric age group. The
accounts of 80 pts treated at Texas Transplant Institute between 1997
and 1999 on global contracts were reviewed for the following informa-
tion: distribution by payor and transplant type and both charges and
costs per case for the identified time frame. Average charges per case
were developed for physician and non-physician transplant care [NPTC]
providers. NPTC includes, but is not limited to, inpatient, outpatient,
pharmacy, lab and radiology. Average cost per case was developed for
NPTC services [direct and indirect] and physician services [direct]. We
have modeled this data to review relative costs and profitability by both
transplant type and payor, specific to our program. In the table below,
autologous HSCT are considered 1.0 and relative ratio of charges is cal-
culated for each category. In conclusion, we have developed a compre-
hensive database that is useful in estimating relative contractual risk by
type of transplant as well as in support of program planning. Programs
contracting for allo transplant must allow for utilization of signific a n t l y
more physician and NPTC resources. 
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TRANSPLANT PHYSICIAN N P T C CONSULTING PHYSICIAN
[ A V G / M E D I A N ] [ A V G / M E D I A N ] [ A V G / M E D I A N ]
Adult Auto 1.0/1.0 1.0/1.0 1.0/1.0
Adult Allo 1.3/1.3 2.3/1.6 1.7/2.0
Adult MUD 1.3/1.3 3.2/3.3 2.4/3.6
Pedi Auto 1.4/1.3 1.5/1.2 0.6/0.9
Pedi Allo 2.4/2.2 2.8/3.2 0.7/0.9
Pedi MUD 3.7/3.5 4.0/3.3 0.6/0.9
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TAXANES TREATMENT OF RELAPSED BREAST CANCER AFTER HIGH-
DOSE CHEMOTHERAPY (HDC) AND AUTOLOGOUS PBPC TRANSPLAN-
T A T I O N
Constenla, M.; Lorenzo, I.; Carrete, N.; Campos, B.; GarcÌa-Arroyo, F.; Rey,
C.; Palacios, P. Hospital Montecelo, Pontevedra, Spain
In the last years a number of patients with advanced breast cancer
(ABC) in remission or with high risk of relapse after primary therapy
were included in programs of HDC with PBPC support. The treatment
of the relapsed patients after this procedure remains controversial.
Recently the Taxanes appear as the most active drugs in ABC. Since 1-
1994 to 10-1999 we studied 78 BC patients, 64 adjuvant (A) and 14
metastatic (M) treated with with high-dose Carboplatin (800mg/m2) ,
Mitoxantrone (30 mg/m2) & Thiotepa (600 mg/m2) for 70p and CTcB
in 8 p. With a median follow-up of 21 m(1-55), 23p relapsed: 15/64 A
and 8/14 M. Chemotherapy prior to the HDC for all the A p was CAF x
4-6 courses and for the M: 2p had received 3 regimens, 3p 2 and 3p only
one; 3p with double transplant and previous taxanes in 3p.Radiotherapy
in 12p. Treatment: Paclitaxel in 7p and Docetaxel 18p (2p with previous
Paclitaxel) both with G-CSF. Number of cycles 148 mean 6.4(2-21)
Patients (n = 23) Characteristics: Sites of relapse: bone 7p; liver 9p; lung
5p; thoracic wall 3p; supraclavicular nodes 3p; other 2p. P.S.(ECOG)
1:16p; 2:5p; MainToxicity (WHO): RBC: G3:1p; Neutrophils
G3:1p;G4:1p. Platelets G4: 2p. Venous G4:2p. Asthenia G2 4p. Alope-
cia G3 all p. Fluid retention G2: 2p. Hepatic G1-2: 3p. No toxic deaths.
Responses: OR: 9/23 (39%) as CR: 1p (thoracic wall 10m); PR: 8p
(34%) lasting >6m 3p; SD 5p >6m (7-20); PD: 8p. Median survival: 21m
(3-32); 95%CI:13-29. Conclusions: Postransplant treatment with tax-
anes is feasible with manageable toxicity and clinical benefit (61%). Fur-
ther strategy of salvage therapy deserve evaluation in clinical trials.
2 9
DOSE ESCALATION OF ETOPOSIDE USED WITH CYCLOPHOSPHAMIDE
AND TBI AS PRE-TRANSPLANT CONDITIONING FOR PEDIATRIC
PATIENTS WITH HEMATOLOGIC MALIGNANCIES
De Santes, K.B.1; Vanichsetakul, P.2; Matthay, K.K.3; Mentzer, W.C.3;
Luna-Fineman, S.4; Cowan, M.J.3 1. University of Wisconsin, Madison, WI;
2. Chulalongkora University, Bangkok, Thailand; 3. University of California,
San Francisco, CA; 4. National Pediatric Oncology Unit, Guatemala City,
G u a t e m a l a
Etoposide is a topoisomerase II inhibitor, commonly used in conjunc-
tion with TBI, as part of the pre-transplant conditioning regimen for
patients with hematologic malignancies. Little data are available regard-
ing the maximum tolerated dose (MTD) of etoposide, when used in this
fashion, for pediatric oncology patients. Children undergoing BMT were
treated with escalating doses of etoposide , in conjunction with
cyclophosphamide (60 mg/kg x 2 days) and TBI (1200 cGy in 6 divided
fractions). Etoposide was administered as a continuous infusion over 48
hours at a starting dose of 1200 mg/m2. The dose was escalated by 300
m g / m2, once at least 3 patients were safely treated at a given dose level.
Of the 32 patients enrolled in this study (median age 7.5 yrs),19 had
ALL,4 AML, 3 CML, 3 NHL, 2 JMML and 1 MDS. Marrow donors
were matched unrelated (13 ), matched siblings (9), 5/6 matched unrelat-
ed (5), 5/6 matched related (3), and autologous (2). Toxicity was graded
according to criteria described by Bearman, et al. One patient developed
grade III CNS toxicity at the 1200 mg/m2 dose level. No further grade
III or IV toxicity was seen until the dose was escalated to 2100 mg/m2,
where 1 of 6 patients developed grade IV (fatal) hepatic toxicity. Fifteen
patients were treated at the 2400 mg/m2 dose level, and all developed
severe grade II stomatitis. One child died of toxic epidermal necrolysis 16
days after BMT, and 1 developed fatal ARDS, of unknown etiology, 3
months post-transplant. Toxicity at this dose level was significant, though
acceptable. Further dose escalation was not undertaken. Eleven of the 32
children are surviving with a median follow up of 51 months. The MTD
of 2400 mg/m2 is higher than has previously been reported for etoposide,
when used in combination with cyclophosphamide and TBI. 
2 8
HIGH DOSE CHEMOTHERAPY AND STEM CELL TRANSPLANT IN
BREAST CANCER: A RANDOMIZED MULTICENTER STUDY OF CD34
SELECTION 
Cornetta, K.1; Yanovich, S.2; Rosenfeld, C.3; Chabannon, C.4; Burtness, B.5; Lotz,
J . P .6; Maziarz, R.7; Williams, S.8; Somlo, G.9; Mills, B.1 0 1. Indiana Univ
Medical Center, Indianapolis, IN; 2. Virginia Commonwealth Univ North Hos -
pital, Richmond, VA; 3. Columbia Hospital at Medical City Dallas, Dallas, TX;
4. Institute Paoli-Calmette, Marseille, France; 5. Yale New Haven Hospital,
New Haven, CT; 6. Hopital Tenon, Paris, France; 7. Oregon Health Sciences
Univ, Portland, OR; 8. Univ Chicago Medical Center, Chicago, IL; 9. City of
Hope Nat’l Medical Ctr, Duarte, CA; 10. Nexell Therapeutics Inc., Irvine, CA
From 1994 through 1997, a total of 255 breast cancer patients were
enrolled at 11 sites on a randomized study to evaluate recovery from
high dose chemotherapy following autologous transplant with CD34
selected or unselected mobilized PBSC. Approximately 80% of enrolled
patients met eligibility criteria, including successful mobilization
(>20CD34 cells/µL PB). Primary endpoints were to assess effects of
CD34 positive selection (Isolex® 300/300i) on engraftment and toxicity.
Fifty patients were discontinued prior to randomization primarily due to
mobilization failure. 107 patients were randomized to receive selected
CD34 cells and 98 to receive unselected PBSC (median dose 3.5 and 4.9
x 106 CD34 cells/kg, respectively). Median time to ANC>500 was 10
days for both test and control groups. Median time to platelets >2 0 , 0 0 0
(10 days for control group and 12 days for test) was significantly differ-
ent (p = 0.002), though there was no significant difference in number of
platelet transfusions. There were no significant differences in frequen-
cy/severity of adverse events, number of infections or days of antibiotic
use. Kaplan-Meier estimates of time to relapse and death are 593 days
and 865 days for the control group, and 710 days and NR (not reached)
for the test group. K-M estimates of median time to relapse for a subset
of patients with Stage II/IIIA disease are 807 days for the control group
( n = 33) and NR for the test group (n = 39), p = 0.04. K-M estimates of
median time to relapse for patients with Stage IIIB/IV disease were 398
days for the control group (n = 65) and 396 days for the test group
( n = 65), p = 0.65. These preliminary analyses suggest that patients trans-
planted during earlier stages of disease may benefit from receiving
CD34-enriched transplant products.
3 0
TRANSPLANTATION OF HAPLOIDENTICAL HEMATOPOIETIC STEM CELLS
IN PATIENTS WITH ADVANCED HEMATOLOGICAL MALIGNANCIES
Devine, S.M.; Stock, W.; Wickrema, A.; Jessop, E.; Thomason, D.; Peace, D.;
Chung, T.; Sosman, J.A.; Sher, D.; van Besien, K. University of Illinois at
Chicago, Chicago, IL
We studied nine patients with advanced hematological malignancies
who lacked a suitably matched related or unrelated donor but instead
received either a 2 or 3 antigen (Ag) mismatched (MM) hematopoietic
stem cell (HSC) graft from a relative. Conditioning consisted of flu d a r a-
bine, thiotepa, total body irradiation (TBI), and antithymocyte globulin
(ATG) (N = 5) or a non-TBI containing regimen of fludarabine, mel-
phalan,and ATG(N = 4).The median recipient age was 39 yrs (range 12-
57). Diagnoses included refractory ALL (2), refractory/relapsed AML
(4), secondary AML (1), CML in blast crisis (1), and refractory
Hodgkins disease (1). The donors were MM for 2Ag (3) or 3Ag (6) and
were a median age of 21 yrs (range 14-45). Donors were mobilized with
G-CSF at 8µg/kg/12hrs and leukapheresed on day 4. All grafts were
CD34 selected using the Isolex 300i® device. The median CD34+ cell
yield after positive selection was 35% (range 10-62%). The median
CD34+ cell dose transplanted was 10.1 x 106/kg (range 6.1-15.7). The
median CD3+ cell depletion was 3.5 logs. Seven of eight evaluable pts
engrafted with a median time to ANC>5 0 0 /µl of 12 days (range 10-18)
and platelets >2 0 , 0 0 0 /µl of 18 days (range 13-40). All seven pts evaluable
for response achieved complete remission. Chimerism studies have
revealed 100% donor cells at all times points post transplant except just
prior to relapse. Only one patient experienced grade II-IV acute GVHD
and none chronic GVHD.The 100 day mortality was 55%. Eight pts
died of graft failure (1), relapse (3), or toxicity and infection (4) between
9 and 188 days post transplant. One patient survives in remission at day
+101. Our results indicate that engraftment can be achieved and GVHD
prevented in most pts with advanced disease who receive a haploidentical
HSC graft.In addition, a non TBI-containing regimen appears effective
at promoting engraftment despite significant immunological barriers.
Improvements in outcome will likely result from transplantation of pts
in earlier stages of disease and from interventions designed to enhance
immune recovery and prevent relapse. 
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CORRELATION BETWEEN MICROMETASTASES IN MARROW AND
PERIPHERAL STEM CELLS OF BREAST CANCER PATIENTS AND THE
EFFECTS OF STORAGE ON TUMOR CONTENT IN THE APHERESIS
P R O D U C T S
Dicke, K.A.; Livingston, D.L.; Fulbright, L.K.; Blumenschein, G.R. Arlington
Cancer Center, Arlington, TX
Between January 1996 and June 1999, 120 Stage III/IV breast cancer
patients (pts) were mobilized using chemotherapy and growth factors.
Marrow involvement was determined using immunofluorescent staining
for cytokeratin with evaluation of 4.2x106 cells (105- 1 . 7 x 1 07). Of the 99
pts with negative aspirates, 93% had negative PSCC. Of the 21 pts with
positive aspirates, median tumor frequency of 1/1.3x106 c e l l s
( 1 / 7 . 7 x 1 02– 1 / 1 x 1 07), 76% also had contaminated PSCC. The median
number of total tumor cells in the PSCC was 5.3x104 ( 5 . 3 x 1 03– 1 . 9 x 1 05) .
Micrometastatic breast cancer in the marrow is predictive for tumor
contamination of PSCC. 3/5 pts with positive marrows and negative
harvests, were mobilized with 3gm/m2 cyclophosphamide. Storage
overnight did not impact CD34+ progenitor content of PSCC (215 vs.
2 0 6 x 1 06 cells p = 0.91)however, there was a reduction in the total num-
ber of cytokeratin+ cells. Thirty PSCC from 23 pts had detectable tumor
cells the day of harvest. After storage, 23/30 PSCC went from a median
of 5.3x104 total tumor cells in the harvest to no detectable tumor cells
(>4 log reduction). A median of 1.2x108 nucleated cells was examined in
the repeat analysis. PSCC with detectable tumor cells after storage
exhibited a decrease from a median of 7.4x104 total tumor cells on the
day of harvest to 2x103 total tumor cells the next day (1.8 log reduction).
The ability to measure micrometastases has demonstrated that cytoker-
atin negative stem cell harvests can be achieved when the patient’s mar-
row is negative, intensive chemotherapy is used for mobilization and
cells are stored overnight prior to freezing to reduce minimal residual
tumor cells by 1.8-4 logs. 
3 3
IMPROVEMENT IN HEMATOLOGICAL PARAMETERS WITH LOW LEVEL
OF CHIMERISM IN B-THALASSEMIC MICE TRANSPLANTED IN UTERO
Donahue, J.1; Kuypers, F.2; Witkowska, E.2; Carrier, E.1 1. University of Cal -
ifornia San Diego, Departments of Medicine and Pediatrics, La Jolla, CA; 2.
Children’s Hospital Oakland Research Institute, Oakland, CA
B-Thalassemia is one of the most common genetic disorders in
humans, afflicting over 50,000 children annually. Allogeneic stem cell
transplant is a viable alternative but is associated with significant mortali-
ty and morbidity. 
We have developed a murine model of in utero transplantation in B-
thalassemic mice to study chimerism, tolerance, and hematological para-
meters. Survival of homozygous fetuses receiving allogeneic fetal liver cells
improved by 40% as compared to controls. Low-level mixed chimerism
was associated with improvement in hematological parameters. The per-
cent of reticulocytes in peripheral blood was decreased by a mean of
52.8% (p = 0.04), and ektacytometry (osmotic fragility) shift toward nor-
mal was observed in 30% of the transplanted animals. Mass spectrometry
detected up to 5% of donor a and b globin in transplanted mice. Hemo-
globin levels improved with postnatal SCF/GCSF/EPO injection as com-
pared to control mice (11.58±4.03 transplanted, and 9.92±0.39 controls,
p = 0.13). Chimerism was tested by FACS analysis over the lifespan of the
animals. Donor cells were detected in CD45 and Ter 119 populations
(0.01-1.6%). The percent of donor cells significantly increased following
postnatal boosts with donor cells(0.3-6%). The highest increase was
observed in the erythroid cell population (0-5.5%). In MLC, the response
of control mice to donor cells increased 30-40% (as compared to pre-
boost response), while the response of transplanted animals did not
change,suggesting tolerance. Cytotoxicity demonstrated higher responses
to donor cells in control mice as compared to in utero transplanted ani-
mals (at 50:1 effector to target ratios, transplanted animals showed 8.66%
target lysis, and controls showed 51.85% target lysis, p = 0.0003). 
This experiment demonstrates that low levels of donor chimerism is
s u f ficient for improvement in hematological parameters in tolerant mice.
The level of chimerism increases with postnatal cytokine and boosts. This
may allow development of successful non-myeloablative transplant regi-
mens in B-Thalassemic patients in the future using prenatal approach. 
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HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM CELL RESCUE
FOR PATIENTS WITH METASTATIC BREAST CANCER: SINGLE INSTITU-
TION, RETROSPECTIVE COMPARISON OF SURVIVAL FOR TANDEM VS
SINGLE TRANSPLANTS
Dillman, R.O.; Barth, N.M.; VanderMolen, L.A.; Nayak, S.K.; Beutel, L.D.;
Chico, S. Hoag Cancer Center, Newport Beach, CA
During 1990-1998, 62 breast cancer patients (pts) with distant metas-
tases were treated with high-dose chemotherapy and autologous stem
cell rescue after responding to induction chemotherapy. A retrospective
analysis was performed to compare survival for pts who underwent tan-
dem (T) vs single (S) high-dose treatments. Chemotherapy consisted of
MiTepa and/or ICE (Dillman et al, Cancer Research Treat 3 7 : 2 7 7 -
89,1996). The reasons for a single transplant were: 12 pts were limited to
one by insurance coverage; 6 developed medical problems that delayed
or precluded a second high-dose treatment; 4 had sufficient cells har-
vested for only S; 3 patients were treated prior to development of the
tandem transplant treatment protocol; and 3 pts declined a second inten-
sive therapy. There were 34 patients with median age 45.8 yrs in the T
group (21 deaths) at a median follow up of 4.6 yrs from the date of the
first stem-cell infusion. There were 28 patients with median age 49.5 yrs
in the S group (17 deaths) at a median follow up of 2.1 yrs. Overall 2-
year survival rates were T-68%, S-32%. Median event-free survival rates
were T-15.5 mos, S-7.4 mos. Median overall survival rates were T-37.3
mos, S-14.6 mos. The only randomized trial that has shown a survival
advantage for high-dose chemotherapy in metastatic breast cancer uti-
lized two high-dose treatment sessions (Bezwoda, J Clin Oncol 1 9 9 5 ) .
Our experience suggests that there is no survival advantage for a single
high-dose treatment while the 4-year survival rate for tandem high-dose
treatments is 40%. This issue should be addressed in a randomized trial
with an intent-to-treat analysis.
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MICHROCHIMERISM SUSTAINS ACTIVE IMMUNITY IN MICE TRANS-
PLANTED IN UTERO WITH C-KIT+ AND SCA+ CELLS
Donahue, J.1; Lee, T.H.2 , 3; Busch, M.2 , 3; Croft, M.4; Carrier, E.1 1. Universi -
ty of California San Diego, Department of Medicine and Pediatrics, La Jolla,
CA; 2. University of California San Francisco, Department of Laboratory
Medicine, San Francisco, CA; 3. Irwin Memorial Blood Center, San Francisco,
CA; 4. La Jolla Insitute of Allergy and Immunology, La Jolla , CA
We have previously detected evidence of postnatal immunity to allo-
geneic c-kit+ cells post prenatal transplantation. To further study this
finding, we have performed experiments in which purified murine sca-
1+/lin- cells and c-kit+/lin- cells of C57BL/6 (H-2b) mice were injected
into Balb/c (H-2d) fetal recipients at 9 and 13 days of gestation.
Chimerism and tolerance/immunity were studied through life.100%
(10/10) and 44 % (4/9) of mice transplanted with c-kit+ and sca+ cells
respectively showed circulating donor cells within the first 6 months
( p = 0.01). The incidence of chimerism in the first month following
boosts did not significantly vary between the boosted c-kit+ (3/5), sca+
(7/9) or allogeneic control (2/3) groups (p = 0.58). However, the degree
of chimerism in the c-kit+ group (1.427%) was significantly higher than
that of the sca + group (0.014%) or allogeneic control group (0.004%,
p = 0.0222). Mice in the sca+ group rejected donor skin grafts at a medi-
an time of 9 days (±0.601), whereas mice in the c-kit+ group at 15 days
(±2.2). Control mice rejected donor skin grafts at 13 days
(±1 ) ( p = 0.001). There was statistical difference between the sca+ group
and controls (p = 0.001). A correlation between chimerism in the fir s t
six months of life and immune response to donor cells was observed in
the sca+ group. All mice tested showed greater response to donor cells
than to third party cells (p = 0.0018). Differences in response to donor
alloantigen between sca+ and c-kit+ groups were significant
( p = 0.0028), with the sca+ group showing higher alloreactivity.
Cytokine quantification demonstrated higher TH1 cytokine release in
all mice tested. The response to donor cells was higher in the sca+
group (p = 0.0067). These results demonstrate development of active
immunity to donor cells post in utero transplantation with sca+/lin- and
c-kit+/lin- cells, which was higher in mice transplanted with sca+/lin-
cells with persistent microchimerism. 
ASBMT: Poster Presentations 
M E D I A N NUMBER OF PATIENTS WITH
ASPIRATE RESULTS TUMOR FREQ. - APHERESIS + A P H E R E S I S
Negative 99/120 (83%) 0 92/99 (93%) 7/99 (7%)
Positive 21/120 (17%) 1/1.3 x 10*6 5/21 (24%) 16/21 (76%)
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FLUCTUATION IN CA-125 FOLLOWING HIGH-DOSE CHEMOTHERAPY
IN OVARIAN CANCER
Donato, M.L.; Gershenson, D.; Champlin, R.E.; Wharton, J.T.; Bevers, M.;
Bodurka-Bevers, D.; Burke, T.; Levenback, C.; Wolf, J.; Bast, Jr., R.C. MD
Anderson Cancer Center, Houston, TX
We have evaluated the fluctuation in CA-125 following administration
of intensive chemotherapy. Twenty-two patients with epithelial ovarian
cancer undergoing high-dose chemotherapy with stem cell rescue were
studied. A baseline CA-125 was obtained on the day of therapy initiation
and then weekly for at least 4 weeks. At the present time, 4 patients
without ovarian cancer undergoing high-dose chemotherapy had weekly
monitoring of CA-125 levels to serve as controls. Twelve of the 22
patients (55%) had at least a 25% rise in CA-125 (range 25% - 325%),
peaking a median of 21 days (range 7 to 30 days) post initiation of
chemotherapy. All patients with a rise in CA-125 had a subsequent fall at
or below baseline and all were at least partial responders to the therapy.
Of the patients without ovarian cancer, none experienced a rise in CA-
125 following the chemotherapy. In conclusion, a significant proportion
of patients with ovarian cancer undergoing intensive chemotherapy will
demonstrate an increase in their CA-125 which may peak up to 4 weeks
post chemotherapy. The increase in tumor marker has been associated
with tumor response in the population studied. It is possible that the rise
in CA-125 represents tumor cell kill and is not a reflection of regimen
toxicity since none of the controls have demonstrated a similar rise so
far. Further evaluation to determine if a rise in CA-125 is a prognostic
indicator is required, and a larger control population is being studied.
3 7
TOTAL CD34+ DOSE/KG PREDICTS LONG-TERM OUTCOME FOLLOW-
ING AUTOLOGOUS BLOOD STEM CELL TRANSLPLANT (ASCT)
Duggan, P.R.1; Chaudry, A.1; Guo, D.2; Luider, J.3; Auer, I.3; Klassen, J.4; Morris, D.1;
Gluck, S.1; Russell, J.1; Stewart, D.1 1. Department of Medicine, Tom Baker Cancer Center,
Foothills Hospital, Calgary, Canada; 2. Epidemiology Department, Tom Baker Cancer Cen -
ter, Foothills Hospital, Calgary, Canada; 3. Flow Cytometry, Tom Baker Cancer Center,
Foothills Hospital, Calgary, Canada; 4. Apheresis, Tom Baker Cancer Center, Foothills Hos -
pital, Calgary, Canada
Introduction: CD34+ dose/kg correlates with early hematopoietic engraftment fol-
lowing ASCT. Less is known about its influence on long-term hematopoiesis. 
Methods: From 01/97 to 04/99, 143 consecutive patients aged 19-66 years (medi-
a n = 46) were identified who underwent ASCT for breast cancer (n = 64), non-
Hodgkin’s lymphoma (n = 45), Hodgkin’s disease (n = 17), myeloma (n = 9) or other
diagnoses (n = 8). Data from these patients were analyzed to determine if total
CD34+ cells/kg infused, CD34+ subsets (CD34+41+, CD34+33+, CD34+90+,
CD34+33-, CD34+38-, CD34+38-DR-), or various clinical factors (engraftment
rate, age, gender, number of prior chemotherapy regimens, conditioning regimen,
diagnosis) were associated with white blood cells (WBC) <4 x 1 09/L, hemoglobin <
120 g/L, or platelets < 150 x109/L measured 6 months post-ASCT. 
Results: Six months following ABSCT, 43% of patients had low WBC, 42% low
platelets, and 38% low hemoglobin. By Spearman’s rank correlation, the total CD34+
cell dose/kg correlated better than any individual subset of CD34+ cells with the 6-
month WBC (p = 0.0011), hemoglobin (p = 0.036) and platelet count (p < 0 . 0 0 0 1 ) .
Although several clinical factors had a significant effect on 6-month blood counts by
univariate analysis, only a total CD34+ cell dose > 10 x106/kg showed a signific a n t
correlation with 6-month WBC, platelets, and hemoglobin by multivariate analysis.
Table 1 shows the percent of patients with low counts at 6 months according to the
total CD34+ cell dose received. Finally, these total CD34+ doses were found to corre-
late significantly with both relapse and mortality at 6 months (table 1). 
Conclusions: Subsets of CD34+ cells are inferior to the total CD34+ cell dose/kg in
predicting long-term marrow recovery. A CD34+ dose of > 10 x106 CD34+ cells/kg
results in a significantly higher chance of normal blood counts at 6 months, and also
seems to be associated with lower relapse and mortality rates.
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PROPIONIBACTERIUM ACNES AND SYNCYTIAL GIANT CELL HEPATI-
TIS AFTER ALLOGENEIC PBSCT
Duffner, U.1; Kontny, H.U.1; Berner, R.1; Greiner, P.1; Pelz, K.2; Schmitt-Gräff,
A .3; Ochs, A.4; Siegerstetter, V.4; Graubner, U.B.5; Niemeyer, C.M.1 1. Univer -
sitäts-Kinderklinik, Freiburg, Germany; 2. Universitätsklinik, Institut für med.
Mikrobiologie und Hygiene, Freiburg, Germany; 3. Universitätsklinik, Patholo -
gisches Institut, Freiburg, Germany; 4. Universitätsklinik, Medizinische Klinik,
Freiburg, Germany; 5. Dr. von Haunerschen Kinderspital, München, Germany
Post infantile syncytial giant cell hepatitis is an uncommon form of
hepatitis. It carries a grave prognosis and is associated with autoimmu-
nity, drug reaction and viral infection. Here we will discuss a possible
new aetiological agent in syncytial giant cell hepatitis in an immuno-
compromised child. 
Case report: A 7 year old girl with juvenile myelomonocytic leukemia
received a MUD PBSCT with Busulfan/Cyclophosphamid/Melphalan
as conditioning regimen. 6 months later she suffered a relapse and a sec-
ond MUD PBSCT was performed after TBI 12 Gy, Fludarabin and
Thiotepa. The clinical course was complicated by acute intestinal
GvHD stage 3 which slowly improved with Cyclosporin A, Prednisone,
Budesonid, Mycophenolatmofetil and Basiliximab. Because of rising
transaminases with ALAT 110 U/L and ASAT 57 U/L a liver biopsy
was performed on day 186. Histology revealed evidence for toxic meta-
bolic damage. Immunosuppressive treatment was tapered. On day 217
ALAT has risen to 581 U/L and ASAT to 243 U/L. A repeat liver biop-
sy was done, now a syncytial giant cell hepatitis was diagnosed. Microbi-
ological studies showed growth of Propionibacterium acnes. 
Syncytial giant cell hepatitis is a uncommon complication of SCT and
has to be viewed as a heterogenous clinical entity. As indicated by a well
studied mouse model Propionibacterium acnes may play an important
role in its aetiology. Propionibacterium acnes primed mice suffer severe
liver injury after LPS injection. The key mediators IL-18 and IL-12
secreted by activated Kupffer cells are responsible for hepatic apoptosis
by upregulation of Fas-Ligand on cytotoxic effector cells and induction
of INF-γ/ T N F -γ pathway. The understanding of this pathopysiology
opens new treatment options utilizing anti-cytokine antibodies which
may ameliorate the chronically relapsing course of the often fatal disease.
3 8
THE EFFECT OF FULLY ALLOGENEIC HEMATOPOIETIC STEM CELL
TRANSPLANTATION ON PREVENTION OF AUTOIMMUNE BRONCHITIS
IN AUTOIMMUNE-PRONE W/B F1 MICE
El-badri-dajani, N.; Steele, A.; Good, R.A. All Children’s Hospital, U.S.F., St.
Petersburg, FL
The purpose of our study is to investigate the effect of hematopoietic
stem cell transplantation on the prevention of development of lung
pathology in W/B F1 mice. W/B F1 mice is an autoimmune-prone
strain that develops a systemic-lupus like syndrome. W/B F1 mice were
transplanted by a preparation of fully allogeneic hematopoietic stem cells
(HSCs) from autoimmune-resistant mouse strains (BALB/c). The trans-
planted mice were followed for survival, engraftment, and signs of devel-
opment of the autoimmune disease. The transplanted mice were free
from the autoimmune disease, have shown excellent prolonged survival,
and were fully engrafted with donor cell phenotype. We have also shown
that a sufficiently large number of hematopoietic stem cells was crucial
for successful engraftment. Histopathological analysis of hearts, kidneys,
and lungs showed absence of the pathology associated with autoimmuni-
ty. Lungs of non-manipulated W/B F1 mice showed extensive infla m-
matory infiltrate that permeated the pulmonary architecture. By con-
trast, the lungs of chimeric mice, transplanted with fully allogeneic
hematopoietic stem cells showed an infiltrate-free, and normal-appear-
ing “lacy” alveolar cytoarchitecture punctuated by blood vessels and
bronchioles. Our data proved that transplantation of hematopoietic stem
cells resulted in complete absence of any histopathology/infla m m a t o r y
lung infiltrate, which led us to postulate that an apoptotic mechanism
may be central in the resolution of mononuclear inflammatory infil t r a t e .
Our data suggest that a Fas-Fas Ligand mediated apoptotic mechanism
may be involved in disappearance of lymphocytic lung infiltrate, and
complete recovery of the lungs of W/B F1 mice transplanted with allo-
geneic hematopoietic stem cells. 
ASBMT: Poster Presentations
TABLE 1 1-5 x1 06/ K G 5-10 x1 06/ K G >10 x1 06/ K G p- V A L U E
WBC <4.0 x109/L 61% 58% 24% 0.0003
Hemoglobin <120 g/L 61% 39% 29% 0.027
Platelets <150 x109/L 70% 46% 29% 0.003
Relapse 36% 31% 15% 0.047
Mortality 52% 20% 16% 0.001
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SUCCESSFUL PRIMARY TRANSPLANTATION OF ALLOGENEIC PERIPH-
ERAL BLOOD STEM CELLS IN PATIENTS WITH SEVERE APLASTIC
A N E M I A
Fahmy, O.A.; Mahmoud, H.K.; Haddad, A.E.; Kamel, A.M.; Nazih, M.A.;
Sobhy, A.M.; Rabie, T.S. Nasser Institute, Cairo, Egypt
Allogeneic peripheral blood stem cell transplantation (PBSCT) is
gaining more popularity in the treatment of different hematologic disor-
ders. However, apart from a few cases, no data exist regarding the feasi-
bility of primary allogeneic PBSCT in heavily pre-transfused patients
with severe aplastic anemia (SAA). Between July 1997 and November
1998, we have transplanted 18 patients with SAA using allogeneic
PBSCs. They were 11 males and 7 females (mean age 19). All patients
received Cyclophosphamide + Antithymocyte globulin (ATG) as the
conditioning regimen. The mean number of Filgrastim - mobilized
CD34+ cells from the HLA-identical siblings was 7.5 X 106/kg recipient
weight. All patients received Methodtrexate + Cyclosporine for graft -
versus - host disease (GVHD) porphylaxis. The mean number of days
for neutrophil and platelet recovery was 12 and 15, respectively. Six
patients (33.3%) died, the main causes of death were intracranial hemor-
rhage, interstitial pneumonitis, CMV infection, acute GVHD and sepsis.
The remaining 12 patients are alive and well for up to two years after
transplantation, with no single case of early or late graft failure. One of
these is having a well controlled limited chronic GVHD. Thus, our data
suggest that allogeneic PBSCT is quite feasible in heavily pre-transfused
patients with SAA and provides a faster reconstitution without increased
incidence of acute GVHD compared to bone marrow transplantation
(BMT). Further follow up is needed to determine the ultimate incidence
of chronic GVHD.
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EFFECT OF STEM CELL INFUSION ON HEMOSTASIS
Gabriel, D.A.; Melton, L.G.; Thompson, C.M.; Kirby, S.; Serody, J.; Wiley, J.;
Bigelow, S.; Capel, E.; Shea, T. University of North Carolina, Chapel Hill, NC
The infusion of stem cells from either peripheral blood or bone mar-
row during bone marrow transplantation may have an impact on hemo-
stasis from multiple etiologies including the heparin dose, DMSO, acti-
vated coagulation factors, cytokines, chemokines, and white blood cells.
For example, the effect of recipient TNFα on the infused monocytes
and de novo tissue factor synthesis could have a profound effect on
hemostasis. We have used a sensitive flow device, Clot Signature Analyz-
er (CSA), that simulates physiologic blood flow to assess the effect of
stem cell infusion on both platelet function and soluble phase coagula-
tion in 20 patients (mean age 42+11 y). Unanticoagulated whole blood
was taken from the central catheter and tested with the CSA to measure
platelet activation and recruitment (platelet hemostasis time, PHT),
platelet adhesion to collagen (collagen-induced thrombosis formation,
CITF) and whole blood coagulation time (CT). Also examined were
aPTT, complete blood counts, platelet counts (PC) and infused product
cellular analysis. Hemostasis parameters were measured 1 hr before infu-
sion, 1 and 24 hrs post infusion for both autografts (18) and allografts
(2). Patients (9F, 11M) included 3 acute leukemics, 5 HD, 5 NHL, 2
MM, 4 breast cancer, and 1 neuroblastoma. Neither the volume of infu-
sion, nor RBC, aPTT or WBC correlated with any parameter. At base-
line, 45% of the patients had abnormal CSA times despite normal
aPTT. All PC decreased after infusion. By the CSA, only 15% of the
patients had normal hemostasis during these times and after 24 hr the
majority of patients had abnormal hemostasis. Since the aPTT was not
altered after infusion, the CSA changes may not be due to heparin.
These results indicate that routine screening coagulation tests can be
misleading in the evaluation of hemostasis. Thus, any invasive procedure
during this period should be approached with caution.
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Vβ SPECTRATYPE ANALYSIS OF CD4+ T CELL RESPONSES TO MINOR
HISTOCOMPATIBILITY ANTIGENS INVOLVED IN GRAFT-VERSUS-HOST
D I S E A S E
Friedman, T.M.; Statton, D.; Jones, S.C.; Murphy, G.; Korngold, R. Thomas
Jefferson University, Philadelphia, PA
Lethal graft-versus-host disease (GVHD) can be induced between
MHC-matched murine strains expressing multiple minor histocompati-
bility antigen (miHA) differences. In the C57BL/6By (B6)->C . B 1 0 -
H 2b/LiMcdJ (BALB.B) irradiation model, both CD4+ and CD8+ d o n o r
T cells can mediate lethal GVHD, whereas in the B6->C X B - 2 / B y
(CXBE) model, only the CD8+ T cells are lethal. CDR3-size spec-
tratyping was used to further analyze the CD4+ T cell responses and
revealed overlapping oligoclonal expansion of Vβ4, 6-10, and 12-14
families in both BALB.B and CXBE recipients injected with host-pre-
sensitized B6 CD4+T cells. The B6->BALB.B CD4+ T cell response
appeared to recognize unique BALB.B-specific miHA, indicated by
additional skewing of Vβ 2 and 11. In addition, the B6->CXBE strain
combination exhibited unique skewing of Vβ 16 and 18. Immunohisto-
chemical staining of lingual epithelial sections from BALB.B recipients
of naive B6 CD4+ T cells correlated with the involvement of several of
the spectratype-skewed Vβ families in GVHD lesions. Magnetic cell
sorting was used to positively select the spectratype-skewed Vβ f a m i l i e s
from the donor B6 CD4+ T cells which were then transplanted into
lethally irradiated BALB.B recipients. All of the mice that received the
skewed Vβ families succumbed to fatal GVHD, whereas the mice that
received the unskewed Vβ families all survived with minimal, if any,
symptoms of GVHD. 
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FAILURE OF COMBINED DONOR LYMPHOCYTE INFUSION (DLI) AND
IL-2 TO CONVERT MIXED TO COMPLETE DONOR CHIMERISM IN
DOGS FOLLOWING NONMYELOABLATIVE HEMATOPOIETIC STEM
CELL TRANSPLANTATION
Georges, G.E.1 , 2; Storb, R.1 , 2; Zaucha, J.M.1; Thompson, J.D.1; Taranova,
A . G .1; Nash, R.A.1 , 2 1. Fred Hutchinson Cancer Research Center, Seattle,
WA; 2. University of Washington, Seattle, WA
Stable mixed hematopoietic chimerism can be established following
nonmyeloablative total body irradiation (2 Gy TBI), transplantation of
dog leukocyte antigen (DLA)-identical littermate marrow and postgraft-
ing immunosuppression with mycophenolate mofetil and cyclosporine.
Previously we have shown that in 8 mixed chimeric dogs, unmodifie d
DLI did not change donor chimerism while infusion of donor lympho-
cytes specific for recipient minor histocompatibility antigens successfully
converted all 8 mixed chimeras to complete donor chimerism within 2 to
10 weeks. We now asked if unmodified DLI combined with IL-2 could
convert mixed to complete donor chimerism following nonmyeloabla-
tive hematopoietic stem cell transplantation. 
Four stable mixed chimeric dogs received unmodified DLI between
day 204-287 with an infused cell dose of 0.9 - 2.5 x108 C D 3+cells/kg, fol-
lowed by recombinant human IL-2 (Chiron) 2 x 105 IU/kg s.c. b.i.d. x 14
days. An increase in wbc and eosinophilia, lethargy, fever, skin erythema
and diarrhea was observed without severe life-threatening toxicity. All
clinical changes resolved after discontinuation of IL-2. Chimerism status
was assessed by quantitative PCR phosphorimage analysis using infor-
mative microsatellite markers with DNA from sorted peripheral blood
C D 3+ cells and granulocytes obtained weekly for 4 months after DLI
and IL-2. There was no significant change in percent donor chimerism
following DLI in these 4 mixed chimeras. Two control dogs receiving
IL-2 alone also did not show change in donor chimerism. 
Once stable mixed chimerism was established, IL-2 and DLI were
unable to perturb the mechanism maintaining immunologic tolerance.
Results from this preclinical model suggest that the addition of IL-2 to
DLI is unlikely to result in an increase in donor chimerism for patients
treated with this nonmyeloablative transplant regimen. 
ASBMT: Poster Presentations 
MEAN ± S D p V A L U E
1 H 24 H BASE VS BASE VS 1 H POST VS
P A R A M E T E R S B A S E L I N E P O S T P O S T 1 H POST 24 H POST 24 H POST
PC 131 ± 66 91 ± 57 4 x 10-8
aPTT (sec) 26 ± 8 34 ± 6 27 ± 6 0.40 0.50 0.50
PHT (min) 8.2 ± 7.2 21.3 ± 10.8 8.6 ± 7.3 2 x 10-5 0.82 2 x 10-5
CITF (min) 10.2 ± 6.4 17.1 ± 9.8 13.0 ± 8.8 2 x 10-3 0.03 0.02
CT (min) 28.2 ± 3.6 30 29.0 ± 1.8 0.046 0.44 0.023
B B & M T
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SINGLE-CENTER EXPERIENCE OF AUTOLOGOUS STEM CELL TRANS-
PLANT (ASCT) AND CONSOLIDATION CHEMOTHERAPY IN PATIENTS
(PTS) WITH MULTIPLE MYELOMA (MM)
Gojo, I.; Fassas, A.; Cottler-Fox, M.; Tricot, G. University of Maryland, Balti -
more, MD
ASCT in MM has been shown to increase the CR rate, disease-free
and overall survival. The optimal conditioning regimen and the addi-
tional benefit of 2nd ASCT are not yet clearly defined. Relapses occur
early and late in the course. In an effort to reduce incidence of late
relapses, we administered post-ASCT consolidation chemotherapy with
non cross-resistant agents. Between 10/97 and 3/99 we treated 50 MM
pts with 2 cycles of Dexamethasone(DEX) pulsing followed by mobiliza-
tion chemotherapy with Cytoxan(CTX)(4.5gm/m2) ( 2 8 p t s ) ,
C T X ( 4 . 5 g m / m2) + E t o p o s i d e ( 2 g m / m2)(19pts) or other(3pts). Condition-
ing regimen consisted of BCNU(300mg/m2) and melphalan(140mg/m2) .
Post-ASCT pts received DCEP i.e. DEX(40mg/d), CTX(300mg/m2/ d ) ,
e t o p o s i d e ( 3 0 m g / m2/d) and cisplatin(15mg/m2/d) by continuous infusion
for 4 days at 3 and 9 months and DEX(40mg/d) for 4 days,
t a x o l ( 1 3 5 m g / m2) and cisplatin(75mg/m2) at 6 and 12 months. G-
CSF(5mg/kg) was given with each consolidation cycle. In 14 pts (>1 2
months after the diagnosis) Gemcitabine(1gm/m2) was added with con-
ditioning regimen, cycle#1 and #3. At the time of this analysis 43, 35, 24
and 15 pts had completed 1, 2, 3 and 4 cycles of consolidation
chemotherapy. CR was achieved in 17(34%) and PR in 7(14%)pts. Cur-
rently, 17 pts are still in a stringently defined CR between 7 and 22
months post-ASCT of which 6 had been heavily pretreated prior to
transplant. The addition of post-ASCT chemotherapy converted 4 pts
with stable disease (SD) to PR, 1pt with SD to CR and 1 pt with PR to
CR. Peri-transplant mortality was 6%. During consolidation only 3 pts
required infusion of additional stem cells due to incomplete platelet
recovery after ASCT, 1 pt experienced a life-threatening but not fatal
complication (extensive cellulitis) and 1 pt died in PR at +9 months due
to PCP. Further follow up is needed to evaluate the efficacy of post-
ASCT intensive chemotherapy in preventing the late relapses. 
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PHASE 1 TRIAL OF LATE GM-CSF TO PROMOTE RECONSTITUTION OF
CELL-MEDIATED IMMUNITY IN PEDIATRIC RECIPIENTS OF ALTERNA-
TIVE DONOR (AD) STEM CELL TRANSPANTATION (SCT)
Grimley, M.S.1; Lee, S.1; Villaneuva, J.1; Stachura, R.2; Gilbert, M.2; Gross,
T .1; Filipovich, A.1 1. Children’s Hospital Medical Center, Cincinnati, OH; 2.
Immunex Corporation, Seattle, WA
Prolonged susceptibility to life-threatening infections following alternative
donor SCT is a major obstacle to the ultimate success of mismatched SCT. The
post transplant recovery of T helper (Th) lymphocytes is delayed in comparison
to the recovery of of cytotoxic T cells and Natural Killer cells. Evidence obtained
suggests that Type 1 Th function remains most depressed following AD SCT
compared to SCT with Matched Sibling Donors (MSD). Furthermore, AD
SCT recipients demonstrate depressed GM-CSF production by PHA stimulat-
ed peripheral blood mononuclear cells (PBMCs) up to six months post SCT. 
We observed that in vitro addition of GM-CSF to normal PBMCs augments
γ-IFN synthesis. We hypothesized that exogenous GM-CSF administered to
AD recipients after SCT that may augment the effector function of antigen
presenting cells, promoting the secretion Th1 cytokines. To test our hypothe-
sis, we designed a Phase 1 trial of thrice weekly GM-CSF (sargramostim, yeast-
derived rhu GM-CSF) 250 micrograms/m2/dose SQ from Day +50 to +150
post SCT in AD SCT recipients. Since opening enrollment, 31 pediatric
patients (pts) have received AD SCT. 21 patients met the eligibility criteria for
study entry and 14 patients have enrolled on study. Pts ranged in age from 10
months to 17 years. Eight pts underwent SCT for non-malignant disease, 6 for
malignant disease, 9 pts received bone marrow from unrelated donors (5 par-
tially cell depleted), 3 pts had unrelated cord blood SCT and 2 pts had maternal
SCT (1 partially T cell depleted). Seven pts had developed GvHD prior to
starting GM-CSF, 2 pts developed GvHD after Day +50 but prior to Day +100
post SCT, and 5 pts did not develop GvHD. Eight patients have completed the
trial. Three patients died prior to Day +150. GM-CSF was discontinued in 1
patient due to disease relapse. Side effects attributed to GM-CSF included: 2
patients had increased WBC (ANC>30,000), one patient had a transient rash, 2
patients had bone pain, and 1 patient was dropped from therapy due to irritabil-
ity experienced after the injections. 
Our results demonstrate that late GM-CSF therapy is well tolerated with
no unexpected side effects or exacerbation of GvHD. Comparisons of type 1
cytokine recovery in these patients and in pediatric pts who did not receive
late GM-CSF are currently being investigated. 
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STEM CELL LABORATORY MANAGEMENT: RESULTS FROM A SURVEY
ON OPERATING AND FINANCIAL PERFORMANCE (1999)
Graham, D.L.1; Colberg , R.T.1; Killion, C.1; Wells, H.J.2; Hane, S.2; Hudak,
L .2 1. The Graham Sjostrand Group, Seattle, WA; 2. American Red Cross,
Rosslyn, VA
The market for cellular therapies especially hematopoietic stem cell
transplants in the treatment of cancers, genetic diseases and autoimmune
disorders has been marked by significant growth and technological inno-
vations. Lacking any recent publicly available data about stem cell lab
management, we sought to understand current issues, trends and perfor-
mance parameters within this community. More specifically, we queried
stem cell lab managers to gain insights into operating performance
(labor, salaries, supplies, use of certain products or technologies, process-
ing volumes) as well as explore key. A survey was designed for execution
on a PC. One hundred sixty seven surveys were sent to 158 different
institutions engaged in stem cell processing. The overall response rate
was 52/167 or 31%. The average annual transplant volume was just over
100. Transplants by type favored autologous with a mean of 73 auto-
transplants performed vs. 30 allotransplants. The most experienced cen-
ters performed more allotransplants relative to autotransplants with the
ratio of autos:allos at 1.7 vs. 2.4 overall. The mean number of cell prod-
ucts processed reached 281. Autologous peripheral blood processing
dominates activity with over 75% of the volume. Overall lab expenses
averaged $367,000. Labor costs represented about 45% of the total with
Supplies accounting for 28%, Special Supplies 10%, Space/Utilities 5%
with all other categories capturing the remaining 12%. Lab costs are
expected to rise over 6% during the next two years. The most important
issues for the lab management community relate to FDA compliance,
the desire for improved lab QA/QC procedures, and FAHCT accredita-
tion. The least important issues are space constraints, competition and
the prospects for industry wide consolidation. The stem cell community
is prepared for moderate growth in treated patients and procedures over
the next two years, but use of stem cell transplants for breast cancer
could greatly affect future volumes.
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I.V. MYCOPHENOLATE MOFETIL (MMF) IN THE PROPHYLAXIS OF
ACUTE GVHD IN STEM CELL TRANSPLANT RECIPIENTS
Guenzelmann, S.1; Shipkova, M.2; Basara, N.1; Lentini, G.1; Roemer, E.1; Hartert,
A . M .1; Fauser, A.A.1; Kiehl, M.G.1 1. Municipal Hospital, Idar-Oberstein, Ger -
many; 2. University Hospital, Göttingen, Germany
Despite immunosuppressive prophylaxis with cyclosporine (CsA), pred-
nisolone and methotrexate (MTX), the incidence reported for aGVHD grade
II - IV after transplantation from HLA matched unrelated donor (MUD) is
78% and for grade III -IV is 36%. Since acute GVHD contributes to morbid-
ity and mortality after MUD-BMT, a more effective prophylactic regimen is
needed in order to prevent these complications. We report on the efficacy of
i.v. MMF in the prophylaxis of GvHD in hematopoietic stem cell recipients. 
Seven patients transplanted for hematologic malignancies (3 ALL, 3 AML,
1 secondary AML; conditioning regimen: 3 TBI/Cy, 2 Bu/Cy, 2
Bu/Cy/Thiotepa; median age 34 years, 21 - 55) were investigated. GvHD
prophylaxis consist of MMF 2x1 g/d, CsA, and prednisone. 
Results on these patients were compared to a matched historical control
group receiving a short course of MTX in addition to CsA and prednisone for
GvHD prophylaxis. Data were assessed with regard to the incidence of
GvHD, severity of mucositis, and time of engraftment. All patients of the
treatment group as well as of the control group received peripheral blood
stem cells from matched unrelated donors. 
Results: All patients receiving CsA/Pred/MMF or CsA/Pred/MTX engraft-
ed. Data on platelet and leukocyte engraftment as well as severity of mucositis
are depicted in the table. We did not observe MMF associated negative side
effects in particular with regard to the intestinal tract.Two patients of the
MMF group died, one due to refractory bowel GvHD and one due to respira-
tory failure related to bacterial pneumonia. 
Conclusion: Our data indicate that MMF might be as effective as MTX in
preventing aGvHD. In addition, platelet as well as leukocyte engraftment are
faster in the MMF treated patients and severity of mucositis is weaken due to
MTX renunciation. 
ASBMT: Poster Presentations
P L A T E L E T S P L A T E L E T S L E U K O C Y T E
>/ 2 0 . 0 0 0µ ≥5 0 . 0 0 0 /µ ≥1 . 0 0 0 /µ M U C O S I T I S ACUTE GVHD
( D A Y S ) ( D A Y S ) ( D A Y S ) ( G R A D E ) (>I I )
MMF 14.3 (4.07) 20.8 (9.57) 13.14 (4.2) 2.7 (1.1) 1/7
Control 16.43 (3.1) 30.5 (21.3) 15 (3.5) 3 (0.5) 1/7
Tab.: Data are given as mean with standard deviation in parenthesis. *; p<0.05 by t-test 
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RANDOMIZED TRIAL WITH FILGRASTIM (G-CSF) TO IMPROVE THE
ENGRAFTMENT AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL
TRANSPLANT, COMPARISON BETWEEN TWO APPROACHSES
Gomez-Morales, E.; Sanchez-Valle, E.; Campos-Cabrera, G.; Ichikawa-
Ishikawa, A.; Monsivais, A.; González-Bautista, M.; Pizzuto-Chávez, J. Hos -
pital de Especialidades, CMN S XXI. Instituto Mexicano del Seguro Social,
M é x i c o
The objective of this study was to obtain a quickly myeloid engraft-
ment and to decrease the staying at the hospital. 
Patients (pts) and methods. From March 1996 to November 1999 we
included 28 pts with hematopoietic malignancies who underwent allo-
geneic BMT or PBSCT from HLA matched sibling donors were ran-
domized to receive G-CSF 10 µg/Kg. or no G-CSF. In a first stage we
compared allogeneic BMT plus G-CSF at day +1 versus BMT without
G-CSF. In a second stage we compared G-CSF at day +7 after PBSCT
or BMT. In the first stage nine pts received G-CSF after BMT, median
age 32 years old (22-50), male 3, female 6, their diagnosis were MDS 1,
ALL 1, AML 1 and CML 6. Nine pts did not receive G-CSF, median
age 25 years old (19-50), male 6, female 3, the diagnosis were ALL 1,
AML 2, and CML 6. In the second stage, 4 pts who underwent PBSCT
were compared with 7 pts who underwent BMT. The median age was
32 years old (23-50), male 6, female 5, the diagnosis were MDS 2, ALL
2, AML 2 and CML 5. We use the International criteria for considered
engraftment. 
Results. In the first stage the median time to reach the engraftment
was 19 days for the G-CSF group versus 22 days in the control group. In
the second stage, the median time to reach engraftment was 13 days. 
Conclusion: G-CSF was useful in allogeneic hematopoietic stem cell
transplantation to improve the engraftment. In the first stage, the differ-
ence was not significant, but when compared G-CSF at day +1 versus
+7, the difference was significant, with more quickly engraftment and
short staying in the hospital, in this case the origin of the stem cells was
not relevant. 
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L-LEUCYL-L-LEUCINE METHYL ESTER TREATMENT OF ALLOGENEIC
DONOR LYMPHOCYTE INFUSIONS PREVENTS LETHAL GRAFT-VERSUS-
HOST DISEASE BUT PRESERVES GRAFT-VERSUS-LEUKEMIA EFFECTS 
Hsieh, M.H.; Flomenberg, N.; Korngold, R. Jefferson Medical College,
Philadelphia, PA
L-leucyl-L-leucine methyl ester (LLME) is a compound previously
demonstrated to prevent graft-versus-host disease (GVHD) in multiple
animal models. However, application of LLME to the clinical setting
has been hampered by toxic effects on stem cells at the concentrations
necessary to purge GVHD-inducing T cells. We sought to circumvent
this problem by testing the efficacy of LLME ex vivo treatment of donor
lymphocyte infusions (DLI) administered following transplantation of T
cell depleted bone marrow (TCDBM). In this setting, effects of LLME
on the stem cells contained within DLI are irrelevant for clinical out-
come. (C57Bl/6xDBA/2)F1 (B6D2) recipient mice (H2b / d) were admin-
istered split-dose irradiation and injected with B6 (H2b) TCDBM. After
13 days, half of the recipients were challenged i.p. with MMD2-8
myeloid leukemia cells (H2d). The following day, recipient mice were
left untreated, or administered either LLME- or mock-treated B6D2-
presensitized B6 splenocytes. At a dose of 2x107 splenocytes, all mice
receiving LLME-treated DLI but no tumor survived indefinitely,
whereas 50% of mice receiving mock-treated cells died from GVHD.
Disease was confirmed through body weight changes, histological analy-
sis, and flow cytometry (lymphoid hypoplasia). Mice receiving tumor
challenge but no DLI had a median survival time (MST) of 26 days.
Leukemia-challenged animals receiving mock-treated DLI exhibited a
MST of 18 days, while recipients of LLME-treated DLI had a MST of
35 days. At a dose of 4x107 splenocytes, all mice receiving LLME-treat-
ed DLI but no tumor survived indefinitely, whereas only 10% of mice
receiving mock-treated DLI survived long term. When challenged with
tumor, mice not receiving DLI had a MST of 32 days, compared to
mock-treated DLI mice (MST of 13 days); whereas all mice receiving
LLME-treated DLI were alive at day 39. In conclusion, these results
suggest that LLME treatment of DLI can prevent lethal GVHD while
preserving GVL effects.
4 8
THE ADDITION OF IMMUNOTHERAPY EARLY IN AN AUTOLOGOUS
T R A N S P L A N T
Holmberg, L.A.1 , 2; Rowley, S.D.1 , 2; Visuthisalechai, S.1; Sandmaier, B.1 , 2;
Heimfeld, S.1; Bensinger, W.I.1 , 2 1. Fred Hutchinson Cancer Research Center,
Seattle, WA; 2. University of Washington School of Medicine, Seattle, WA
Interleukin 2 (IL2) has anti-tumor activity in patients with hematolog-
ic malignancies and certain solid tumors. Between 11/1995-4/1999, 33
patients with advanced disease (platinum-refractory Ovarian Cancer
( n = 3), stage IV Breast Cancer chemorefractory (n = 17) /chemorespon-
sive (n = 1), NHL/HD (n = 5) and Multiple Myeloma (MM) (n = 7 ) )
were treated with high dose chemotherapy, busulfan (9-12 mg/kg), mel-
phalan (100 mg/m2)and thiotepa (500 mg/m2), followed by the infusion
of IL2-incubated autologous/syngeneic PBSC and additional escalating
doses and duration of continuous infusion (CI) IL2. Cryopreserved
PBSC, previously mobilized by chemotherapy/G-CSF (n = 31) or G-
CSF alone (n = 2), were thawed and incubated for 24 hours at 37°C,
5.5% CO2 in X-vivo 10 medium, supplemented with glutamine, gen-
tamycin, DNase, heparin, IL2 (6000 IU/ml) and 1% human serum albu-
min. A median of 62x106 MNC, 0.43x106 colony-forming units, 0.6x106
CD3+/CD16+ cells, 22X106 CD3+/CD16- cells and 0.7X106 C D 3 -
/CD16+ cells/kg were infused. As determined by 5 1Cr-release killing
assays, a median of 6611 Natural Killer and 860 Lymphokine-Activated
Killer lytic units were given. After the infusion of IL2-activated PBSC,
the maximum tolerated dose of CI IL2 was 0.6X106 I U / M2 for 4 weeks.
A neutrophil count ≥ 500 and platelet count (untransfused) ≥ 2 0 , 0 0 0
c e l l s / m m3 were reached at a median of 12 days. There were no treat-
ment-related deaths. With a median follow-up of 17 months (range 8-
47), 12 patients (36.4%) have died of progressive disease at 6-25 months.
Nine patients with Breast cancer have died; 9 remain alive and 5 have no
evidence of disease progression. All HD/NHL and MM patients remain
alive but 1 NHL and 1 MM patient have relapsed at 20 and 11 months,
respectively. All Ovarian Cancer patients have died of progressive dis-
ease. This study suggests that the addition of IL2-incubated PBSC with
CI IL2 post-transplant is well tolerated and may prolong survival in
patients with Lymphoma, MM, and Breast Cancer. 
5 0
HIGH DOSE THERAPY AND AUTOLOGOUS TRANSPLANTATION FOR
T-CELL NON-HODGKIN’S LYMPHOMAS: THE STANFORD EXPERIENCE
Hu, W.W.; Cao, T.M.; Higgins, J.P.; Negrin, R.S.; Stockerl-Goldstein, K.E.;
Johnston, L.J.; Shizuru, J.A.; Taylor, T.L.; Blume, K.G.; Horning, S.J. Stanford
University Medical Center, Stanford, CA
The T/NK-lymphoid neoplasms are comprised of a heterogenous group of
diseases. Aside from the International Prognostic Index (IPI) for patients with
non-Hodgkin’s lymphoma (NHL), T-cell phenotype may represent an indepen-
dent unfavorable prognostic factor. Few analyses of high dose therapy (HDC)
and autologous hematopoietic cell transplantation (AHCT) for patients with
NHL have evaluated the role of phenotype on outcome. 
A review of 427 patients with NHL treated with AHCT from March 1988 to
June 1999 identified 63 patients (14.8%) with a diagnosis of T/NK-lineage
NHL. Immunophenotyping was not available for 16 patients (3.7%). 
Cases were identified by review of surgical pathology, immunohistochemistry, and
graft-purging data. The REAL classification was used to assign a histology (Table): 
Three-year event-free survival (EFS), freedom from progression (FFP) and over-
all survival (OS) for all 63 patients are 39% [95%CI:26%-52%], 39% [27%-51%],
and 53% [40%-66%], respectively. The median EFS and FFP are 1.0 year. The
outcomes for 348 patients with B-lineage NHL include EFS 48% [43%-53%],
FFP 56% [50%-62%] and OS 56% [ 50%-62%]. The median EFS and FFP are
2.0 and 5.0 years. 
For the T/NK NHL patients, FFP does not appear to be influenced by histol-
ogy nor IPI, but appears to be influenced by disease status at AHCT, with induc-
tion-failure disease faring most poorly compared to patients transplanted in CR1
( p = 0.016) or CR2 (p = 0.07). Thirty percent of these patients had induction-
failure disease at AHCT. 
A significant proportion of patients undergoing AHCT for NHL have T/NK-
lineage disease. The aggressiveness of disease is reflected by a high number of
patients with induction-failure disease and their higher failure rates (p = 0 . 0 5 2 ) .
However, a percentage of patients do enjoy continuous disease-free survival fol-
lowing AHCT for this diverse subgroup of lymphomas. 
ASBMT: Poster Presentations 
H I S T O L O G Y NO. PTS %
Anaplastic large cell lymphoma 10 (16)
Lymphoblastic lymphoma 8 (13)
Peripheral T-cell lymphoma, not otherwise specified 27 (43)
Angiocentric lymphomas 8 (13)
Mycosis fungoides/Sezary syndrome 4 (6)
Angioimmunoblastic lymphoma 3 (5)
Hepatosplenic γ∆ lymphoma 1 (2)
Adult T-cell lymphoma 1 (2)
Anaplastic large cell lymphoma, Hodgkin’s-like 1 (2)
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LOW DOSE TOTAL BODY IRRADIATION PLUS STEM CELLS VERSUS
DONOR LYMPHOCYTE INFUSIONS FOR AUGMENTATION OF DONOR
CHIMERISM: IMPLICATIONS FOR BONE MARROW TRANSPLANTATION
FOR SICKLE CELL ANEMIA
Iannone, R.; Luznik, L.; Engstrom, L.W.; Fuchs, E. Johns Hopkins Oncology
Center, Baltimore, MD
Allogeneic bone marrow transplantation (BMT) can cure sickle cell
anemia (SCA) but is associated with significant toxicity. Non-myeloabla-
tive (NM) BMT reduces toxicity but may result in a level of donor
chimerism that is too low to prevent the manifestations of SCA. Donor
lymphocyte infusions (DLI) can augment donor hematopoietic
chimerism but may also result in GVHD. Based on results of syngeneic
BMT following low dose TBI in mice, we hypothesized that administer-
ing T-depleted bone marrow (BM) after low dose TBI would also be an
effective method to augment donor chimerism after NM-BMT. 
Stable low level (2.28-5.7%) donor chimerism was established in
C3H.SW (H-2 b, CD45.1 negative) recipients of 100 million B6-Ly5.2
(H-2 b, CD45.1 positive) spleen cells IV and 200mg/kg cyclophos-
phamide, 3 days later. Four weeks later, groups of 2 or 3 mice were given
100cGy TBI plus graded doses (0 to 10 million) of T-cell depleted B6-
Ly5.2 BM or DLI with B6-Ly5.2 spleen cells (10 million -100 million)
with or without 10 million T-cell depleted B6-Ly5.2 BM cells. Donor
chimerism was measured by flow cytometry of peripheral blood at 11
and 16 weeks after augmentation. At 20 weeks, donor chimerism in
splenic T cells and BM myeloid cells was measured. 
Summary: 1.Donor chimerism was augmented more rapidly, and to a
greater extent, by stem cell infusion after low dose TBI than by DLI.
2.Chimerism is more effectively augmented when marrow stem cells are
added to DLI. 
Conclusion: T-depleted BM after low dose TBI is an effective alterna-
tive to DLI for augmenting donor hematopoietic chimerism following
non-myeloablative BMT. 
5 2
EFFECTS OF MIXED HEMATOPOIETIC CHIMERISM ON HEMATOLOGIC
PARAMETERS AND DISEASE PROGRESSION IN A MOUSE MODEL OF
SICKLE CELL ANEMIA: IMPLICATIONS FOR NON-MYELOABLATIVE
BONE MARROW TRANSPLANTATION
Iannone, R.1; Luznik, L.2; Engstrom, L.W.2; Noffsinger, L.2; Hawkins, A.L.3;
Casella, J.F.1; Askin, F.B.3; Fuchs, E.2 1. Johns Hopkins Medical Institutions,
Divisions of Pediatic Hematology and Oncology, Baltimore, MD; 2. Johns Hop -
kins Oncolgy Center, Division of Immunology/Hematopoiesis and Hematologic
Malignancies, Baltimore, MD; 3. Johns Hopkins Medical Institution, Depart -
ment of Patholgy, Baltimore, MD
Non-myeloablative bone marrow transplantation (NM-BMT) result-
ing in mixed hematopoietic chimerism is a promising new treatment for
sickle cell anemia (SCA). The fraction of normal red blood cells (RBCs)
required to prevent disease progression is not known. Recurrent stroke
and pain crises in patients receiving chronic transfusions, whose sickle
cell fraction is less than 30%, suggests that progressive organ damage
occurs. Using a mouse model of SCA, we attempted to determine the
threshold of sickle RBCs below which organ pathology does not result.
We also examined the relationship between myeloid bone marrow
chimerism and peripheral RBC chimerism. Forty five B6-Ly5.2 male
mice were lethally irradiated and given varying proportions of marrow
from B6-Ly5.2 male and female mice transgenic for human alpha,
gamma and sickle beta hemoglobin. Semi-quantitative cellulose acetate
hemoglobin electrophoresis was performed on all animals at 10 weeks.
Selected animals were sacrificed at 11 and 14 weeks and examined for:
peripheral blood myeloid chimerism by X-Y FISH, spleen weight, hgb
concentration (when possible), peripheral blood smear [scored 0(normal)
-16(sickle) based on hypochromia, polychromasia, nucleated RBCs and
abnormal shapes] and pathologic inspection of liver and spleen [scored 0
(normal) - 8 (sickle) based on sinusoidal congestion, hemosiderin deposi-
tion (spleen and liver); loss of follicular architecture, extramedullary
hematopoiesis (spleen) and degree of infarcts (liver)]. 
Results:(see table) 
Summary: 1.Normal myeloid chimerism greater than 50% results in
nearly 100% normal hgb chimerism. 2.Anemia persists until nearly full
normal myeloid chimerism is achieved. 3.Organ pathology can occur with
sickle hgb levels below 30% and severity correlates with sickle hgb level. 
Conclusions: As in humans, organ damage can occur even when sickle
hgb levels are reduced to 30%. Therefore, NM-BMT may be most
effective if sickle hgb levels are reduced to zero. When sub-optimal
chimeras result, post-BMT augmentation of donor chimerism should be
considered (see abstract #6259). 
ASBMT: Poster Presentations
% S P L E E N % S P L E E N EST NL L I V E R
W T N O R M A L W E I G H T N O R M A L H G B S M E A R C H I M E R I S M I N F A R C T P A T H O L O G Y
( G ) H G B ( G ) M Y E L O I D ( G / D L ) S C O R E ON SMEAR (%) ( + / - ) S C O R E
22.9 10 0.8 10 13.5 12.5 + 5.5
25.5 10 0.7 15.5 13 12.5 + 6.5
26.5 10 0.7 23 16 5 + 6
25.5 10 0.65 4.5 4.8 14.5 12.5 + 4.5
24.5 50 0.5 22 9 65 + 5.5
24 60 0.3 25.5 9 50 + 4.5
26.2 60 0.44 30.5 6.4 12.5 50 +/- 3.5
25.1 70 0.2 40 5.5 65 - 4
25 70 0.3 32 8.5 50 - 3
26 75 0.23 39 9.2 6 65 + 4
28.3 80 0.2 31 4 82.5 - 2
25.9 90 0.095 52 11.7 1.5 95 - 0.5
28.5 90 0.075 77.5 12.9 1 95 - 0
23.8 95 0.1 81.5 2 92.5 - 0.5
29.3 100 0.1 98 1 100 - 0
31 100 0.095 94.5 14.0 0.5 100 - 0
% DONOR % DONOR
N % DONOR % DONOR SPLEEN T-CELLS BM MYELOID CELLS
( M E A N ± S E M ) ( M E A N ± S E M ) ( M E A N ± S E M ) ( M E A N ± S E M )
Treatment 11 Weeks 16 Weeks 20 Weeks 20 Weeks
None 3 1.7 (0.6) 8.5 (4.6) 14 (7.8) 8.5 (9.9)
TBI Alone 2 0.7 (0.7) 4.4 (2.5) 2.2 (0.5) 3.2 (1.8)
TBI + 3 Million Marrow 3 10.6 (3.6) 32 (6.9) 26 (5.5) 40 (10.8)
TBI + 10 Million Marrow 3 12.1 (1.0) 56 (4.2) 32 (0.6) 71 (5.8)
10 Million Spleen Cells 3 1.8 (0.9) 6.1 (2.9) 11.6 (4.2) 4 (2.0)
100 Million Spleen Cells 3 2.3 (1.0) 5.6 (1.3) 13.7 (0.3) 8 (0.6)
10 Million Spleen Cells
+ 10 Million Marrow 2 4.6 (0.9) 13.2 (10.3) 25.5 (0.5) 32 (6.0)
100 Million Spleen Cells
+ 10 Million Marrow 3 1.9 (0.5) 11.8 (5.5) 23.3 (1.4) 28.7 (4.7)
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CYTOTOXICALLY IMPAIRED DONOR T CELLS CAN SUPPORT SHORT-
TERM BUT NOT EXTENDED ALLOGENEIC MARROW ENGRAFTMENT
FOLLOWING MHC I/II MISMATCHED BONE MARROW TRANSPLANTA-
T I O N
Jiang, Z.; Levy, R. University of Miami School of Medicine, Miami, FL
We are interested in the role of donor T-cell cytotoxic function in
BMT and GVHD. Previous studies showed that T-cells from fas-L/per-
forin double deficient donors (B6-cdd) could induce GVHD in a MHC
class I/II mismatched model (H-2b → H - 2d). The present study was
examined the capacity of cytotoxically impaired donor T-cells to establish
chimerism following BMT. 5x106 T-cell depleted B6-Ly5.1 marrow was
transplanted into sublethally irradiated Balb/c recipients with differing
numbers of T-cell populations from B6-cdd or wild type B6 donors.
Chimerism was assessed by: 1) short-term CFU assay to examine lineage-
committed progenitor cells in recipient spleens and 2) peripheral
chimerism to evaluate longer-term engraftment. Varying dosages of TBI
were tested to determine the level that prevented donor CFU activity.
Few colonies were detected without T-cells added to the marrow innocu-
lum after sublethal 7.0 Gy irradiation. The addition of B6-cdd T-cells
was found to support the presence of committed progenitors in Day 5
recipient spleen. Compared to normal T-cells, cdd T-cells exhibited
slightly less capacity (1x106 B6-cdd T-cells: 90±3 colonies/2.5x105 s p l e n o-
cytes vs. 0.5x106 wild type B6 T-cells: 73±11 colonies/2.5x105 s p l e n o-
cytes). Ly5.1 staining demonstrated the colonies were donor marrow
derived. Enriched T-cell subsets also supported the presence of these lin-
eage-committed progenitors. Examination of peripheral chimerism
(PBMC) demonstrated that, for the first few weeks following BMT,
recipients of both B6 and B6-cdd T-cells contained up to 94% donor
derived cells. However, by 3-4 weeks, a large percentage of donor-
derived PBMCs in recipients of B6-cdd T-cells were undergoing apopto-
sis, replaced by host derived cells. In contrast, recipients of wild type B6
T-cells continued to demonstrate >95% donor derived populations.
These findings demonstrated that cytotoxically impaired T-cells could
support short-term donor cell engraftment. However, as reported by oth-
ers (Blood, 92(6):2177-81, 1998.), granule/fas-L dependent donor T-cell
cytotoxic function is apparently required for long-term engraftment.
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CONTRASTING TISSUE INJURY IN EXPERIMENTAL MODELS OF
GRAFT-VERSUS-HOST DISEASE ELICITED ACROSS RELATED MINOR
HISTOCOMPATABILITY ANTIGEN BARRIERS
Jones, S.C.1; Friedman, T.M.1; Statton, D.M.1; Murphy, G.2; Korngold, R.1
1. Kimmel Cancer Institute, Thomas Jefferson University, Philadelphia, PA; 2.
Department of Pathology, Anatomy and Cell Biology, Jefferson Medical Col -
lege, Philadelphia, PA
Naive C57BL/6 (B6) CD4+ T cells mediate severe graft-versus-host
disease (GVHD) when transferred into lethally irradiated, minor histo-
compatability antigen (miHA) disparate BALB.B recipients. The CXBE
recombinant inbred strain expresses a subset of the BALB.B repertoire of
miHA, and develops a much less severe form of GVHD. CDR-3 size
spectratype analysis has allowed us to molecularly characterize the CD4+
TCR Vβ response to the multiple miHAs responsible for GVHD in
these two strain combinations. The data indicated a number of overlap-
ping responses in both strain combinations, as well as evidence for speci-
ficities directed against unique BALB.B miHA. To better understand the
pathogenesis of severe GVHD mediated by CD4+ T cells, we have begun
to characterize the differences in tissue-specific pathology between the
B 6 ->BALB.B and B6->CXBE combinations. Immunohistochemistry of
day 30 post-bone marrow transplant CXBE and BALB.B lingual epitheli-
um reveals a similar degree of CD4+ T cell infiltration. This is supported
by the presence of equivalent numbers of apoptotic keratinocytes in the
epithelium of both the CXBE and BALB.B recipients. On the other
hand, a striking contrast in tissue pathology was observed in the intestinal
mucosa. Clinically, CXBE recipients do not present with signs of intesti-
nal GVHD, compared to symptoms of diarrhea and prolapsed bowel in
the BALB.B mice. Moreover, there is a significant difference in the num-
ber of apoptotic crypt epithelial cells in the small intestine of the CXBE
versus the BALB.B. This data also correlates with a decrease in the num-
ber of donor CD4+ intraepithelial lymphocytes in the crypt epithelium of
the CXBE compared to the BALB.B. Interestingly, symptoms of intesti-
nal GVHD are also not observed when host pre-sensitized donor CD4+
T cells are transplanted, suggesting that this tissue site may prove valu-
able in understanding the pathogenesis of severe GVHD in the B6-
>BALB.B strain combination. 
5 4
DOMINANT PERIPHERAL TOLERANCE AND DIMINISHED GVH REAC-
TIVITY AFTER DLI THERAPY: A CASE OF MISTAKEN IDENTITY?
Johnson, B.D.; Becker, E.E.; Truitt, R.L. Medical College of Wisconsin, Mil -
waukee, WI
Maintaining tolerance to self-antigens involves clonal deletion (cen-
tral tolerance) as well as regulation of self-reactive T cells in the
periphery (dominant peripheral tolerance). Depletion of immunoregu-
latory T cells in normal naive mice can result in autoimmune disease.
Here, we examined the role of donor-derived regulatory T cells pro-
duced by the host thymus after allogeneic BMT in suppressing the
alloreactivity of splenic T cells given as donor leukocyte infusion (DLI)
therapy. Lethally irradiated AKR mice (H-2 k, T h y 1 . 1+) were given
TCD BM from C57BL/6 donors (H-2b,Thy 1.1+ and infused 21 or 28
days later with 30x106 spleen cells from Thy1-congenic donors (H-
2b, T h y 1 . 1+) to stimulate DLI therapy. In vivo depletion of marrow-
derived Thy1.2+ T cells with allele-specific mAb resulted in lethal
GVHD after DLI. Control mice given no antibody developed signifi-
cantly less GVHD after DLI. There was a higher percentage of
infused CD8+DLI cells in the spleens of Thy1.2 depleted chimeras
than in the nondepleted controls. Suppressive activity mediated by the
T h y 1 . 2+cells was detected in vitro, but only with cells from chimeras
given DLI. These results implicated donor marrow-derived regulatory
T cells in suppressing GVH reactivity after DLI. To confirm that the
cells were coming from the repopulated thymus, host mice were
thymectomized, then irradiated, transplanted and given DLI on day
28. The severity and intensity of GVHD in athymic hosts was equiva-
lent to that of euthymic hosts depleted of marrow-derived Thy1.2 reg-
ulatory cells with mAb. Using TCR, CD4 and CD8 deficient mice as
BM donors, we found that the regulatory T cells were α βT C R+ a n d
mostly CD4+. Regulatory activity was diminished when BM from
FasL-deficient donors was used for BMT, implicating a role for
Fas:FasL interactions. We suggest that donor-BM-derived
immunoregulatory T cells emerging from the host thymus “mistake”
the alloreactivity of DLI cells as “autoaggression” against the new self.
5 6
RITUXIMAB WITH IFOSFAMIDE, MITOXANTRONE AND ETOPOSIDE
(RIME), FOR RELAPSED OR REFRACTORY B-CELL NON-HODGKIN’S
LYMPHOMA, PRIOR TO HIGH-DOSE THERAPY AND ASCT, AND POST-
T R A N S P L A N T
Joyce, R.M.1 , 2; Krasner, C.1 , 2; Kennedy, L.1; Uhl, L.1 , 2; Smith, T.1; Giallom -
bardo, N.1; Hurley, D.1; Levine, J.1 , 2; McDermott, D.1 , 2; Avigan, D.1 , 2 1. Beth
Israel Deaconess Medical Center, Boston, MA; 2. Harvard Medical School,
Boston, MA
This is a pilot phase Ib/II study of the combination of rituximab and
ifosfamide 6 grams/m2, mitoxantrone 8mg/m2 and etoposide 300mg/m2,
and g-csf, prior to HDC-ASCT. It is open to a heterogeneous patient
population with a variety of B-cell (CD20+) NHL, including patients
with refractory or multiply relapsed disease not routinely eligible for
HDC-ASCT. Pre-clinical data suggests that rituximab can reverse resis-
tance to etoposide and other chemotherapuetic agents. The primary
objective is safety of this combination with particular attention to infec-
tious complications. The secondary objectives are to assess the ability to
render a lymphoma-free hematopoietic stem cell product, and to over-
come chemotherapy-resistance. Eleven patients have been treated to
date. Four patients with refractory disease have achieved a PR and are
now receiving HDC-ASCT. The first, a 63 yo women with diffuse large
cell lymphoma, relapsed 4 months after CHOP, was subsequently
refractory to 3 cycles of MINE, and progressed on ESHAP, is now in
PR undergoing HDC-ASCT. The second patient is a 49 yo man with
primarily refractory diffuse aggressive lymphoma, progressed on CHOP
and ESHAP, now in PR after three cycles of RIME, preparing for
HDC-ASCT. A third patient is a 58 yo woman with multiply-relapsed
mantle cell lymphoma, is in CR prior to HDC-ASCT. The fourth is a
58 yo man with primary refractory diffuse large NHL in PR. The
response rate in the six fully evaluable patients is 6/6. Five additional
patients are too early for evaluation. Serial examination of bone marrow
and stem cells for tumor contamination using PCR, immunocytochem-
istry and clonogenic assays are ongoing. Toxicity has been mild : Two
episodes of uncomplicated febrile neutropenia and one episode of grade
3 rapidly reversible ifosfamide neurotoxicity. Enrollment is continuing.
This regimen may increase the availability of HDC-ASCT to otherwise
unfavorable candidates. 
ASBMT: Poster Presentations 
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BUCY WITH AND WITHOUT VP-16 FOR HLA-MATCHED, SIBLING
BONE MARROW TRANSPLANTATION
Kalaycio, M.; Roshini, G.; Pohlman, B.; Andresen, S.; Boparai, N.; Bolwel, B.
Cleveland Clinic Foundation, Cleveland, OH
We started preparing patients with acute myelogonenous leukemia
(AML) with BuCy (Busulfan 16 mg/kg, Cyclophosphamide 120 mg/kg)
for allogeneic bone marrow transplant (BMT) in November 1988. In
September, 1994 we added VP (Bu 14 mg/kg, Cy 120 mg/kg, VP-16 50-
60 mg/kg) to this regimen. All patients received unmanipulated donor
marrow with GVHD prophylaxis consisting of cyclosporine A or FK-506
in combination with either methylpredonisolone or methotrexate. We
have now treated 51 patients with either preparative regimen, followed by
HLA-matched sibling BMT, and have retrospectively reviewed our expe-
rience with both regimins to determine if either regimen is superior.
Patient characteristics at time of BMT are listed in the table. 
The table graphically illustrates our recent tendency to treat older
patients with more advanced disease. With these differences in mind,
there was no statistically significant difference between the two regimens
with respect to median bilirubin level, engraftment, time to engraftment,
length of stay or incidence of >Grade II Acute GVHD (30 vs 19%;
p = 0.51). However, there was significantly more severe mucositis (55%
vs 10%; p = 0.0001) in the BuCyVP group. With the mean follow-up
period of 2 years were not significantly different between the two treat-
ment groups (34 and 38% vs 52 and 52%; p = 0.23 and 0.23). The differ-
ences in toxicity and the similarity in survival persisted when the two
groups were adjusted for differences in age and remission status by mul-
tivariate analysis. We concluded that BuCy is less toxic and has similar
e f ficacy to BuCyVP in this patient population.
5 9
MPA/MPAG LEVELS DURING IV MYCOPHENOLATE MOFETIL (CELL-
CEPT™) PROPHYLAXIS OF ACUTE GVHD IN BMT/SCT RECIPIENTS
Kiehl, M.G.1; Shipkova, M.2; Guenzelmann, S.1; Basara, N.1; Schuetz, E.2; Arm -
strong, V.W.2; Hartert, A.M.1; Oellerich, M.2; Fauser, A.A.1 1. Clinic for Bone
Marrow Transplantation, Idar-Oberstein, Germany; 2. University of Göttingen,
Göttingen, Germany
Transplantation of bone marrow or peripheral blood stem cells from an
HLA-matched related or unrelated donor is an effective, potentially cura-
tive treatment for malignant hematological disorders. Since graft versus
host disease (GvHD) contributes to morbidity and mortality after stem cell
transplantation, a more effective prophylactic regimen is needed to prevent
this complication. MMF (oral formulation) has been shown to prevent
acute GvHD in SCT recipients without gut involvement. We are report-
ing the first data of an ongoing trial using the i.v. formulation of MMF (2 x
1g/day) in combination with cyclosporine A and prednisolone for the pro-
phylaxis of aGvHD in SCT recipients. Ten hour concentration time curves
were determined after the first dose and on the 5th day of treatment. Pre-
dose concentrations were determined on days 1 to 4. MPA and MPAG
were quantified by reversed phase hplc. Twenty-two patients (7 ALL, 7
CML, 8 AML) have been included in this protocol so far. Data on MPA
and MPAG levels (mean + sd) are available from 14 patients at the time of
analysis. Data on day 5 are depicted in the table. One patient demonstrat-
ing lowest MPA levels at all time points did not respond and developed
severe life threatening gut GvHD. At this time we have not observed nega-
tive side effects on hematopoiesis or GI tract. On the contrary, engraftment
seems to be accelerated in MMF treated patients. MMF in the prophylaxis
of GvHD demonstrated the feasibility and effectiveness suggesting that
MMF might not only be an alternative to MTX for the prevention of
GvHD, MMF also revealed less side effects compared to MTX. 
MPA and MPAG levels in mg/l. Data are give as median and standard
deviation (in parenthesis).
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MODULAR TEACHING FOR THE PROGENITOR CELL TRANSPLANT
P A T I E N T
Kemp, J.A.; Dickerson, J.T. Methodist Hospital, San Antonio, TX
Information and teaching provided to the progenitor cell transplant
(PCT) patient is often a complex and difficult process for both the
patient and caregiver. Inability to process information and apply princi-
ples of self-care can result in poor outcomes. The goals of this project
were to develop a consistent method for teaching PCT patients/care-
givers, to encourage retention of information, and allow the
patient/caregiver to focus on aspects of self care related to the phases of
treatment. A multidisciplinary team developed a three part modular
teaching program. Three teaching modules were designed to refle c t
information relative to the three phases of PCT; pre-transplantation,
transplantation, and post-transplantation. A three-part multidisciplinary
documentation tool was designed to allow for clear communication
among caregivers as to the progress of teaching. The structured content
of the tool allows for consistent documentation that systematically
r e flects the content of the patient education modules. Within 24-72
hours following discharge, patient interviews are held to determine
retention of information regarding self care. Patient responses regarding
knowledge and retention of information are documented on the “BMT
Patient Education Audit Form”. Outcome achievement including reten-
tion of information and the effectiveness of teaching are compiled and
reported quarterly to the Quality Assurance Committee. Quarterly and
annual review of teaching outcomes provide the staff with the opportu-
nity to revise the content of the modules and/or teaching strategies.
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HAPLOIDENTICAL STEM CELL TRANSPLANTATION IN CHILDREN
Klingebiel, T.E.1; Lang, P.1; Schumm, M.1; Bader, P.1; Schlegel, P.G.1;
Eyrich, M.1; Greil, J.2; Niethammer, D.1; Handgretinger, R.1 1. Childrens
University Hospital, Tuebingen, Germany; 2. Childrens University Hospital,
Erlangen, Germany
Positively selected HLA-disparate CD34+ progenitor cells were isolat-
ed from the peripheral blood of parental donors by the MACS technique
and transplanted into 39 pediatric patients (31 malignant and 8 non-
malignant diseases, median age 7.25 years). 14 of the 31 children with
malignant disease were not in remission. 26 donors were HLA three-loci
mismatch, 8 two-loci and 5 one-locus mismatch. The purity of the
CD34+ stem cell graft was 98 – 99%, the median number of transplant-
ed CD34+ cells was 20.7 x 106/kg (range 5.4 - 50.4 x 106/kg). The medi-
an number of T-lymphocytes was 1.55 x 104/kg. The time to reach
>1 0 0 0 /ml neutrophiles or to reach independence from platelet substitu-
tion was 11.4 or 28 days, respectively. Only a short term (7 pts) or no
prophylaxis (32 pts) for GvHD was necessary. GVHD (grade≥II) was
seen in 6 patients and notably only in those who had received donor
lymphocyte infusion. The B-lymphocyte contamination of the isolated
CD34+ cells was 0.2 % and no EBV-associated lymphoproliferative syn-
drome occured. Primary engraftment was seen in 34 patients. Non-
engraftment/rejection occurred in two/three patients, respectively. In
four of these 5 patients, a successful second transplant was performed
with CD34+ cells from the same donor after an immunological recondi-
tioning. The speed of the recovery of T-, B- and NK-lymphocytes was
dependent on the number of transplanted CD34+ cells and was more
rapid if the number of CD34+ was>20 x 106/kg. 16 of the 39 (41%)
patients are alive and disease-free after a median follow-up of 6 months
(range 1- 41 months). The main cause of death was relapse of the under-
lying nonmalignant disease (13/39 patients); 10 children died of trans-
plant-related causes (VOD 2, infection 7, nonengraftment 1). The over-
all survival is 0.38 (SE 0.09).
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I N F U S I O N I N F U S I O N A F T E R A F T E R A F T E R A F T E R A F T E R I N F U S I O N
MPA 0.02 (0.3) 2.75 (3.3) 1.09 (0.7) 0.55 (0.3) 0.71 (0.9) 0.19 (0.4) 0.59 (0.4) 0.04 (0.5)
MPAG 44.8 (40) 56.6 (50) 56.2 (39) 54.4 (50) 51 (42) 41.8 (46) 31.6 (38) 30.8 (40)
M E D I A N A G E F E M A L E F E M A L E R E M I S S I O N
N A G E >4 0 % DONOR % %
BuCy 21 36 10 52 38 90
BuCy VP 30 43 60 40 60 73
p = 0.005 <0.001 0.382 0.124 0.129
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RELATIONSHIP BETWEEN CELL DOSE AND ACUTE GRAFT VERSUS
HOST DISEASE FOLLOWING ALLOGENEIC PERIPHERAL BLOOD STEM
CELL TRANSPLANTATION
Klumpp, T.R.; Herman, J.H.; Sabol, P.J.; Mangan, K.F. Temple University,
Philadelphia, PA
There are conflicting reports regarding the incidence of acute graft-
versus-host disease (AGVHD) following allogeneic peripheral blood
stem cell transplantation (PBSCT) as opposed to allogeneic bone mar-
row transplantation (BMT). In order to address this issue, we examined
the relationship between the incidence of AGVHD, cell source (pbsc vs
marrow), cell dose, and other relevant clinical and laboratory parame-
ters among 99 patients undergoing HLA-matched sibling PBSCT or
HLA-matched sibling BMT. For the purpose of this analysis we exclud-
ed patients receiving submyeloablative transplants, second transplants,
or unrelated donor transplants, and patients who died prior to day +14
following transplant. The study included 71 patients undergoing BMT
and 28 patients undergoing PBSCT. Diagnoses were well-balanced
between the two groups and included AML (n = 31), CML (n = 2 7 ) ,
myeloma (n = 9), non-Hodgkin’s lymphoma (n = 8), aplastic anemia
( n = 7), and other hematologic malignancies (n = 17). Conditioning reg-
imens were well-balanced between the two groups and included BUCY
( n = 67), CYTBI (n = 15), MELTBI (n = 9), CYATG (n = 6) and
VPTBI (n = 2). The median CFU-GM, CD34, mononuclear cell
(MNC), and total nucleated cell (TNC) doses are indicated in the table.
The median age of patients undergoing BMT was 37 years, vs 43 years
among patients undergoing PBSCT (p = 0.05). The incidence of grade
2-4 acute graft-versus-host disease among patients undergoing PBSCT
was 68%, versus 27% among patients undergoing BMT (p = 0 . 0 0 0 2 ) .
Statistical analysis indicates that cell dose and cell source (marrow vs
pbsc) both appear to be associated with the risk of AGVHD following
allogeneic transplant. We hypothesize that the conflicting reports
regarding the relationship between stem cell source and AGVHD may
be attributable to variations in cell dose between transplant centers. A
prospective, randomized trial specifically targeting cell dose will be
required to definitively resolve this issue. 
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FLUDARABIN PLUS LOW-DOSE TBI FOLLOWED BY ALLOGENEIC
STEM CELL TRANSPLANTATION IN ADVANCED HEMATOLOGIC MALIG-
N A N C I E S
Kobbe, G.; Aivado, M.; Hünerlitürkoglu, A.; Schneider, P.; Rieth, C.; Rong,
A.; Hildebrand, B.; Pape, H.; Heyll, A.; Haas, R. University Düsseldorf, Düs -
seldorf, Germany
Eight patients with advanced hematologic malignancies (AML 3,
MDS 2, CML 1, NHL 2, median age 55.5 years, range 44-64) received
a conditioning regimen of Fludarabin 3x 30mg/m2 plus low-dose TBI
(2Gy) followed by unseparated, G-CSF mobilized peripheral blood stem
cell grafts (median 8.78x106CD34+cells/kg, range 4.72-13.1) from their
HLA-identical sibling donors. Mycophenolate-mofetil (MMF, day 0-28)
and Cyclosporine A (CsA, day -1-56) were given to facilitate engraft-
ment and prevent acute graft versus host disease (GvHD). Sequential
molecular chimerism-studies using STR-PCR and FISH were per-
formed on bone marrow, CD34+cells, CD3+cells and granulocytes.
Patients with persistent mixed chimerism on day 60 were scheduled to
receive a single infusion of 10x106 donor lymphocytes per kg. 
Regimen related toxicity was minimal. All patients had evidence of
donor cell engraftment on day 14. Donor hematopoiesis disappeard by
day 28 in one Patient with AML in 2nd relapse and progressive disease.
All other evaluable patients, including one with chemotherapy refractory
NHL in relapse, are alive in CR (2) or PR (2) and continue to present
with mixed chimerism (median follow up 71 days, range 15-92) with
donor cells ranging from 42-95% (bone marrow) and 62-90% (blood).
One patient developed steroid responsive acute GvHD II°. Four patients
received donor lymphocyte infusions so far. 
We suggest that non-myeloablative allogeneic stem cell transplanta-
tion from HLA-identical sibling donors using Fludarabin/LD-TBI and
MMF/CsA is associated with minimal toxicity and results in a state of
mixed chimerism in the majority of patients. The immunotherapeutic
e f ficacy of this approach in hematologic malignancies remains to be
determined. 
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A COMBINATION OF UNRELATED ALLOGENEIC CD34+ CELL TRANS-
PLANTATION AND SEQUENTIAL T-CELL ADD BACK AFTER REDUCED
INTENSITY CONDITIONING 
Kobbe, G.; Schneider , P.; Aivado, M.; Hünerlitürkoglu, A.; Rieth, C.; Rong,
A.; Niederste-Hollenberg, A.; Haas, R.; Heyll, A. University Düsseldorf, Düs -
seldorf, Germany
Seven patients (median age 44, range 31-48) with AML in relapse (2),
multiple myeloma (2) or CML (3) at high-risk for treatment related
complications (6 unrelated donor, 1 preexisting organ impairment) were
treated with a less intensive conditioning regimen (Melphalan 1x 140-
200mg, Thiotepa 2x 5mg/kg, Cyclophosphamide 2x 60mg/kg and ATG
4x 5-10mg/kg) followed by transplantation of mobilized, T-cell depleted
allogeneic peripheral blood stem cell grafts. Sequential low-dose T-cell
( 5 x 1 05- 2 x 1 06CD3+/kg) add-backs were given at day 50 and 100. Mobi-
lized apheresis products were processed on the Isolex 300i (median
CD34+-recovery 49%, range 30-84, median purity 91%, range 55-98)
and contained a median of 3.96x106CD34+cells/kg (range 1.96-5.7) and
0 . 3 8 x 1 05CD3+cells/kg (range 0.07-1.58). All patients received
Cyclosporine A and G-CSF post-transplant. 
Toxicity consisted of alopecia, nausea and moderate to severe mucosi-
tis (WHO II-IV°). There was no case of life threatening VOD or acute
GvHD >II°. One patient with myeloma, who had previously received
two autografts died on day+1 of acute pulmonary failure due to capillary
leakage. Median time to granulocytes >0 . 5 x 1 09/l and platelets >2 0 x 1 09/ l
was 11 days (range 8-12) and 13 days (range 10-19). One patient devel-
oped steroid responsive GvHD II° following the first lymphocyte infu-
sion. One patient (sAML in relapse, family donor) relapsed on day 180
and died of progressive disease. There are 5 patients alive in hematologic
remission (median follow up 110 days, range 6-362) with a median of
95% donor hematopoiesis (range 61-100). The protocol is feasible, with
moderate toxicity, rapid engraftment and absence of severe GvHD and
life-threatening opportunistic infections even in the unrelated setting. A
longer follow up on a greater number of patients is needed to comment
on long term tumor control and immune reconstitution. 
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NONINVASIVE IMAGING OF RADIOLABELED ANTIGEN-SPECIFIC
HUMAN T LYMPHOCYTES TRANSDUCED TO EXPRESS NGFR AND HSV-
TK AFTER ADOPTIVE TRANSFER IN SCID-MICE
Koehne, G.; Gallardo, H.F.; Zanzonico, P.; May, C.; Balatoni, J.; Tjuvajev,
J.; Blasberg, R.; Sadelain, M.; O’Reilly, R.J.; Larson, S.M. Memorial-Sloan
Kettering Cancer Center, New York, NY
In order to examine the migration of genetically altered antigen-specif-
ic T lymphocytes to tumors after adoptive transfer in vivo, we have
exploited the capacity of transduced T cells expressing HSV-TK to selec-
tively incorporate radiolabeled 2’-flu o r o - 2 ’ d e o x y - 1 - b - D - a r a b i n o f u r a n s y l -
5-iodo-uracil (FIAU) into the DNA. We hypothesized that labeling
w i t h1 3 1I-FIAU would allow imaging of transduced T cells with planar
gamma camera in vivo. EBV-specific donor T cells were transduced with
an MLV-based dicistronic vector, NIT, encoding a mutant NGFR and
herpes simplex thymidine-kinase (HSV-TK). We labeled NIT trans-
duced EBV-specific T cells with 100µCi/ml of 1 3 1I-FIAU for three hours.
On testing three days later in a 5 1CR release assay, we found no difference
in the cytotoxic potential of unlabeled versus 1 3 1I-FIAU labeled NIT+ T
cells. EBV+-lymphoma bearing SCID-mice were injected i.v. with 30x106
in vitro labeled (3-10µCi) NIT+ E B V - s p e c i fic T cells. Animals were seri-
ally imaged (4h-4 days) with a gamma camera for 30 min. To acquire
high-count images, animals were sacrificed 4 days after T cell injection
and imaged for 12h. These images and autoradiograms of animals
showed highly specific localization of the cells in the tumor only, with
high tumor to normal tissue ratios (liver: 32; spleen: 17; muscle: 160). In a
separate experiment, we injected T cells in animals bearing an autologous
E B V+-lymphoma (left flank) and a mismatched allogeneic lymphoma
(right flank). The labeled HLA-restricted EBV-specific T cells selectively
targeted the autologous tumor. Thus, in vitro labeling with 1 3 1I-FIAU of
HSV-TK transduced T lymphocytes is feasible without compromising
the immune function of these cells. Localization of adoptively transferred
T cells can be imaged in vivo in the host over time. This approach should
facilitate comparative analyses of T cells generated against different virus-
s p e c i fic or tumor-specific antigens for their capacity to home to and to
induce regression of targeted tumors in vivo.
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HSC SOURCE C F U - G M C D 3 4 M N C T N C
Marrow 2.9x104 4.2x104 1.1x108 3.2x108
Blood 13.9x104 6.0x106 5.2x108 9.1x108
p-value <0.01 <0.01 0.01 <0.01
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C D 8+ BARRIER T-CELLS REJECT MHC-MATCHED ALLOGENEIC MAR-
ROW VIA AN ANTIGEN SPECIFIC EFFECTOR PATHWAY INDEPENDENT
OF GRANULE AND CD95L MEDIATED CYTOTOXICITY
Komatsu, M.; Jurecic, R.; Levy, R. University of Miami, Miami, FL
It is evident that host cell populations with “barrier” function can
reject donor hematopoietic progenitor cells following allogeneic BMT.
Studies in mice have demonstrated that T, TNK, and NK cells are key
players in the rejection of MHC-disparate marrow. Although it has
largely been assumed that cell-mediated cytotoxicity - presumably gran-
ule and/or Fas-L dependent - are crucial for barrier function, direct evi-
dence for this effector mechanism has not been demonstrated. The pre-
sent study investigated resistance against MHC-identical marrow
allografts (BALB.B—>B6) to determine the host barrier population and
to address whether cytotoxic function by such cells was crucial for barri-
er activity. To address this issue, we analyzed barrier function in cytotox-
ically deficient mice. Host resistance was assessed by in vitro CFU assays
to determine the presence of donor progenitors in the host spleen and
marrow, post 2x106 BMT. Results demonstrated that host CD8+ T - c e l l s
but not CD4+ or NK1.1+ cells are required for the rejection of primitive
(CFU-HPP) as well as lineage-committed (CFU-IL3, CFU-GM) donor
progenitors. Recombinant inbred BALB/c x B6 (RI) donor marrow
expressing previously characterized immunodominant CTL antigens
was rejected; however, RI donor marrow lacking these antigens was not.
These results suggest host resistance to MiHA disparate donor progeni-
tors is elicited in an MHC-restricted antigen specific manner. B6 mice
d e ficient in perforin, granzyme B, or Fas-L efficiently rejected the donor
marrow progenitors. Surprisingly, cytotoxically double (perforin/Fas-L)
deficient (cdd) mice also showed unimpaired rejection. Rejection of
increasing doses of marrow (6-12x106) by cdd mice demonstrated com-
parable resistance to that of cytotoxically normal recipients. Notably,
rejection by cdd mice was also specific for the immunodominant MiHA
CTL antigens expressed by donor progenitors. These observations
demonstrated that the highly antigen specific CD8+ barrier T cell popu-
lation can effectively reject donor progenitors via effector pathway(s)
independent of granule and Fas-L mediated cytotoxicity.
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CYTOKINE GENE POLYMORPHISM IN ALLOGENEIC BONE MARROW
TRANSPLANT RECIPIENTS AND DONORS
Kuyu, H.; Manning, C.; Case, D.; Hurd, D.D. Comprehensive Cancer Center
of Wake Forest University, Winston-Salem, NC
The level of cytokine production is related to differences in the DNA
sequence in the promoter/enhancer regions of each cytokine gene. Certain
high producer cytokine genes are associated with graft rejection in solid
organ transplants. Various cytokines have been suggested to be associated
with post-BMT complications. By using a commercially available Cytokine
Genotyping Tray which detects genotypes for TGF-beta, TNF-alpha, IL-
10, IL-6 and IFN-gamma (One Lambda, Inc.), we initiated a retrospective
study on allogeneic BMT recipients and donors to assess the correlation
between cytokine gene polymorphism (CGP) and clinical outcome of
alloBMT. Cytokine alleles were identified using archived genomic DNA
which was obtained for HLA typing. Cytokine genotypes were grouped as
high, intermediate or low producers (HL/IP/LP). We have studied 15
CML patients who underwent unrelated alloBMT (7 mismatches) between
12/1/95 and 10/15/98. Median age was 41(range 19-50). Preconditioning
regimens → CY/TBI (10), CY/TBI/ARA-C (4), TBI/ATG/melphalan (1).
GVHD prophylaxis → MTX/CSA (11) or CSA/steroids (4). Median # of
in-patient days before day +100 was 54. Median time to WBC recovery
(ANC >500) was 20 days. Median time to platelet recovery (>2 0 , 0 0 0 ,
unsupported) was 53 days. 8/12 evaluable patients had grade II-IV
aGVHD. 9/10 evaluable patients experienced cGVHD (6 extensive, 4 lim-
ited). 6/15 patients are alive and in CR (4 matched, 2 mismatched). One
patient died from recurrent disease and one patient died from graft failure.
Cause of death for others varied and included infections, GVHD, ARDS,
etc. Genotyping results are as follows: For recipients: TNF-
a l p h a→3/15HP-12/15LP; IL-10→5/15HP-5/15IP-5/15LP; IL-
6→11/15HP-4/15LP; TGF-beta→7 / 1 5 H P - 3 / 1 5 I P - 4 / 1 5 L P - 1 / 1 5 N D ;
I F N - g a m m a→3/15HP-8/15IP-3/15LP-1/15ND. For donors: TNF-
a l p h a→12/13LP-1/13ND; IL-10→4/13HP-5/13IP-4/13LP; IL-
6→10/13HP-3/13LP; TGF-beta→11/13HP-1/13IP-1/13LP; IFN-gam-
m a→3/13HP-8/13IP-1/13LP-1/13ND. Cytokine gene polymorphism can
easily be detected in BMT recipients and donors. Current size of the study
is not sufficient for meaningful statistical analysis. In this ongoing evalua-
tion, a larger number of patients are being studied and results will be avail-
able for presentation at this meeting. 
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THE CORD BLOOD TRANSPLANTATION (COBLT) STUDY: THE FIRST
TWO YEARS OF RECRUITMENT AND COLLECTION BY THE COBLT
CORD BLOOD BANKS
Kurtzberg, J.1; Wagner, E.L.2; Cairo, M.S.3; Carter, S.L.2; Kernan, N.A.4;
Jensen, L.5; Gindy, L.6; Issitt, L.1; Fraser, J.K.6 1. Duke University, Durham,
NC; 2. The EMMES Corporation, Potomac, MD; 3. Georgetown University,
Washington D.C., DC; 4. Memorial Sloan-Kettering Cancer Center, New
York, NY; 5. National Heart, Lung and Blood Institute, Bethesda, MD; 6.
Univeristy of California - Los Angeles, Los Angeles, CA
The COBLT Study is a phase II multicenter study sponsored by the
NHLBI designed to determine if banked, unrelated cord blood can serve
as an adequate hematopoietic stem cell source for adults and children
with malignancies, inherited marrow failure or inborn errors of metabo-
lism. As part of this study, three cord blood banks were established to
collect and cryopreserve 15,000 cord blood units (CBUs). During the
planning phase a Standard Operating Procedure detailing all recruit-
ment, collection, processing, and cryopreservation procedures was writ-
ten. In addition, collection and processing bag sets were designed, a bar
code label set was produced, an Internet data collection system for real
time data entry was developed, and a study-specific algorithm to deter-
mine eligibility for banking was written and validated. 
In October 1997 recruitment activities were initiated at hospitals serv-
ing ethnically diverse populations. Donors with high risk characteristics,
delivery complications, or a first degree relative with a malignancy were
excluded. Donors were required to consent to infectious disease testing
and to give a detailed medical history designed to identify a risk of inher-
ited blood diseases. Two years after the initiation of recruitment activi-
ties, 1794 CBUs (50.3% White, 15.1% Black, 7.0% Asian, 15.6% His-
panic, 12.0% Mix/Other) have passed all COBLT Study eligibility
criteria and are available for analysis. These CBUs were collected from
donors with a mean age of 29.5 years (SD ±5.5). The mean CBU collec-
tion volume of these units is 80.9 ml (SD ±26.1). The mean viable nucle-
ated cell count post processing is 9.3 x 108 (SD ±4.0), and a mean nucle-
ated cell recovery of 77.8 % (SD ±9.8). The mean CD34+ cell count is
2.8 x 106 (SD ±3.3). Summaries of the delivery, collection, processing,
and cryopreservation processes will be described. Factors affecting CBU
volume and cell counts will also be presented.
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PREDICTIVE VALUE OF THE DIGENE HYBRID CAPTURE (DHC) CMV
DNA ASSAY IN PATIENTS (PTS) THAT HAVE UNDERGONE ALLOGENE-
IC STEM CELL TRANSPLANTATION (ASCT)
Lanzkron, S.M.1; Hodak, P.2; Bachier, C.1; LeMaistre, C.F.1 1. Texas Trans -
plant Institute, San Antonio, TX; 2. Southwest Texas Methodist Hospital, San
Antonio, TX
We compared the DHC Assay with routine CMV viral culture (cx.)
and shell spin (ss.) viral assay for the detection of CMV infection in
ASCT pts. Pts. were screened weekly with all 3 test. A result of >2 . 1
pcg/ml was considered a positive (+) result on the DHC test. Of 23 pts.
tested 7 were CMV negative with CMV negative donors prior to ASCT.
12 pts. had + DHC results and 11 pts. were negative. Of the12 + pts., 6
had + cx. and/or ss. results. CMV seropositive pts had significantly more
+ cx.s than those that were CMV negative (p = 0.03), this was not true for
DHC assay results. The time from + DHC result to a + cx report was 3
days in 2 pts., 7-10 days in 2 pts. and 30 days in the final 2 pts. All but 1 of
the pts. with + cx.s had DHC values of >30 pcg/ml and 1 pt. with lower
values did not require therapy. Of the 6 pts. with + DNA assays and nega-
tive cx. results, 4 were not treated. These pts. had values between 2.4 and
64 pcg/ml and have not had any clinical evidence of disease. Of the 11pts.
without + DNA tests one had a + urine cx. and fevers and was treated
with gancyclovir with resolution of symptoms. Another pt. ws found on
autopsy to have viral inclusions in the lung consistent with CMV. In all
patients with evaluable results the CMV DNA decreased toward 0 when
therapy was started. Overall the sensitivity and specificity of the DNA test
when compared to cx. or ss. results was 86% and 63% respectively (table).
We conclude that the DHC test may be useful when + at high levels in
predicting pts. with clinical disease and in these pts. can allow for early
treatment. Pts. with high levels can be treated and if cx.s are negative at
one month therapy can be discontinued.
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ESTIMATED TIME TO ENGRAFTMENT DETERMINATIONS IN PATIENTS
UNDERGOING AUTOLOGOUS PBSCT
LeFever, A.1; Murphy, B.1 , 2; Merrill, S.2; Treisman, J.1; Taylor, R.1 1. St.
Luke’s Medical Center, Milwaukee, WI; 2. Marquette University, Mil -
waukee, WI
Autologous peripheral blood stem cell transplants (PBSCT) represent
standard support following high-dose chemotherapy for treating breast
cancer. Complications such as relapse and the inability of some patients
to engraft indicate a need to more closely monitor a patient’s progress
throughout engraftment. We have characterized the growth kinetics of
cell populations following high-dose chemotherapy and PBSCT and
developed a model of engraftment. 
We studied daily post-transplant white blood cell (WBC) counts fol-
lowing PBSCT from 39 stage II or IIIa patients with breast cancer to
investigate methods to monitor the engraftment process. A hyperbolic
growth model fit the data for these 39 patients best, and with this model
a prediction of a patient’s estimated time to engraftment (TTE) is possi-
ble. Using statistical uncertainties of model parameters we have obtained
a simulated confidence interval for identifying significant changes in a
patient’s estimated TTE, which is updated daily while the patient is hos-
pitalized. 
Using this model we can: (1)quickly identify patients who will be expe-
riencing difficulties in engraftment; (2)evaluate effects of various drugs
and treatment on engraftment; and (3)estimate hospital stays with confi-
dence. 
A real-time evaluation of the model is currently being conducted to
determine the possibility of using it in a clinical setting. By creating a
mathematical model to fit WBC data, we have obtained valuable predic-
tions and information that can be used by physicians to support decisions
regarding patient progress. A model for platelet engraftment is currently
being developed. 
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ANTI-THYMOCYTE GLOBULIN (ATG) THERAPY FOR STEROID RESIS-
TANT ACUTE GRAFT-VERSUS-HOST DISEASE: RELATED VERSUS UNRE-
LATED DONOR TRANSPLANTATION
MacMillan, M.L.; Weisdorf, D.J.; Davies, S.M.; DeFor, T.E.; Ramsay, N.K.;
Wagner, J.E.; Blazar, B.R. University of Minnesota, Minneapolis, MN
High dose steroids for acute GVHD induce a durable remission in
50% of cases. A variety of second line therapies have been used with suc-
cess in about one-third of cases. In the largest single institutional study
to date, we examined the response of 109 bone marrow transplant
(BMT) patients treated from 1990-99 with ATG (15 mg/kg/dose bid x 5
days) for steroid refractory acute GVHD. Median age was 17 years
(range, 0.4 to 52 years). Sixty-three percent were males. There were 45
related (38 HLA-A, B, DRB1 matched/7 mismatched) and 64 unrelated
(20 matched/44 mismatched) donors. Preparative therapies included
cyclophosphamide and TBI (n = 71), TBI with other chemotherapy
( n = 15), chemotherapy alone (n = 22) or ATG (n = 1). GVHD prophy-
laxis consisted of cyclosporin (CSA) and methotrexate (MTX) (n = 6 3 ) ,
CSA and prednisone (n = 9), MTX, ATG and prednisone (n = 1 3 ) ,
FK506 (n = 2), MTX alone (n = 4), T-cell depletion (n = 15), and other
( n = 3). Prior to initial therapy severe acute GVHD was observed in 50
patients (grade III in 33; grade IV in 17). Median time from BMT to
first line treatment was 28 days (range 7 - 91 days). Median time from
first line therapy to initiation of ATG was 14 days (range 1 - 95 days).
Prior to therapy organs involved included skin (n = 89), lower GI tract
( n = 44), upper GI tract (n = 24) and liver (n = 14). Probabilities of sur-
vival with 95% confidence intervals are shown in the table below.
Response rates and prognostic factors relating to ATG responses in
these various patient groups are being analyzed. In summary, ATG rep-
resents an active therapy but better strategies are needed for steroid
refractory acute GVHD. 
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FLUDARABINE BASED PREPARATIVE REGIMEN MAY IMPROVE
ENGRAFTMENT RATES AFTER ALTERNATE DONOR HEMATOPOIETIC
CELL TRANSPLANTATION (HCT) IN FANCONI ANEMIA (FA)
MacMillan, M.L.1; Auerbach, A.D.2; DeFor, T.E.1; Wagner, J.E.1 1. University of
Minnesota, Minneapolis, MN; 2. The Rockefeller University, New York, NY
Graft failure (GF) is the primary obstacle to successful HCT in patients
with FA. Between February 1995 and September 1998, 25 patients with FA
were transplanted with T cell depleted marrow from alternate donors.
Preparative therapy consisted of cyclophosphamide (CY) 40 mg/kg, total
body irradiation (TBI) 450-600 cGy and anti-thymocyte globulin (ATG) with
cyclosporin A and methylprednisolone as GVHD prophylaxis. Primary and
secondary GF occurred in 11 of 24 evaluable patients. Analysis of risk factors
for primary GF revealed somatic lymphocyte mosaicism (i.e. presence of T
cell population failing to demonstrate excessive chromosomal breakage after
DEB exposure, p = 0.04) and lower graft cell dose (i.e.<median of 3.4 x 107
nucleated cells/kg, p = 0.05) were associated with GF. Stratifying patients on
the basis of somatic lymphocyte mosaicism (i.e., presence of ≥10% DEB resis-
tant T cells), the probability of neutrophil engraftment was 42% (95% CI,
14-70%) and 83% (94% CI 61-100%) for patients with and without somatic
lymphocyte mosaicism, respectively. We hypothesize that incomplete abla-
tion of DEB resistant host lymphocytes by low dose CY/TBI contributes to
the high risk of GF. To promote better engraftment with further immuno-
suppression, we added fludarabine (FLU, 140 mg/kg) to CY (40 mg/kg), TBI
(450 cGy) and ATG (150 mg/kg). Between April and December 1999, 7
patients with FA have undergone alternate donor HCT using this preparative
regimen (Table). The proportion of patients who achieved primary engraft-
ment (6 of 6 evaluable patients) was greater than previously observed (15 of 24
evaluable patients; p = .14). No patient experienced severe regimen related
toxicity. Larger patient numbers and longer follow-up are needed to verify
these preliminary encouraging results.
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SURVIVAL AFTER STEROID THERAPY FOR ACUTE GHVD: 196 RELAT-
ED COMPARED TO 255 UNRELATED DONOR TRANSPLANTS
MacMillan, M.L.; Weisdorf, D.J.; Wagner, J.E.; DeFor, T.E.; Ramsay,
N.K.; Davies, S.M.; Blazar, B.R. University of Minnesota, Minneapolis, MN
Acute graft-versus-host disease (GVHD) remains a major cause of
morbidity and mortality after allogeneic bone marrow transplantation
(BMT). In a retrospective analysis, the response of 451 BMT patients
who received prednisone, 60 mg/m2, for 14 days followed by an 8 week
taper, as initial therapy for acute GVHD at a single institution from
1990-99 was examined. Median age was 27 years (range 0.3 to 52 years)
with 41% being <18 years. Sixty percent were males. Stem cells were
HLA-A, B, DRB1 matched related (n = 196) or unrelated (URD)
( n = 127) or mismatched URD grafts (n = 128). Preparative therapies
included cyclophosphamide and TBI (n = 337), TBI with other
chemotherapy (n = 54), chemotherapy alone (n = 55) or ATG (n = 5 ) .
GVHD prophylaxis consisted of cyclosporin (CSA) and methotrexate
(MTX) (n = 288), CSA and prednisone (n = 17), MTX, ATG and pred-
nisone (n = 37), FK506 (n = 15), MTX alone (n = 11), T-cell depletion
( n = 73), and other (n = 10). Severe acute GVHD was observed in 144
patients prior to initiation of steroid therapy (grade III in 121, and grade
IV in 23). Median time to initiation of steroid therapy was 30 days
(range 8 - 94 days). For the entire cohort of patients, probability of sur-
vival 1 year after initiation of treatment was 53%. Probabilities of sur-
vival (with 95% confidence intervals) after initiation of steroids based on
type of donor are shown in the table below. Response rates and prognos-
tic factors for responses in these patients are being analyzed. More effec-
tive therapies for GVHD are needed.
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A G E S T A T U S D E B TIME TO
( Y R S ) A T M O S A I C N C C D 3 4 + C D 3 + A N C>5 0 0 C H I M E R I S M A C U T ES U R V I V A L
P T / S E X H C T ( % ) D O N O R ( 1 07/ K G ) ( 1 07/ K G ) ( 1 05/ K G ) ( D A Y S ) ( % D O N O R ) G V H D ( D A Y S )
1 28/F AA 7 6/6 URD BM 0.2 6.1 1.0 10 100 0 223+
2 5/M AA 100 6/6 URD BM 0.4 8.6 0.2 13 100 1 142+
3 15/M AML 100 4/6 URD UCB 1.8 0.2 80 43 100 2 98
infection
4 9/M AA 100 6/6 URD BM 0.2 2.4 5.7 14 100 0 75+
5 6/M AA 100 5/6 URD BM 0.3 6.2 1.0 18 100 0 51+
6 17/M AA 100 6/6 URD BM 0.2 1.3 1.0 13 100 0 27+
7 7/F AA 100 5/6 URD BM 0.4 0.3 1.0 NE 100 0 5+
SURVIVAL AFTER MATCHED URD MISMATCHED URD ALL URD MATCHED SIBLING
GVHD TREATMENT (n = 1 2 7 ) (n = 1 2 8 ) (n = 2 5 5 ) (n = 1 9 6 )
30 days 88% (83-93%) 90% (85-95%) 89% (85-93%) 92% (89-95%)
100 days 72% (65-79%) 66% (58-74%) 69% (64-74%) 76% (70-82%)
6 months 61% (53-69%) 48% (40-56%) 54% (48-60%) 67% (61-73%)
12 months 54% (46-62%) 40% (32-48%) 47% (41-53%) 57% (50-64%)
SURVIVAL AFTER ATG TREATMENT ENTIRE COHORT (n = 1 0 9 ) UNRELATED DONOR (n = 6 4 )
30 days 80% (73-87%) 78% (68-88%)
6 months 38% (29-47%) 37% (25-49%)
12 months 29% (21-37%) 26% (15-37%)
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IMMUNEMODULATION WITH IL-2 INDUCED RENAL ALLOGRAFT
REJECTION 
Mahmood, T.1; Sullivan, K.1; Brooks, J.2; Miller, A.1; Safah, H.1 1. Tulane
Medical School, New Orleans, LA; 2. Oschner Hospital, Baton Rouge, LA
Post-transplant immune therapy with IL-2,a cytokine known to be an
immune modulator,in an ongoing SWOG protocol,has been proposed
to reduce the relapse rate by eliminating tumor cells which survived the
preparative regimen or were infused with the marrow or stem cells.
However the effect of IL-2 on a previously transplanted solid organ is
unknown. We present here the case of a 22 year old white male with
Alports’ syndrome who several years age had recieved a kidney allograft
from his father. Three years later he developed an EBV associated NHL
which did not respond to withdrawal of immunosupression and relapsed
within a month of conventional chemotherapy. His baseline creatinine
of 1.5 did not change through these treatment modalities. He was trans-
planted on this SWOG protocol( #9438). Due to lack of data from the
literature as to the fate of the transplanted kidney, and at the patients
request, he was randomized to recieve IL-2 consolidation. On day 2 of
IL-2, his creatine started to rise. He developed pain over the transplant-
ed kidney site and proceeded to develop acute renal failure requiring
removal of the kidney. He was subsequently maintained on hemodialy-
sis. The results of his flow cytometry studies were as follows: Pre-IL-2
leucocyte antibody screen: HLA class I &II 0%; CD3 86%; CD3+CD8+
84%; CD3+CD4+ 9%; CD3-CD8+ 3%. Post IL-2: HLA class I
33%(A2, B12); class II 17%(DR4); CD3 98%; CD3+8+ 68%;
CD3+CD4+ 34%; CD3-CD8+ 31%. 
IL-2 is thought to work as an immune modulator by stimulating the
proliferation of antigen-specific T cells, inducing the secretion of other
lymphokines, and by augmenting the cytolytic function of cytotoxic T
lymphocytes and natural killer cells. What effect this may have on a
renal allograft which requires immunosuppression is unknown. Our case
suggests that IL-2 may play a role in causing or augmenting renal allo-
graft rejection. 
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PENTOSTATIN: A NOVEL TREATMENT FOR STEROID REFRACTORY
ACUTE GVHD
Margolis, J.H.; Phelps, M.L.; Chen, A.; Grever, M.R.; O’Donnell, P.V.;
Vogelsang, G.B. Johns Hopkins, Baltimore, MD
Pentostatin, one of the purine nucleoside analogs, is known to
decrease lymphocyte number and function. We have investigated Pento-
statin for the treatment of GVHD. Nine patients with steroid refractory
GVHD have received salvage therapy with Pentostatin. Mean age is 30
(range 6 months to 50 years). Diagnoses include aplastic anemia(1), lym-
phoma(3), acute leukemia(4), and SCIDS(1). Four had HLA identical
sibling donors , 3 had HLA identical unrelated donor, and 2 had mis-
matched related donors. GVHD was graded using the Keystone criteria.
Seven patients had grade IV GVHD, 2 had grade III GVHD. All
patients failed high dose steroids as primary GVHD treatment.
Cyclosporine or FK-506 was continued during treatment except in two
patients because of HUS/TTP. Prior to receiving Pentostatin many of
the patients had also failed salvage therapy with ATG(3), MMF(3),
Daclizumab(2) and Infliximab(1). The doses of IV Pentostatin used for
treatment were 0.125mg/m2/day, 0.5mg/m2/day, 1mg/m2/day, or
2 m g / m2/day for three consecutive days. Four patients who showed a
response received additional doses. Therapy was well tolerated. Four
patients achieved a CR and a PR was observed in 2, giving an overall
response rate of 66%. Skin GVHD resolved in 5/6 patients. Gut GVHD
resolved in 8/8 patients. Liver GVHD resolved in 4/8 patients. The 45
day (post Pentostatin) survival was 56%, however overall mortality was
78%. The results suggest that Pentostatin has activity in the treatment
of GVHD. The dose and schedule of treatment are currently being
investigated. Once the optimal dose and schedule are determined, stud-
ies should be done to formally evaluate effic a c y .
7 4
ELECTROGASTROGRAPHIC CHANGES IN PATIENTS AFTER ALLOGENE-
IC STEM CELL TRANSPLANTATION
Mandanas, R.A.1 , 2; Lin, X.M.3; Chen, J.Z.3 1. Cancer Care Associates - OKC,
Oklahoma City, OK; 2. OUHSC, Oklahoma City, OK; 3. Lynn Institute for
Health Care Research, Oklahoma City, OK
Recipients of allogeneic bone marrow or stem cells often develop gas-
trointestinal complaints months to years after transplantation. We inves-
tigated 15 patients (9F, 6M, mean age 41.1 years) 2 months to 6 years out
from their allotransplants for any impairment of gastric myoelectric activ-
ity and compared their results to 13 healthy subjects (7F, 6M, mean age
31 years). Symptoms were graded from 0 (none) to 4 (severe) and includ-
ed nausea, vomiting, diarrhea, abdominal pain, anorexia, heartburn and
bloating. Gastric myoelectric activity was non-invasively assessed using
electrogastrography (Digitrapper EGG, Medtronic-Synectics, Shore-
view, MN). The electrogastrogram (EGG) was recorded for 30 min in
the fasting state and 60 min after a test meal (500-kcal turkey sandwich).
Overall and minute-by-minute spectral analyses were performed to com-
pute the dominant frequency and power of the EGG, the percentage of
normal 2-4 cycles/min (cpm) slow waves, the percentage of tachygastria,
bradygastria or arrhythmia and the instability coefficient (IC, minute-by-
minute variation) of the EGG dominant frequency. Patients showed a
s i g n i ficantly higher percentage of arrhythmia (no obvious rhythmicity
observed in the EGG) in both fasting (17.61 ± 3.86% vs. 7.1 ± 2 . 1 7 % ,
p<0.02) and fed (11.4 ± 2.65% vs. 4.19 ± 1.04%, p<0.02) states. The per-
centage of normal 2-4 cpm slow waves was also lower in the patients but
the difference was not statistically significant. In addition, the patients
showed a significantly higher instability coefficient of the dominant fre-
quency in the fasting state than in controls (0.51 ± 0.06 vs. 0.29 ± 0 . 1 8 ,
p<0.008). Both groups showed a normal response to the test meal: a sig-
n i ficant postprandial increase in the dominant frequency and power. The
total average symptom score was 5.00 ± 0.97 in the patients and 0 in con-
trols. Patients after allogeneic stem cell transplantation show impaired
gastric slow wave rhythmicity but still preserved post-prandial responses
as shown by electrogastrography.
7 6
QUALITY OF LIFE (QOL) OF PATIENTS WITH CHRONIC GRAFT-VER-
SUS-HOST DISEASE (CGVHD): EFFECTS OF THALIDOMIDE
Miller , S.M.; Sharda, S.; Meyers, C.; Taylor, K.; Rodrigue, J.; Wingard,
J.R.; Mehta, P. University of Florida, Gainesville,, FL
QOL of patients with cGVHD has not been well studied. We hypoth-
esized that QOL may be impaired with cGVHD and that thalidomide
may improve QOL through its ability to improve sleep, nutrition, and
anxiety as reported in other patient populations. We evaluated QOL by
use of the Transplant Symptom Frequency Questionnaire (TSFQ)
instrument in which patients were asked to rate 30 separate symptoms
on a 0-4 scale (0 = never, 1 = rarely, 2 = sometimes, 3 = o f t e n ,
4 = always). Fourteen patients were evaluated at baseline; 7 continued on
their present regimen, 7 others were placed on thalidomide mostly in
order to taper prednisone. Patients on thalidomide were re-evaluated
one month after starting thalidomide and tapering prednisone. Patients
were between 18 and 59 years of age (mean age: 43±15.2 years); 9 were
male, 5 were female and their underlying diagnoses were chronic myel-
ogenous leukemia (8), acute lymphoblastic leukemia (4), non-Hodgkins
lymphoma (1), and myeloproliferative disease (1). Patients were receiv-
ing one or more of the following anti-GVHD medications: prednisone
(11), tacrolimus (6), cyclosporine (5), or mycophenolate (5). At baseline,
the most commonly reported QOL problems were poor sleep (mean
score 3.0±l.2), fatigue (2.l±l.4), changed bodily appearance (2.1±1 . 5 ) ,
fragile skin (l.9±l.7), anxiety (l.6±l.l) mood swings (l.7±l.2), and depres-
sion (l.4±l.5). In patients started on thalidomide, there was improvement
in amount of sleep (l.8 to 0.9, p = 0.03), changed bodily appearance (2.l
to l.0, p = 0.1), overeating (l.5 to 0.9, p = 0.1), poor appetite (l.l to 0.7,
p = 0.02), nausea (l.l to 0.6, p = 0.1), headache (l.l to 0.7, p = 0.04), and
fever (0.4 to 0, p = 0.004). The improvement in QOL in patients on
thalidomide may be related to effects of thalidomide or to prednisone
tapering. In either case, a side benefit of thalidomide in patients with
cGVHD may be to improve QOL. 
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URINARY TUMOR NECROSIS FACTOR α ( T N Fα) LEVELS IN PATIENTS
(PTS) UNDERGOING BONE MARROW TRANSPLANTATION: ARE THEY
MORE USEFUL THAN SERUM LEVELS?
Miller, S.M.; Sharda, S.; Sola, M.; Reddy, V.; Wingard , J.R.; Mehta, P.
University of Florida, Gainesville, FL
T N Fα and other cytokines mediate graft-versus-host disease (GVHD)
in pts undergoing allogeneic BMT and engraftment syndrome in pts
undergoing autologous BMT. We hypothesized that urinary measure-
ments may be more reliable than serum measurements since they mea-
sure an entire 24 hour period. We therefore studied urine and serum
levels of TNFα in 7 pts undergoing autologous and 6 pts undergoing
allogeneic BMT. Pts undergoing autologous BMT had age range from
33 to 6l, mean 49 ± 4 years and diagnoses of MM (3), breast cancer (2),
and NHL (2). Pts undergoing allogeneic BMT had age range from 19 to
6l, mean 41 ±13 years, and diagnoses of ALL (l), AML (2), and CML (3).
Urine and serum measurements were done before and after conditioning
therapy, and weekly after BMT. In 7 pts undergoing autologous BMT,
mean serum level was 15.5 and median 5.2 pg/ml prior to the start of the
preparative regimen. After autologous BMT, levels decreased in 6 of the
7 pts with decrease in mean values from l5.5 to 8.5 pg/ml and in median
from 5.2 to 2.5 pg/ml. In pts undergoing allogeneic BMT, serum TNFα
levels increased after BMT from 4.9 to ll.8 pg/ml. In all pts who devel-
oped GVHD, TNFα continued to increase (l5.3 ± 18.1 pg/ml). In con-
trast, urine TNFα levels were variable in pts undergoing autologous
BMT. In pts undergoing allogeneic BMT, urine TNFα levels rose ini-
tially and then dropped abruptly at the time of peak serum levels (l.9 to
l.l ng). We conclude that urine levels are variable in pts undergoing
autologous and allogeneic BMT and are not useful for following clinical
course or predicting outcome. We speculate that low urine levels of
T N Fα be a contributory factor for serum accumulation and predisposi-
tion to GVHD.
7 9
USE OF A SINGLE CENTRAL VENOUS CATHETER FOR APHERESIS AND
DOSE INTENSIVE CHEMOTHERAPY WITH OR WITHOUT TRANSPLANT
Murphy, K.L.; Whittaker, B.G.; Sulak, M.; Webster, K.; Lynch, J.; Ericson,
S. West Virginia University Hospitals, Morgantown, WV
Purpose: Peripheral Blood Stem Cell (PBSC)Transplantation is con-
sidered standard treatment for many diseases. Historically, our program
used two central venous catheters (CVC): a double lumen hemo-dialysis
CVC for apheresis and a triple lumen non-tunneled CVC for
chemotherapy and supportive therapies. Using one multi-lumen CVC
for stem cell apheresis and treatment became a priority with the frequent
use of peripheral blood stem cells. 
Method: A literature review and product search was completed. A
triple lumen, 12FR, antibiotic impregnanted multi-use catheter, Arrow-
gardBlue®,(Reading, Pennsylvania)was selected for trial. The CVC was
inserted by our surgical-oncology physicians at the patient bedside.
They were used in all patients undergoing apheresis and autologous
transplantation. In addition, they were used in patients receiving dose
intensive chemotherapy if stem cell apheresis was anticipated with count
recovery, as well as, in patients having PBSCs collected for storage in the
event of disease relapse. 
Results: Over a 24-month period beginning January 1997, 98 of 105
consecutive patients had the ArrowgardBlue® placed for apheresis and
dose intensive chemotherapy with or without transplant. The catheters
were in place for variable lengths of time with data collection ending at
the time of discharge from the transplant unit. The median number of
days from insertion to time off study was 24, range 2-63. There were no
documented increases in patient discomfort or complications, diffic u l t y
in pheresis procedures or problems using the CVC on the inpatient or
outpatient transplant unit with the ArrowgardBlue®. A cost savings of
$75,000 using a single multi-purpose catheter was appreciated over the
24-month period with the elimination of a second invasive procedure. 
Conclusion: We successfully and safely changed our practice to the use
of a single CVC for stem cell apheresis, dose intensive chemotherapy
and supportive therapies. The patients avoided a second invasive proce-
dure. Significant financial savings were realized by using one CVC.
7 8
INTERLEUKIN-7 ADMINISTRATION AFTER ALLOGENEIC BONE MAR-
ROW TRANSPLANTATION ENHANCES THYMOCYTE, T AND B CELL
R E C O N S T I T U T I O N
Muriglan, S.J.; Kappel, B.J.; Rotolo, J.; Van Den Brink, M.R. Memorial
Sloan-Kettering Cancer Center, New York, NY
BACKGROUND: Prolonged immunodeficiency is an important late
complication of allogeneic T cell-depleted (TCD) bone marrow trans-
plantation (BMT). Previous studies by Bolotin et al. (Blood 88:1887) and
Abdul-Hai (Exp. Hematol. 24:1416) have demonstrated that interleukin-
7 (IL-7) administration after murine syngeneic BMT results in enhanced
immune reconstitution. 
METHODS: We used murine models for syngeneic BMT (CBA →
CBA) and MHC-matched minor mHAg-mismatched allogeneic BMT
(B10.BR → CBA) to determine the effects of IL-7 on T and B cell
reconstitution after syngeneic or allogeneic BMT with or without
GVHD. IL-7 was administered as continuous infusion at 1 microg/day
with subcutaneously implanted osmotic pumps. IL-7 was kindly provid-
ed by BIP. 
RESULTS: Administration of IL-7 from day 14 to 28 to recipients of
allogeneic TCD BMT resulted on day 28 in significantly increased
numbers of thymocytes (51±7 x 106) compared to control animals (31±3
x 106; P<0.05), splenic T cells (21±5 x 106 vs. 8±1 x 106; P = 0.01) and
splenic B cells (294±46 x 106 vs. 113±9 x 106; P = 0.01). No graft-versus-
host-disease as determined by weight loss or clinical GVHD index was
found in any of the recipients. Administration of IL-7 from day 0 to 14
had no significant effect on numbers of thymocytes and splenic B and T
cells in recipients of allogeneic TCD BMT when analyzed on day 28.
However, recipients of syngeneic BMT treated with IL-7 from day 0 to
14 had increased numbers of thymocytes at day 14. Finally, IL-7 admin-
istration had no effect on thymopoiesis and numbers of splenic T and B
cells in recipients of allogeneic bone marrow + T cells when analyzed at
day 28, and we observed no increase in GVHD morbidity and mortality. 
CONCLUSION: IL-7 administration after allogeneic TCD BMT
can enhance T and B cell reconstitution without causing any GVHD
morbidity or mortality. 
8 0
YIELD AND IN VITRO CLONOGENIC PROPERTIES OF CD34+ CELLS
MOBILIZED WITH SCF AND G-CSF FOR AUTOLOGOUS PERIPHERAL
STEM CELL TRANSPLANT OF A PATIENT WITH STAGE IV NEURO-
B L A S T O M A
Narendran, A.; Doyle, D.; Freedman, M.; Saunders, E.F.; Armstrong, C.;
Vanek, W.; Lau, W. The Hospital for Sick Children, Toronto, ON, Canada
We have recently transplanted a 3 year old child with advanced neu-
roblastoma, with CD34+ cells from peripheral blood after treatment
with SCF and G-CSF. She had been treated with MADDOC protocol
and whole abdominal irradiation. Prior to apheresis and stem cell collec-
tion, she received SCF 20 µg/kg S.C. once daily for four consecutive
days given with 10 µg/kg of G-CSF given S.C. on the same days. Total
WBC count increased from 2.2 to 40.4x109/L during this period. Blood
was collected on day 4 with a CD34+ cell yield of 10.42x106 /Kg. CD34
selection was performed on an isolex machine with an ultimate yield of
6 . 3 8 x 1 06 /kg. The yield was 68% compared to an approximate yield of
45% usually seen with G-CSF alone with similar purity. A sample of
these cells were cultured in methyl cellulose with recombinant cytokines:
EPO, SCF, G-CSF and IL-3, for 14 days, with control CD34+ cells
from another individual mobilized with G-CSF alone. 
Results 
Input: 1.5 x 103 CD34+ cells . 
Colonies CFU-E Mixed CFU-GM 
Patient (SCF+G-CSF) 260 +/- 5 56 +/- 7 210 +/- 12 
Control (G-CSF) 114 +/- 6 7 +/- 1 133 +/- 3 
The colonies formed from the patient contained more cells per
colony, indicating a heightened proliferative response. In addition, they
also included a significantly higher proportion of colonies of mixed lin-
eages. We recommend stem cell mobilization with SCF plus G-CSF in
patients with compromised marrow function due to prior aggressive
chemotherapy and radiation. 
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CROSS-PROTECTIVE MURINE GRAFT-VERSUS-LEUKEMIA RESPONSES
TO PHENOTYPICALLY DISTINCT MYELOID LEUKEMIA LINES
Patterson, A.E.; Korngold, R. Kimmel Cancer Institute, Thomas Jefferson
University, Philadelphia, PA
A c-myc retrovirus-transformed myeloid leukemia line, MMB3.19, of
C57BL/6 (B6) H2b origin, was developed to investigate graft-versus-
leukemia (GVL) activity in murine bone marrow transplantation (BMT)
models. It was previously determined that both naive and leukemia-pre-
sensitized unfractionated or CD4+ T cells alone are capable of mediating
GVL activity to MMB3.19 challenge in both syngeneic (B6) and minor
histocompatability antigen allogeneic (C3H.SW->B6) strain combina-
tions. In the present study, MMB3.19 and two other similarly derived,
yet phenotypically diverse, B6 myeloid leukemia lines (MMB1.10 and
MMB2.18) were investigated for potential shared tumor antigens in the
syngeneic GVL model. Morphologically, all three tumor lines are blastic
with high cytoplasmic:nuclear ratios, but MMB2.18 displays dendritic
processes, whereas MMB1.10 and MMB3.19 have a more rounded
appearance. Flow cytometric analysis of the three lines revealed similar
constitutive surface molecule expression of Mac-1, Mac-2, F4/80, LFA-
1, B7-1, B7-2, H2Kb, H2Db and macrophage scavenger receptor, consis-
tent with macrophage/monocytic lineages. In vitro 5 1Cr-release assays
using MMB3.19-primed T cell effectors demonstrated equivalent specif-
ic lysis of all three leukemia line target cells. In addition, ELISPOT
analysis of MMB3.19-primed CD4+ T cells revealed significant
increased frequencies of tumor-reactive IL-2-, IL-4-, and IFNγ- s e c r e t-
ing cells when restimulated with each of the three leukemia lines. How-
ever, when either MMB3.19-primed unfractionated or CD4+ T cells
alone were administered in a BMT setting, a protective GVL effect was
seen only in those mice challenged with MMB1.10 or MMB3.19, but
not MMB2.18. Therefore, in vitro experiments suggest that the three
distinct myeloid leukemia lines express common antigen(s) that stimulate
cross-reactive unfractionated or CD4+ T cells while BMT experiments
indicate that at least two of the lines share a common MHC class II-
restricted tumor antigen that can elicit a cross-protective in vivo T cell
GVL response. 
8 3
AMIFOSTINE (AMI) CYTOPROTECTION (CP) OF ESCALATING DOSES
OF MELPHALAN (MEL) AND AUTOLOGOUS HEMATOPOIETIC STEM
CELL TRANSPLANTATION (AHSCT): A PHASE I-II STUDY
Phillips, G.L.1; Hale, G.A.1; Nath, R.1; Reece, D.E.1; Kniska, A.1; Adams, V.1;
Flomenberg, N.2; Filicko, J.2; Vesole, D.3 1. University of Kentucky/Markey
Cancer Center, Lexington, KY; 2. Thomas Jefferson University Medical Col -
lege, Philadelphia, PA; 3. Medical College of Wisconsin, Milwaukee, WI
Background: RRT is dose-limiting with AHSCT, preventing full eval-
uation of the dose response curve of certain antineoplastics. While AMI
provides CP with certain conventional-dose therapies, its ability to
increase the MTD of high-dose therapy (HDT) requiring AHSCT is
unclear. Purpose: To increase the MTD of HDT with MEL using
AHSCT. Methods: AMI (740 mg/m2 IV over 15”) was given 24’ and 15”
before MEL. The initial MEL dose was 220 mg/m2 15” IV; (in other
studies, MEL 220 mg/m2 produced severe mucosal RRT in > 80% pts;
Moreau et al, BJH 1996; 95:527-30, and is felt to be the MTD). MEL
dose was escalated by 20 mg/m2 in groups of 4 pts with plans to stop if >
gr III RRT in >1 pt at a given level. MEL pharmacokinetics were also
measured, and will be reported separately. Results: To date, 34 cancer
pts ineligible for other HDT/AHSCT protocols have been entered,
including AML (n = 3), breast cancer (n = 10), myeloma (n = 11), lym-
phoma (n = 8), and ovarian cancer (n = 2). Doses of MEL (mg/m2) of
220 in 12, 240 in 5, 260 in 6, 280 in 9 and 300 in 2 pts. have been given
without > grade II mucosal RRT. One patient (220mg/m2) with prior
cardiomyopathy died of cardiotoxicity; no other treatment-related
deaths were noted. Median recovery of ANC and platelets to minimal
levels occurred at days +13(10-38) and +15(8-40), respectively. No com-
plications have forced interruptions of AMI. As of 01 December 1999,
26 pts are alive, including 17 without progression, days +39 to +533.
Conclusions: AMI, as given above, may provide CP vs MEL at >2 8 0
m g / m2 with AHSCT; dose escalation (if possible) to a new MTD, and
PK studies are ongoing. 
Supported by NIH (RO3# 1R3CA80666-01), Glaxo-Wellcome and
ALZA. 
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PHARMACOKINETIC BASED INDIVIDUALIZED IV BUSULFAN THERAPY
IN MARROW TRANSPLANT PREPARATIVE REGIMENS
Perry, S.L.; Salzman, D.E.; Carabasi, M.H.; Vaughan, W.P. University of
Alabama at Birmingham, Birmingham, AL
Dose adjustment of oral busulfan in preparative regimens may lower
VOD, graft failure and relapse risks. IV busulfan (Busulfex) reduces
pharmacokinetic variability making measurements simpler and more
reliable. Between 3/15 and 11/15/99, 18 pt received Busulfex in one of
three regimens (Bu/Flu-10 pt, Bu/Cy2-1pt), and Bu/Cy/VP-7pt). Diag-
noses included AML (3), NHL (8), HD (3), and CML (4). Pt age range
was 22-64 years (median-46). The scheduled dose was 27.5 mg/M2/ 2 h r
Q6HX16. The first patienthad samples drawn after test dose Busulfex,
the remainder had samples drawn with the first treatment dose. Initially,
12 levels were obtained. AUC was calculated using WinNonlin and dose
adjustment made following the 7th dose of Busulfex. By the end of the
study it was clear that 5 levels (drawn at 5 min after the 2 hr infusion,
then at 1, 2, 3, and 4 hours post infusion)were sufficient to obtain AUC
with <10% CV. Target AUC was individualized by protocol and patient
condition to be “low” (900-1000 µM-min), “intermediate” (1000-1200)
or “high” (1200-1400). Sample collection and analysis were successful in
all 18 pt, 10 required increases in Busulfex dose, 3 required decreases
and 5 needed no adjustment. All pt engrafted with no incidence of
VOD. With median follow up of 180 d (range 21-270), 11 pt are cur-
rently alive (10 disease free). One of 6 autograft pt died from relapsed
HD. Three of 12 allograft pt died from transplant complications
(AGVHD, pseudomonas sepsis, and cerebral hemorrhage), and 3 died
from relapse (NHL, HD, and accelerated phase CML). One of the 6
remaining pt (AML) has relapsed. We conclude that pharmcokinetically
directed therapy with Busulfex can be performed reliably and simply in
all patients and has the potential to improve outcomes in marrow trans-
plantation by permitting individualized dosing to reduce risk of compli-
cations, graft failure and relapse.
8 4
IMAGING CORRELATES OF NEUROLOGICAL ADVERSE EVENTS IN
PATIENTS RECEIVING TACROLIMUS FOR PREVENTION OF GRAFT-VS-
HOST DISEASE
Przepiorka, D.1; Sangha, M.2; Kumar, A.J.2 1. Baylor College of Medicine
Center for Cell and Gene Therapy, Houston, TX; 2. University of Texas M.D.
Anderson Cancer Center, Houston, TX
Neurological adverse events are not uncommon after allogeneic trans-
plantation, and imaging studies are used to assist with identifying the eti-
ology. Tacrolimus is a new immunosuppressive drug for prevention of
GVHD, and several neurological toxicities have been reported with
tacrolimus use. Characteristic changes in cortical white matter on CT
scan or MRI of the brain have been ascribed to tacrolimus, but it is
unclear if these imaging abnormalities correlate with clinical symptoms.
Over a 6-year period of time, 477 adults received a myeloablative
preparative regimen and an unmanipulated marrow or blood stem cell
transplant using a tacrolimus-based regimen for GVHD prophylaxis,
and 128 patients had CNS imaging studies after transplantation.
Records were available to review for 120 episodes of neurologic adverse
events in 99 patients. The indications for imaging included 39% with
altered mental status, 33% headache, 12% focal findings on neurological
exam, 11% seizure, and 6% altered vision. Overall, 58% of the imaging
studies were abnormal. Imaging abnormalities were found in 85% with
seizure, 71% with focal neurological exam, 60% with altered mental sta-
tus, 57% with visual changes, and 44% with headache. Only 16% of all
neurological adverse events were ascribed to tacrolimus; the remainder
were due to other transplant-related complications. White matter
changes consistent with tacrolimus toxicity were seen on only 42% of
the imaging studies in the patients with a clinical picture consistent with
tacrolimus toxicity (less than 2% of all patients receiving tacrolimus).
However, 13% of patients with neurologic complications not ascribed to
tacrolimus were also found to have white matter changes on CNS imag-
ing. Moderate-to-severe neurological toxicities due to tacrolimus with
characteristic imaging abnormalities occur in a relatively low proportion
of patients receiving tacrolimus, and imaging changes thought diagnostic
of tacrolimus can be seen in the absence of clinical sequelae.
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INFLUENCE OF HEALTH INSURANCE STATUS ON OUTCOMES OF
ALLOGENEIC SIBLING-DONOR HEMOPOEITIC STEM CELL TRANS-
PLANTATION FOR AML AND CML
Roy, V.; Ali, L.I.; Vesely, S.K.; Carter, T.H.; Selby, G.B. University of Okla -
homa Health Science Center, Oklahoma City, OK
Allogeneic hemopoietic stem cell transplantation involves intensive and
expensive treatment for prolonged period of time. While various medical
conditions have been shown to influence transplant outcomes, the effect
of race and socio-economic factors is relatively unstudied. We analyzed
the outcomes of 59 consecutive patients who underwent sibling-donor
allogeneic stem cell transplantation for myeloid malignancies (AML-
CR1, n = 30; CML-CP1, n = 29) at a single tertiary care institution. All
patients had been followed at least 16 months post-transplant. The results
are presented in the table below. The Uninsured (Uin) were signific a n t l y
younger than Insured (In) (p = 0.017, Fisher’s Exact test) and more likely
to be non-Caucasian (p = 0.07). Similar number of AML and CML
patients were present in the In and Uin groups. There was no difference
in survival between Caucasian and non-Caucasian patients (data not
shown). There was a statistically significant difference in survival rates
between the In and Uin patients by log-rank test(p = 0.03). Mortality
rates were compared at less than 30 days, 31-99 days, and more than 100
days post-transplant. Mortality rate was similar in the first 30 days after
transplant when all the patients were hospitalized (p = 0.42). A trend for
increased mortality in the Uin group was seen after 30 days, which
became statistically significant after 100 days post-transplant(p = 0 . 0 2 7 ) .
Increased delayed mortality likely represents the Uin patients’ inability to
seek or comply with medical care because of lack of socio-economic
resources. During the early post-transplant period, when patients are in
hospital, the resources of a comprehensive health sciences center can
compensate for their socio-economic deficiency but the Uin patients
become at increased risk of death after they return to their pre-transplant
social setting. Optimizing the availability of socio-economic support is
likely to improve outcomes of this patient group.
8 5
FIRST SUCCESSFUL RELATED DONOR CORD BLOOD (CB) BANK: A HIGH-
LY EFFICIENT RESOURCE FOR PEDIATRIC STEM CELL TRANSPLANTATION
Reed, W.F.1; Smith, R.S.1; Trachtenberg, E.1; Vinson, M.1; Hanes, D.2; Haaz,
S .1; Taylor, K.V.1; Lubin, B.H.1 1. Children’s Hospital Oakland Research
Institute, Oakland, CA; 2. Alta Bates, Berkeley, CA
Background: Umbilical CB is a viable source of HSCs for transplantation.
Results from over 1100 CB transplants demonstrate: (1) diminished potential for
graft-versus-host disease; (2) ability to cross histocompatibility barriers; (3) absence
of risk to the newborn donor and (4) decreased risk of CMV transmission. While
current banks focus on CB collections to support unrelated HSC recipients, they
cannot easily respond to the unique requirements for collection of CB from a spe-
c i fic sibling, often born at a hospital without the facilities to collect CB. 
Design/Methods: To address this need, we hypothesized that a CB bank could
be developed focusing on families with a child who might utilize the sibling’s CB
for transplantation (i.e., a child with leukemia, sickle cell anemia, thalassemia, etc.).
To test this hypothesis, and with NIH support, we initiated a program that offers
the collection of CB free of charge to families across the US. We use a case man-
agement model. Samples are collected by obstetricians/midwives and transported
to our laboratory for processing, testing, molecular HLA typing and storage. 
Results: In the first year, we have collected over 200 sibling CB units from 22
states. Almost all of the collections (>90%) were performed at community hos-
pitals. Six units (3%) have been successfully used for transplantation and 7 more
are being considered. The mean collection volume and nucleated cell count for
all units stored in our bank are 63 ml (excluding anticoagulant) and 4.1x108,
respectively. Approximately 25% are HLA identical with the intended recipi-
ent; 60% are 3/6, 4/6 or 5/6 matches. The table below shows characteristics of
collected and transplanted units. 
Conclusion: We conclude that remote-site collection of specific CB units
can be successfully accomplished and that collection of CB from siblings of
patients with potentially transplantable disease should be encouraged.
8 6
TRISOMY 17Q IN A PATIENT WITH RELAPSED ACUTE MYELOGENOUS
LEUKEMIA (M1)POST-MATCHED SIBLING BONE MARROW TRANS-
PLANT CONFERS RESPONSIVENESS TO RETINOIC ACID
Robertson, K.A.; Bullock, H.A.; Vance, G.H.; Pollok, K.; Bailey, J.; Cornetta,
K.; Thomson, B.G.; Smith, F.O. Indiana University, Indianapolis, IN
Although retinoic acid (RA) is effective therapy for promyelocytic
leukemia with t(15,17), the impact of multiple copies of chromosome 17
(including RA receptor-alpha) on the RA-responsiveness of AML cells
has not been described. We present a patient who developed trisomy
17q in his relapsed AML post-BMT that displayed responsiveness to RA
with growth inhibition, differentiation, and apoptosis. TS was diagnosed
at age 2 months with M1-AML (48,XY, +8, +12). He received a
matched-sibling BMT in first relapse following conditioning with TBI
(1375 cGy) and Cytoxan (120mg/kg). He engrafted by day 28, but
relapsed on day 57. His AML cells evolved into two clones, one with tri-
somy 17 and one with a derivative chromosome 13 as t(13;17)(q10;q10)
making his AML cells trisomy for 17q. RT-PCR analysis for PML-RAR
was negative. Degranulated granulocytes/blasts were noted in the
peripheral blood. Parental consent was obtained and blood drawn for
analysis of RA-responsiveness. Mononuclear cells were isolated by Ficol
sedimentation and suspended in IMDM media with 10% FCS. Cells
were incubated with RA (10 micromolar) or ethanol vehicle. Serial cell
counts, differential morphology, and apoptosis by morphology and ter-
minal-transferase assay were performed. Control-cells grew exponential-
ly while RA treated cells exhibited nearly complete inhibition of growth.
After 5 days, 54% of the cells were mature (metas, bands, and PMN’s)
with RA treatment compared to 15% for control cells. After 5 and 7
days, 12% and 18% of the cells were apoptotic with RA compared to
0% and 2% respectively in the control cells. These findings suggest that
RA may be useful in leukemia with karyotypic changes resulting in mul-
tiple copies of RA-receptors. The implications are that up-regulated or
induced-expression of the RA receptors may sensitize leukemia cells to
the differentiating, growth inhibitory, and apoptosis-inducing effects of
RA which may be useful either pre or post-transplant. 
8 8
PRELIMINARY EXPERIENCE WITH ONCE DAILY INTRAVENOUS
BUSULFAN (BU): A COMPARISON WITH CONVENTIONAL ORAL BU IN
COMBINATION WITH FLUDARABINE AS CONDITIONING FOR ALLO-
GENEIC BMT
Russell, J.A.; Chaudhry, A.; Duggan, P.; Stewart, D.; Ruether, J.D.; Gluck,
S.; Morris, D.; Brown, C.B. Alberta BMT Program, Calgary, AB, Canada
We have studied the feasibility of single daily dosing of an IV prepara-
tion of busulfan (BU) (Busufex, Orphan Medical). Myeloablative condi-
tioning comprising fludarabine (FLU) 50mg/m2 on days -6 to -2 plus
busulfan (BU) on days -5 to -2 inclusive (FLUBUP) was given to 48
adults. Twenty-three received BU 1mg/kg PO QID and 25 received IV
BU 3.2 mg/kg in a 3-hour infusion. The IV and PO BU groups respec-
tively included comparable numbers of patients with high risk malignan-
cy (56% vs. 62%). Because there were more unrelated (UD) or genotyp-
ically mismatched related donors (MMRD) in the IV BU group (52% vs
26%, p = 0.08) more of these patients received bone marrow rather than
blood (78% vs 44%, p = 0.04). All patients received acute GVHD pro-
phylaxis with cyclosporin A plus “short” methotrexate and folinic acid.
Ninety-six percent of the IV BU group and 57% of the PO BU group
were also given antithymocyte globulin (ATG, Thymoglobulin)
4.5mg/kg over 3 days pretransplant (p = 0.002). 
There were no significant differences in hepatic toxicity or stomatitis
between regimens. Hemorrhagic cystitis occurred in 16% of IV BU
patients and 13% of the PO BU group. One patient with subtherapeutic
phenytoin levels had a convulsion 8 hours after the third IV BU dose. In
each group there was a single case of graft failure in UD BMT recipi-
ents. One transplant-related death, from GVHD,has occurred before
day 100 in a recipient of PO BU. 
So far, daily IV BU seems as well tolerated as the oral drug, has present-
ed no unexpected toxicities, and is more convenient than QID dosing. 
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R E C I P I E N T N U M B E R T R A N S P L A N T S TRANSPLANTS BEING
D I S E A S E ( % ) P E R F O R M E D ACTIVELY CONSIDERED
Malignancy 98 (41%) 1 (6yo - myelodysplasia 1 (ALL in 2nd remission)
with monosomy 7)
SCD 68 (34%) 2 (3yo - recurrent acute 2 (9yo - s/p CVA, 
chest, pain, and 3yo - and 2yo HLA 4/6 highly
acute chest, s/p splenectomy) motivated family)
Thalassemia 26 (14%) 2 (2yo and 4yo, both 2 (3yo and 5yo - 
transfusion dependent) transfusion dependent)
Other non-malignant 14 (8%) 1 (3yo - aplastic 1 (12yo - aplastic anemia)
hematological condition anemia HLA 4/6)
Genetic Immunodeficiency 4 (2%) 0 1 (2yo - GCD)
Metabolic/storage 2 (1%) 0 0
I N S U R E D U N I N S U R E D
(n = 4 5 ) (n = 1 4 ) p =
Mean Age (years) 36.8 27 0.017
% Caucasian 82 42 0.075
Diagnosis - AML 22/45 (49%) 8/14 (57%) 0.59
Grade III-IV AcGVHD 7/45 (16%) 0/14 0.181
Extensive ChGVHD 16/41 (39%) 2/10 (20%) 0.462
Mortality <30 d 1/45 (2%) 1/14 (7%) 0.421
Mortality 31-99 d 3/44 (7%) 3/13 (23%) 0.125
Mortality ≥100 d 6/41 (15%) 5/10 (50%) 0.027
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B CELL RECONSTITUTION FOLLOWING NON-MYELOABLATIVE, T
CELL DEPLETED, ALLOGENEIC PERIPHERAL BLOOD STEM CELL
TRANSPLANT (PBSCT)
Savage, W.J.1; Bleesing, J.H.2; Brown, M.R.2; Linton, G.M.1; Malech, H.L.1;
Horwitz, M.E.1 1. Laboratory of Host Defenses, National Institute of Allergy
and Infectious Diseases, National Institutes of Health, Bethesda, MD; 2.
Department of Clinical Pathology, National Institutes of Health, Bethesda, MD
We evaluated B cell recovery after PBSCT in 9 patients (median age:
12 years) with chronic granulomatous disease, a congenital immunode-
ficiency not associated with B cell defects. The conditioning regimen
consisted of cyclophosphamide, fludarabine, and anti-thymocyte glob-
ulin. Patients received CD34 enriched, T cell depleted grafts from
HLA-identical siblings. Donor lymphocyte infusions (DLI) were given
at +30 and +60 days. In the 8 of 9 patients who engrafted, peripheral
blood B cell counts fell to a nadir at +4 weeks (median: 5 cells/µL ,
range: 0-15 cells/µL) but rose to the normal range by +7 weeks (medi-
an 145 cells/µL, range: 11-398 cells/µL). They remained normal at
+13 weeks (median: 118 cells/µL, range 2-254 cells/µL). B cells were
95% and 86% CD5+ at +7 and +13 weeks, respectively. Peripheral
blood memory B cells, identified by surface CD27 expression, consis-
tently remained ≤5% of total B cells up to one year after PBSCT. The
predominance of the CD5+ B cell subset and the paucity of CD27+
memory B cells resemble early B cell ontogeny. This observation could
indicate a prolonged delay of functional recovery, which will be corre-
lated with responses to recall and neo-antigens. Donor/recipient
chimerism analysis in 5 patients studied at +13 weeks revealed that B
cells were 62, 100, 73, 96, 9% donor origin; neutrophils were 62, 73,
43, 87, 9% donor origin; T cells were 2, 100, 21, 94, 10% donor ori-
gin, respectively. Donor B cell engraftment correlated more with neu-
trophil engraftment (r2 = 0.85, p<0.05, Pearson’s correlation coeffi-
cient) than with T cell engraftment (r2 = 0.59; p>0.10). B cell
chimerism did not correlate with CD27+ memory B cell counts. In
summary, non-myeloablative, T cell depleted, allogeneic PBSCT fol-
lowed by DLI, is associated with accelerated quantitative, but naïve, B
cell reconstitution. This reconstitution represents mixed donor/recipi-
ent chimerism that correlates with donor myeloid engraftment.
9 1
STUDIES OF CELLULAR BARRIERS FOR TRANSPLANTATION OF
HEMATOPOIETIC STEM CELLS (HSC)
Scheffold, C.; Scheffold, Y.C.; Negrin, R.S.; Shizuru, J.A. Department of
Medicine, Stanford University, Stanford, CA
An idealized approach to allogeneic bone marrow (BM) transplanta-
tion is to transplant hematopoietic stem cells (HSCs) with populations of
immune cells that can reconstitute responses against tumor antigens and
pathogens but not cause graft-versus-host disease. One major obstacle to
transplantation of HSC grafts is increased resistance to engraftment and
thus engraftment failure. The cellular barriers to allogeneic BM engraft-
ment are poorly understood. Prior studies show that intact pathways of
cytotoxicity are not required for resistance to engraftment. Thus, non-
s p e c i fic factors such as cytokines may be mediating BM resistance. In
order to study cellular barriers to allogeneic HSC engraftment, we
transplanted Thy-1l o, Lin- / l o, Sca-1+ HSCs across major histocompatibil-
ity barriers into knockout mice. These recipient mice were deficient for
the Th-2 cytokines IL-4 or IL-10, or the Th-1 cytokine, IFN-µ. We
also studied transplantations into perforin and FAS-ligand deficient
mice. The strain combination studied was AKR/J (H-2K) into C57/BL6
( H - 2D). We first studied engraftment kinetics by administration of titrat-
ed numbers (300-10,000) of HSCs from AKR/J into wildtype C57/BL6
recipients. We noted a high level of resistance to engraftment since even
10,000 HSCs could rescue only 45% of the lethally irradiated recipient
mice. Graded numbers of HSCs into IL-4, IL-10, and IFN-γ r e c i p i e n t
mice showed no decrease in this barrier to engraftment. Interestingly,
using perforin knockout or FAS-ligand deficient recipient mice, there
appeared to be a slight reduction in the barrier since lower numbers of
HSCs (1,000 and 3,000) were capable of rescuing a significant percent-
age of mice. We then pretreated recipient wildtype mice with an anti-
body directed against determinants of natural killer cells (asialo-GM1)
and noted profound reduction in the resistance to engraftment. In con-
clusion, it appears that the removal of certain cytokines known to be
important in skewing T cell responses does not reduce the barrier to
allogeneic HSC engraftment. 
9 0
EVALUATION OF IMMUNOLOGICAL THERAPIES FOR HER2 EXPRESS-
ING TUMORS USING BIOLUMINESCENCE
Scheffold, C.1; Scheffold, Y.C.1; Edinger, M.1; Kornacker, M.1; Contag, C.H.2;
Negrin, R.S.1 1. Department of Medicine, Stanford University, Stanford, CA;
2. Department of Pediatrics, Stanford University, Stanford, CA
Antibody-based therapies have been shown to be successful approach-
es for the treatment of hematological disorders and solid tumors. The
HER2 receptor protein is over-expressed in a variety of adenocarcino-
mas including early and metastatic breast (10-40%) and ovarian cancer.
With sufficient restrictive tissue expression patterns, HER2 protein
allows selective tumor-targeting using antibody-based immunological
therapies. We labeled HER2 expressing tumor cells through constitutive
expression of an optical reporter gene (luciferase) and monitored cellular
proliferation in vivousing a sensitive photon detection system. HER2
over-expressing human breast (BT-474) and human ovarian cancer cells
(SK-OV-3) were transfected with an expression vector containing a
m o d i fied fir e fly luciferase gene under the control of a CMV promoter
and stable cell lines were selected via resistance to geneticin. Cell viabili-
ty and proliferation was monitored in culture and in vivofollowing injec-
tion into irradiated severe combined immunodeficiency (SCID) mice.
An intensified charge couple device camera (ICCD) was used for detec-
tion. Detected photons that were emitted from the labeled tumor cells
and transmitted through murine tissue revealed tumor load in the ani-
mals. As a new therapeutic strategy to eradicate minimal residual disease
after bone marrow transplantation, we are studying a combination thera-
py with in vitroactivated NK-like T cells, termed cytokine induced killer
(CIK) cells, and a humanized HER2xCD3 bispecific antibody. Alone,
neither therapy resulted in significant tumor cell lysis in culture or in
vivo. However marked synergy was observed in culture, when both bis-
p e c i fic antibody and CIK cells were utilized. These synergistic results
were also observed in vivowhere dramatic tumor regression, assessed by
light emission was observed following injection of both CIK cells and
b i s p e c i fic antibody. Response to therapy could be detected as early as 24
hours after treatment. Potentiating cellular immunotherapies with bispe-
c i fic antibodies may increase specificity and effectively target tumor cells
that were previously poor targets.
9 2
DETECTION OF GENOMIC EBV DNA AND INCIDENCE OF EBV-LYM-
PHOPROLIFERATIVE DISORDERS (EBV-LPD) IN PATIENTS AFTER
ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT)
Schimmelpfennig, C.H.1; Bandt, D.2; Kabus, B.1; Freiberg-Richter, J.1;
Prange, G.1; Naumann, R.1; Thiede, C.1; Bornhäuser, M.1; Rethwilm, A.2;
Ehninger, G.1 1. Medizinische Klinik and Poliklinik I, Universitätsklinikum
Carl Gustav Carus, TU Dresden, Dresden, Germany; 2. Institut für Virologie,
Universitätsklinikum Carl Gustav Carus, TU Dresden, Dresden, Germany
Introduction: EBV-LPD is an uncommon, but serious complication
after allogeneic HCT, especially if infusion of donor lymphocytes (DLI)
or EBV specific T-cells are not available. We have followed 68 patients
after allogeneic HCT for activation of latent EBV by PCR and looked
for the incidence of EBV-LPD. 
Methods: A nested PCR for detection of EBV-EBNA specific
sequences was performed using whole blood. 68 patients (28 related, 40
unrelated, 53 matched, 15 mismatched, 11 T-cell depleted, 57 no T cell
depletion) at different timepoints after allogeneic HCT were examined.
The clinical diagnosis of EBV-LPD was confirmed by histology. 
Results: In 11/68 patients a positive EBV-PCR signal was detected. In
these patients the day of first detection was d 34, 35, 43, 49, 81, 84, 84,
253, 294, 411 and 420. In 10/11 of these patients none developed any
clinical signs of EBV infection and all 10 patients reverted to EBV nega-
tivity without intervention. 1/11 patient developed an EBV-associated
lymphoma and was successfully treated with Cidovovir, anti CD20
Moab and DLI of a second unrelated donor. 
Conclusion: In contrast to the very low incidence of EBV-LPD we
found an incidence of 16,2 % for genomic EBV-reactivation. These data
seem to indicate that there is replication of EBV after allogeneic HCT
but there is also sufficient cytotoxic control of EBV- associated B-cell
proliferation. 
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SUCCESSFULL TREATMENT OF AN EBV-ASSOCIATED LYMPHOMA
AFTER ALLOGENEIC BONE MARROW TRANSPLANTATION (BMT)
WITH CIDOFOVIR, ANTI CD 20 MOAB AND DONOR LYMPHOCYTE
INFUSION (DLI
Schimmelpfennig, C.H.1; Freiberg-Richter, J.1; Platzbecker, U.1; Thiede, C.1;
Prange, G.1; Naumann, R.1; Hänel, A.2; Hänel, M.2; Bornhäuser, M.1;
Ehninger, G.1 1. Medizinische Klinik and Poliklinik I, Universitätsklinikum
Carl Gustav Carus, TU Dresden, Dresden, Germany; 2. Klinikum Chemnitz,
Innere Medizin III, Chemnitz, Germany
EBV-associated lymphoproliferative disease (EBV-LPD) is a serious
complication after hematopoietic cell transplantation. Treatment strate-
gies include reduction of immunosuppression and infusion of donor lym-
phocytes (DLI) or EBV-specific T-cells. Recently, it has been shown that
E B V - s p e c i fic monoclonal antibodies (Moab) induce regression of EBV-
LPD. In organ transplanted patients Foscavir is efficient in treatment of
EBV-LPD. Here, we report the clinical course of a 36 year-old patient
with an eleven year-old history of M. Hodgkin, II B, in 3. CR and sec.
AML FAB M1 in early relapse, who underwent allogeneic, unrelated,
HLA-identical BMT. Conditioning consisted of Busulfan 6,6 mg/kg,
Fludarabin 150 mg/m2 and ATG 10 mg/kg. On day + 49 he developed
rapidly growing generalized lymphadenopathy and diffuse intravascular
coagulation. Diagnosis of EBV-LPD was confirmed by biopsy of a lym-
phnode and by positive EBV-PCR of peripheral blood and lymphnode
tissue. Immunosuppression was stopped. Because the donor of this
patient was not available, we decided to start virostatic treatment with
cidofovir (Vistide) and anti CD20 Moab (Mabthera) on day + 59. Finally,
on day + 64, the patient recieved 5 x 106/kg CD 3-positive donor lym-
phocytes of a second unrelated, HLA C micro-mismatched donor. After
the first application of cidofovir/ anti CD20 Moab there was no further
progression of the EBV-LPD. After DLI there was a rapid regression of
lymphadenopathy. On day + 77 detection of EBV-DNA was negative.
We observed cutaneus GvHD (Grade II) but no severe decline in
hematopoiesis. Conclusion: In this patient with EBV-LPD the adminis-
tration of cidofovir and anti CD 20 Moab might have enhanced the anti-
lymphoma effects after having stopped immunosuppression. DLI even
from a mismatched second donor seems to be feasible. 
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NEUROCOGNITIVE FUNCTION OF PEDIATRIC LEUKEMIA PATIENTS
RECEIVING HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT)
COMPARED TO NORMAL SIBLINGS
Shah, A.J.; Weinberg, K.I.; Kappor, N.; Crooks, G.M.; Kohn, D.B.; Epport,
K.; Engilman, R.; Leonard, E.; Parkman, R. Childrens Hospital Los Angeles,
Los Angeles, CA
Survival for pediatric acute leukemia has increased dramatically over
the past thirty years. As there have been more survivors, long-term
sequelae of anti-leukemic therapy are being recognized. We have begun
to evaluate patients pre and post hematopoietic stem cell transplant
(HSCT) and compare their neurocognitive function with their normal
siblings. This preliminary study evaluates six patients with acute
leukemia who received a HSCT using Busulfan and Cytoxan as a condi-
tioning regimen. None of the patients received cranial irradiation. Using
the Peabody Picture Vocabulary Test (PPVT), patients evaluated prior
to HSCT had a lower receptive vocabulary than their normal siblings
(87.2 vs. 94), but the difference was not significant (p = 0.39). Similar
results were seen in those patients evaluated post HSCT as compared to
their normal siblings (85.4 vs. 94, p = 0.26). Although these results are
not statistically significant due to small numbers of patients, the results
represent a clinical decrease in receptive vocabulary. 
Using the Wide Range Assessment of Learning and Memory, patients
evaluated pre HSCT had lower memory and attention than their normal
siblings [96.5 vs. 107, p = 0.7 (n = 3)] Patients who were post HSCT had
a mean value of 80 compared with a mean value of 93.6 for normal sib-
lings, p = 0.53 (n = 2). These results represent a clinical decrease in
memory and attention. 
Although the results in this preliminary evaluation are not statistically
s i g n i ficant, with increased sample sizes these results may be clinically rel-
evant. Since these results suggest that receptive vocabulary tests decrease
compared to normal siblings, every effort should be undertaken to meet
the educational needs of patients receiving intensive chemotherapy and
HSCT. The results also show that patients have a decrease in their
memory and attention both pre and post HSCT. The cause and the sig-
n i ficance of these changes need to be further investigated. 
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HIGH DOSE CHEMOTHERAPY (HDC) AND AUTOLOGOUS PERIPHERAL
BLOOD STEM CELL TRANSPLANTATION (APBSCT) FOR 45 PATIENTS
WITH BREAST CANCER: RESULTS OF THE MOST EXPERIENCED CEN-
TER IN TURKEY.
Seref, K.; Ozturk, B.; Arpaci, F.; Ozet, A.; Yylmaz, I.; Ayta, H.; Yavuz,
A.A.; Pak, Y.; Yucel, I.; Yalcyn, A. Gulhane Military Medical Academy,
Ankara, Turkey
The objective of this study was to assess the toxicity and efficacy of
HDC with APBSCT in women with metastatic or high risk ( ≥9 axillary
nodal involvement) stage II-III breast cancer. Forty-five women with
either metastatic (n = 23) or high risk (n = 22) breast cancer were
enrolled in the study and treated with HDC followed by APBSCT. At
the time of transplant, the median age was 39 years (range 26-64 ). All
patients were pretreated with standard chemotherapy regimens.
Metastatic patients with progression or stable disease after first-line
chemotherapy were excluded. PBSC were harvested using filgrastim and
the conditioning regimens ICE (ifosfamide, carboplatin, etoposide) and
CNV (cyclophosphamide, mitoxantrone, etoposide) were used. The
median number of CD34 (+) cells infused were 5.40 x 106 /kg (range
1.82-19.87 x 106 /kg). G-CSF or GM-CSF were used in 39 patients in
posttrasplant period. Median duration of leukopenia (<l e u k o c y t e
1 0 0 0 / m m3 ) was 11 days (0-24) and that of thrombocytopenia
(<5 0 . 0 0 0 / m m3) was 11 days (0-27). In early transplant period (0 - +30th
day), 4 (17%) patients were died due to sepsis, renal failure, ARDS and
intracranial hemorrhage in the metastatic group and no death was seen
in the high risk group. The most common grade II-III toxicities were
mucositis (74%), nausea/vomiting (59%), diarrhea (33%). There were
no grade 4 non-hematological toxicity. The median follow-up for
metastatic and high risk groups were 14 months (range 1-30) and 13
months (range 1-31), respectively. The overall survival rates were 55%
in metastatic and 77% in high risk groups for two years. In conclusion,
HDC and APBSCT is a potentially highly effective and safe treatment
of women with high risk breast cancer in adjuvant setting. Although 4
deaths were seen, our results for metastatic breast cancers are compara-
ble to those of most other BMT centers. 
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VITAL SIGNS IN THE BONE MARROW TRANSPLANT UNIT (BMTU) :
ARE THEY NEEDED IN THE MIDDLE OF THE NIGHT (MON)?
Sharda, S.; Carter, J.; Wingard, J.R.; Mehta, P. University of Florida,
Gainesville, FL
Middle of night (MON) vital signs are routinely done in a BMTU;
however they interrupt sleep and may not always be necessary. We eval-
uated the need for MON (1am to 5am) vital signs by retrospectively
reviewing charts of 20 patients transplanted from Aug-Nov 1999.
Patients had mean age of 47 yrs; 9 were females and 11 were males.
Underlying diagnoses were ALL (3), AML (4), CML (1), CLL (1), MLL
(1), MM (5), NHL (3) and breast cancer (2). Types of transplants were
autologous (9), matched related allogenic (5) and MUD (6). Vital signs
were taken on 457 of 543 nights that were reviewed. Interventions per-
formed as a result of vital signs occurred in 20 instances (4.4%). Seventy
five percent of supportive care interventions took place between day +6
and +21. In 15 instances the nurse made the intervention based on preset
supportive care guidelines; in 5 instances a physician was called, and in 3
a change in treatment was made. The abnormal vital signs leading to
intervention were fever (17), bradycardia (2) and hypertension (1). The
interventions were antipyretics (17), cultures (4), EKG (1) and other
medications given (2). Daytime events were reviewed to determine if
nighttime interventions could be predicted. Factors assessed were pain,
nausea/vomiting, diarrhea, G-I complaints, CNS disturbance, insomnia,
fever, blood pressure, heart rate, mucositis, rash, respiratory distress,
serum levels of K, Mg, phosphorus and creatinine, chemotherapy,
antibiotics, steroids, hyperalimentation, transfusion, day of stem cell
infusion and surgical procedure. The daytime factors associated with
MON intervention were fever (present in 65% of patients needing
MON interventions vs 15% in others, p = 0.00l), CNS disturbance (20%
vs 6%, p = 0.009) and elevated creatinine (l5% vs 3%, p = 0.007). Strate-
gies to further characterize these “at risk” subgroups should be devel-
oped so as to minimize nighttime disturbances and sleep interruption. 
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EVIDENCE OF AN AUTOANTIBODY INHIBITING ENGRAFTMENT IN A
PATIENT WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) TREATED
WITH HIGH DOSE IMMUNOSUPPRESSION AND AUTOLOGOUS STEM
CELL RESCUE
Shaughnessy, P.J.1; Ririe, D.W.1; Ornstein, D.L.1; Kissack, B.1; Bickford, D.J.1; Moli -
na, R.2; Bachier, C.3; Lanzkron, S.3; LeMaistre, C.F.3 1. Wilford Hall Medical Cen -
ter, Lackland AFB, TX; 2. Arthritis Diagnostic and Treatment Clinic, San Antonio ,
TX; 3. Texas Transplant Institute, San Antonio, TX
We report the case of a 32 year old female treated with high dose
immunoablation for WHO grade IV, dialysis dependent lupus nephritis. Stem
cells were mobilized with cyclophosphamide and GCSF, and 4.07x106C D 3 4
selected cells/kg were collected using the cell pro column. The preparative
regimen was cyclophosphamide, 50mg/kg q day on D-5 to D-2, and ATG
30mg/kg q day on D-4 to D-2, with solumedrol 1mg/kg given prior to each
ATG dose. The patient failed to engraft and a bone marrow biopsy on D28
showed aplasia. Previously collected unmanipulated stem cells (2.84x106C D 3 4
cells/kg) were infused on D35. There continued to be no evidence of autolo-
gous engraftment and the patient developed fusarium fungemia and CMV
pneumonitis. On D52 the patient was given unmanipulated stem cells from an
HLA identical sibling (3x106CD34 cells/kg). The patient eventually expired on
D62 from sepsis and refractory hypotension. Autopsy revealed an aplastic bone
marrow and diffuse fusarium infection in the lungs. All viral titers done during
the hospital course for hepatitis, EBV, CMV, and parvovirus were negative.
Renal function improved after D28 with decreased serum creatinine and
improved urine output without dialysis, but later deteriorated from the use of
nephrotoxic drugs and multiorgan system failure. Progenitor assays were done
with and without patient serum. When the patient’s cells were plated with her
own serum the colonies had abnormal shapes and non adherent cells, and sig-
n i ficantly fewer BFU-e colonies than when plated with no serum. Our obser-
vations in this case suggest the presence of an autoantibody in the patient’s
serum directed against the her own cells. This case demonstrates the potential
b e n e fit of high dose immunosuppressive therapy for restoring renal function in
lupus nephritis, but also illustrates the dangers of this procedure. Analyses of
progenitor assays may be beneficial prior to similar therapy in the future. 
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TANDEM CYCLES VS SINGLE CYCLE OF HIGH DOSE CHEMOTHERAPY
AND STEM CELL TRANSPLANT FOR METASTATIC BREAST CANCER
RESULTS IN HIGHER RESPONSE RATE
Stadtmauer, E.A.; Ragi, J.; Tsai, D.E.; Mick, R.; Porter, D.L.; Laport, G.;
Schuster, S.; Luger, S.A.; Sickles, C.; Stroble, F. University of Pennsylvania
Cancer Center, Philadelphia, PA
A randomized trial of induction chemotherapy followed by a single
cycle of high-dose chemotherapy (HDC) and stem cell transplant (SCT)
for responding metastatic breast cancer (MBC) showed no benefit over
cycles of CMF maintenance chemotherapy. We hypothesized two cycles
of HDC and SCT may be superior to one cycle in the same patient pop-
ulation. Between 9/95 and 9/97, 42 women with responding MBC
received cyclophosphamide 3 g/m2 and taxol 250 mg/m2 followed by G-
CSF mobilized SC collection. Pts then received melphalan 140mg/m2
with SCT. Pts then went on to a second course of HDC with STAMP
V followed by a second SCT. The results of this group were contrasted
to a similar group of 37 women with responding MBC treated on a prior
trial between 2/93 and 10/95 who underwent G-CSF mobilized SC col-
lection followed by a single cycle of STAMP V followed by SCT. The
Single SCT group was favorable as 41% were in CR at time of SCT vs
19% for Tandem SCT. No SCT related mortality was noted with Sin-
gle SCT but 4.8% mortality from Tandem SCT. Median hospital LOS
was 19 with Single SCT and 29 with Tandem SCT. Tandem SCT was
highly successful in impoving remission status for patients in PR pre-
SCT 23/34(67%) vs 5/22(23%). Where Single SCT failed, Tandem
SCT converted 5/34(15%) PR pre-SCT to CR. With a median follow-
up of Single SCT of 38 months and Tandem SCT 36 months, RFS is
promising for Tandem SCT at 2 years (32% vs 19%) but overall survival
is similar (52% vs 44%). These results suggest multiple cycles of HDC
with SCT yield a high rate of response and may extend early RFS and
may be a superior approach than Single SCT for responding MBC.
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HIGH-DOSE MELPHALAN AND CISPLATIN WITH PERIPHERAL BLOOD
PROGENITOR SUPPORT IN PATIENTS WITH BREAST CANCER
Somlo, G.; Doroshow, J.H.; Chow, W.; Forman, S.; Leong, L.; Margolin, M.;
Morgan, R.; Raschko, J.; Shibata, S.; Molina, A. City of Hope National Med -
ical Center, Duarte, CA
We have tested tandem cycle high-dose chemotherapy (HDCT) with
melphalan (Mel) and cisplatin (Cis) followed by peripheral blood prog-
enitor cell support (PBPC). Fifty patients with high-risk primary (n = 1 7 )
or stage IV breast cancer (n = 29) or other malignancies (n = 4) partici-
pated in a phase I-II trial between 8/91 and 8/98. Patients received 2
cycles of escalating doses of Mel 20-151.8 mg/m2 and fixed dose Cis 200
m g / m2 divided between days 1 and 8 followed by PBPC. There were no
toxic deaths. Delayed platelet recovery defined the maximum tolerated
dose (MTD) of Mel at 101.2 mg/m2/cycle. Seventy two percent of
patients treated at the MTD received both cycles. Of 29 patients with
stage IV breast cancer 18 % were in complete response (CR) prior to
HDCT; of 21 patients not in complete response (CR) prior to HDCT,
14% achieved CR after the first and an additional 24% reached CR after
the 2nd cycle (overall CR conversion: 38%). At a median follow-up of 34
months (range, 4-84 months) 3-year progression-free and overall sur-
vival were 31% (95% CI, 13-48%) and 51% (95% CI, 32-70) for the 29
patients with stage IV breast cancer. Complete response following
HDCT was associated with substantial reduction in the risk of disease
progression [risk ratio (RR):0.27, 95%CI, 0.13-0.79];and death (RR:
0.27, 95% CI, 0.09-0.79) regardless of sites of metastatic involvement
pre-HDCT. 
Tandem cycle high-dose Mel and Cis is feasible and is associated with
s i g n i ficant activity in patients with stage IV breast cancer. Comparison
of tandem versus single cycle HDCT is warranted.
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POSSIBLE ROLE FOR DOSE-INTENSIVE CYCLOPHOSPHAMIDE, ETOPO-
SIDE, CISPLATIN (DICEP) AS RE-INDUCTION AND STEM CELL MOBI-
LIZATION THERAPY FOR RELAPSED OR REFRACTORY NON-HODG-
KIN’S LYMPHOMA (NHL)
Stewart, D.A.1 , 2; Guo, D.1; Gluck, S.1 , 2; Morris, D.1 , 2; Chaudhry, A.1 , 2;
Klassen, J.2; Brown, C.1 , 2; Russell, J.A.1 , 2 1. Tom Baker Cancer Centre, Cal -
gary, AB, Canada; 2. Foothills Hospital, Calgary, AB, Canada
Background: Single agent high dose melphalan 180-200mg/m2 (HDM) +/-
TBI 500cGy has been the standard autologous stem cell transplant (ASCT)
conditioning regimen in Calgary for NHL. Since 1995, dose-intensive
cyclophosphamide 5.25g/m2, etoposide 1.05g/m2, cisplatin 105mg/m2 ( D I C E P )
re-induction therapy has been preferentially used for tumor cytoreduction and
stem cell mobilization for patients with refractory or bulky relapsed NHL. The
purpose of this study was to determine if DICEP re-induction is associated with
improved event-free (EFS) following HDM/ASCT. 
Patients and Methods: Seventy-one consecutive patients aged 22-69 years
(median 45) received HDM/ASCT for relapsed (n = 49) or refractory (n = 2 2 )
aggressive histology NHL. Re-induction chemotherapy consisted of either
DICEP (n = 37), standard-dose salvage (n = 27), or no re-induction (n = 7 ) .
Cox proportional hazards models were constructed to identify factors inde-
pendently associated with relapse. 
Results: Fifty-three (75%) of the patients had failed one prior chemothera-
py regimen. DICEP patients were more likely to have refractory disease
(43% vs 18%, p = 0.02), bulk>5cm (51% vs 35%, p = 0.04) and marrow infil-
tration (27% vs 6%, p = 0.03). With a median follow-up of 32 months (3-
99mo), the projected 3-year EFS was 36% (95% CI = 25-51%) for all 71
patients. By multivariate analysis, factors independently associated with
relapse were refractory disease status (relative risk (RR) = 3.6, p = 0 . 0 0 2 ) ,
progressive disease at stem cell collection (RR = 3.1, p = 0.002), failing more
than 1 prior chemotherapy regimen (RR = 10.9, p<0.001), and not using
DICEP re-induction for patients who had failed only 1 prior chemotherapy
regimen (RR = 4.7, p = 0.002). None of the 71 patients experienced early
treatment-related mortality. The median number of CD34+ cells collected
for the DICEP patients was 17.9 x106/kg (range 2.2 to 129.8 x106/kg); all but
1 (97%) patient in a single apheresis. 
Conclusion: This study suggests that DICEP may improve the results of
HDM/ASCT for relapsed or refractory NHL when used for patients who
have failed only 1 prior chemotherapy regimen. 
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PT CELLS PT CELLS NL DONOR NL DONOR
W/O SERUM W SERUM W/O SERUM W SERUM
BFU-e 2.2x105 .27x105* 1.7x105 2.2x105
CFU-GM 1.3x105 .46x105 2.1x105 1.6x105
*p = .05
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TOTAL BODY IRRADIATION DOES NOT AFFECT OUTCOME IN
PATIENTS AUTOGRAFTED FOR MULTIPLE MYELOMA
Taylor, T.L.; Hu, W.W.; Johnston, L.J.; Shizuru, J.A.; Negrin, R.S.; Chao,
N.J.; Long, G.D.; Blume, K.G.; Stockerl-Goldstein, K.E. Stanford University,
Stanford, CA
Purpose: To compare transplant outcomes using total body irradiation
(TBI) with melphalan (Group I) versus carmustine (BCNU) and mel-
phalan (Group II). 
Patients and Methods: Data of 83 consecutive patients with multiple
myeloma who had been treated with autologous hematopoietic cell trans-
plantation (AHCT) were reviewed. Their median age was 52 years. Ten
(17%) obtained a complete remission before AHCT. Cyclophosphamide
(4gm/ m2) was given for peripheral blood hematopoietic cell (PBHC) col-
lection stored for “back-up.” PBHC used for AHCT were collected after
administration of etoposide (2gm/m2). Group I (n = 48) received fraction-
ated TBI for a total of 12 Gy followed by melphalan (140mg/m2). Group
II (n = 35) received BCNU 550 mg/m2 and escalating doses of melphalan
ranging from 100 mg/m2 to the maximum tolerated dose of 200 mg/m2. 
Results: With a median follow up of 26 months, there were no differ-
ences in overall survival (Group I 42+10%, Group II 56+15%, p = 0 . 5 2 )
at four years. Disease-free survival (Group I 37+8%, Group II 47+13%,
p = 0.24) and relapse rates (Group I 58+8%, Group II 48+14%, p = 0 . 1 9 )
did not vary. Neutrophil engraftment was significantly different, favoring
radiochemotherapy with no differences in infectious complications. The
length of hospitalization was a median of 14 days (Group I) versus 5 days
(Group II,p = 0.003). Two treatment related deaths (2.4%) occurred in
Group I due to disseminated aspergillus infection and veno-occlusive dis-
ease. Proportional hazards analysis showed improved disease-free survival
and lower relapse rate for patients with no history of prior radiation ther-
apy and a beta-2-microglobulin level of ≤ 3mg%. Patients treated for less
than 6 months had improved overall survival when compared to patients
with more extensive treatment (71% versus 51.4%, p = 0.01). 
Conclusion: Our results show that outcomes are comparable with frac-
tionated TBI or BCNU used in combination with melphalan. Treat-
ment related complication differed, but these were manageable and
acceptable consequences of AHCT. 
1 0 2
NOD-SCID STUDIES ON ADENOVIRUS P53 PURGING OF STEM CELL
P R O D U C T S
Talmadge, J.E.1; Hirai, M.1; Shabram, P.4; Johnson, R.3; LaFace, D.4; Wen,
S . F .4; Mills, K.2; Vaillancourt, M.4; Neugebauer, S.4; Maneval, D.4 1. Uni -
versity of Nebraska Med Ctr, Omaha, NE; 2. Miltenyi Biotec, Auburn, CA; 3.
Schering Plough, NJ; 4. Canji,Inc., San Diego, CA
Co-culture with replication-deficient recombinant adenovirus (rAd)
vectors capable of expressing the wild-type p53 gene (rAd-p53) can
purge breast cancer stem cell products. In studies of clonogenic growth
inhibition using breast cancer (BrCa) cell lines, we demonstrated the
e f ficacy of this approach and its dependence on virus particle number
(PN), co-incubation volume, time and temperature. Following infection
with rAd-bgal, X-Gal staining demonstrated that tumor cells (TC) were
2,000-fold more susceptible to rAd transduction than peripheral stem
cells (PSC). PSC were also used in “spiking” studies with a 0.1% TC
contamination and revealed that a 400:1 PN:PSC ratio could result in 6
logs of killing following a 4 hr co-culture. rAd-p53 co-culture was shown
to be safe, with marginal effect on hematopoietic progenitor cell func-
tion as measured by BFU-e, CFU-GM, HPP-CFC and NOD-SCID
competitive re-population assays. In the NOD-SCID studies, re-popula-
tion was demonstrated by CFU-c assay, flow cytometry for lymphocyte,
monocyte, granulocyte, platelet and erythroid origin precursors and
DNA analysis for human alu-sequences in a limiting dilution type of
assay. Ex vivo studies with PSC products from BrCa patients demon-
strated a significant loss of contaminating TC and an increase in TC
apoptosis following a 4 hr co-incubation with rAd-p53. These studies
revealed that the demonstration of ex vivo purging efficacy requires TC
isolation, quantification and analysis of apoptosis. Studies at scale
demonstrated limited adsorption of adenovirus particles to freezing bags
and retention of CFU-c function. These studies also demonstrated the
potential for re-infusion of free virus within the stem cell product. In
summary, purging of BrCa patient stem cell products using rAd-p53
appears to be a safe and effective procedure.
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UNCOMMON INFECTIONS AFTER BLOOD MARROW TRANSPLANT
Trabasso, P.; Vigorito, C.A.; Aranha, F.P.; Oliveira, G.B.; Eid, K.B.; De
Souza, C.A. Campinas State University Hospital, Campinas, Brazil
Opportunistic infections in bone marrow transplant (BMT) recipients
are a common consequence of high grade and extended neutropenia and
immunosupression. Our main objective was to describe six cases of
uncommon infectious diseases complicating BMT that occurred in
BMT Unit of Campinas State University Hospital. All patients received
identical sibling BM or PBSCT and the conditioning regimen was
BU/CY2; GvHD prophylaxis was CSA/MTX, except in Case 2, where
conditioning regimen was TBI/CY2. Case 1. Male, 41yrs, CML 1st CP.
He developed abdominal pain and diarrhoea on day +8; direct faeces
examination revealed Paracoccidioides brasiliensis. Case 2. Female, 10
yrs, CML 2nd CP. On day +13, she developed pustules in right leg. The
culture of pustules was positive to Fusarium sp. Case 3. Female, 49 yrs,
refractory AML M4. Patient developed dyspnoea, jaundice and enlarge-
ment of liver and spleen on day +3. The chest X-ray showed pleural
effusion. Either the pleural effusion and blood samples were positive to
Prototheca zoopfi. Case 4. Male, 40 yr.-old, CML in 1st CP. On day
+525 he developed fever (39ºC) plus respiratory symptoms. The culture
of lung biopsy was positive to Mycobacterium tuberculosis. Case 5.
Female, 30 yrs, CML in CP. She developed hemorrhagic cystitis on day
+353 and urine culture was positive to Mycobacterium tuberculosis.
Case 6. Female, 39 yrs, CML in 1st CP. On day +293 she developed
fever, respiratory frequency increasing and thoracic pain. Chest X-ray
showed mixed interstitial and alveolar infiltrate. The culture of broncho-
alveolar lavage was positive to Mycobacterium chelonae. Deep and
extended immunosupression, associated with the GvHD prophylaxis
raise the risk of the recipients of BMT to develop opportunistic infec-
tions. Rigorous clinic observation, with emphasis in specific knowledge
of its epidemiology can alert to unusual infections and should be remem-
bered in the developing countries.
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GENERATION OF DENDRITIC CELLS IN VITRO FROM PATIENTS WITH
BREAST CANCER, AND LYMPHOMA AND NORMAL DONORS: DIFFER-
ENCES IN STEADY STATE VERSUS MOBILIZED BLOOD
Syme, R.M.1; Callaghan, D.H.1; Bitner, S.1; Stewart, D.2; Gluck, S.1 , 2
1. University of Calgary, Calgary, AB, Canada; 2. Tom Baker Cancer Centre,
Calgary, AB, Canada
Dendritic cells (DC) are potent antigen presenting cells, which are inte-
gral to the initiation of T cell immunity. The ability to culture these cells in
vitro has allowed DC immunotherapy to be investigated as a mechanism to
enhance immune responses for a variety of malignancies. We want to estab-
lish an immunotherapy program for patients undergoing high dose
chemotherapy. This is the time when a patient would likely have minimal
residual disease, and when specifically targeted immune cells may eradicate
the remaining cancer. We examined the optimal time for generating DC,
and also undertook a comparison of DC generated from normal donors and
patients’s with non-Hodgkin’s lymphoma or breast cancer. Experiments
were conducted to compare DC cultured pre and post mobilization. Blood
was obtained from consenting patients prior to G-CSF administration with
or without chemotherapy. A sample of apheresis product was obtained at
the time of apheresis. Dendritic cells were cultured from PBMC (10X106)
by culturing the adherent cells in the presence of IL-4 and GM-CSF. After
7 days resultant DC were harvested and examined for yield, morphology,
phenotype and function. All cell populations yielded highly pure dendritic
cells as assessed by light microscopy, and flow cytometry. The average cellu-
lar yield was better from apheresis (2.9 X106) than blood (2.4 X106). Table
one shows the differences of peripheral blood versus apheresis in 3 different
populations. In all experiments examined, DC from breast cancer patients
functioned better than DC from lymphoma patients in a mixed lymphocyte
reaction. There was an average 3.1 fold increase in cell number for breast
cancer patients, 1.6 for lymphoma, and 1.2 for healthy donors. Together
this data suggests that the optimal timing of culturing dendritic cells from
patients may differ with the type of underlying disease, and suggests that
there are differences in their functional capabilities. 
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BREAST CANCER NON-HODGKIN’S LYMPHOMA NORMAL DONORS
Apheresis (x106) 2.4 (2.25 - 2.63) 2.3 (1.31 - 5.0) 5.0 (4.5 - 5.4)
Peripheral Blood (x106) 1.15 (0.75 - 1.6) 2.9 (1.6 - 5.0) 2.5 (1.1 - 4.2)
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TREATMENT OF SEVERE STEROID-RESISTANT GVHD WITH A MONO-
CLONAL INTERLEUKIN-2 RECEPTOR ANTAGONIST (DACLIZUMAB [DC])
Willenbacher, W.; Basara, N.; Kirsten, D.; Lentini, G.; Hartert, A.M.;
Rajewski, A.; Günzelmann, S.; Kiehl, M.G.; Fauser, A.A. Center for BMT &
Hematology-Oncology, Idar-Oberstein, Germany
GvHD is a major contributor to morbidity and mortality after
BMT/PBSCT. In GvHD refractory to standard therapy (Pred/CSA),
i n t e n s i fied by MMF, we applied DC in a dose of 1mg/kg for 5 days fol-
lowed by weekly maintenance therapy (MT) using single dose (1mg/kg)
DC in fifteen pts. (8 m,7 f). Eleven pts. were treated for aGvHD and 4
pt. for extensive cGvHD. Diagnosis were CML (4), AML (8), MDS (2)
and ALL (1), median age was 45 years (21-61).Six pts. had a matched
sibling PBSCT, six a MUD-PBSCT and three received a mismatched
unrelated donor graft. There were no acute toxicities besides easily con-
trolled hypotension and nausea (WHO II°) in one pt.. Two of seven pts.
revealed a complete response which was durable at 6 months(* in Table
1). Of four patients treated for cGvHD 3 responded (1 complete, 2 par-
tial)at day +28. Response was durable in 2 pts. at 6 mo.. Eight of eleven
deaths were due to refractory or recurrent GvHD. 3 pts. died from
relapse (1), ARDS (1) and cerebral toxoplasmosis (1), respectively. DC as
part of therapy for uncontrolled GvHD appears to be a safe, well tolerat-
ed and an effective salvage treatment deserving further studies. 
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R E S P O N S E AT D + 28 OF DC TREATMENT ( A G V H D )
OVERALL GVHD GRADE STAGE OF SKIN GVHD STAGE OF LIVER GVHD STAGE OF GUT GVHD
IV -> I * 4 -> 1 0 -> 0 0 -> 0
IV -> I 1 -> 1 3 -> 1 4 -> 1
IV -> I * 4 -> 1 1 -> 1 3 -> 2
III -> 0 3 -> 0 0 -> 0 0 -> 0
IV -> I 2 -> 0 0 -> 0 4 -> 1
IV -> I 2 -> 0 4 -> 0 4 -> 1
IV -> IV 1 -> 1 1 -> 1 4 -> 4
IV -> IV 2 -> 1 3 -> 4 4 -> 4
IV -> IV 1 -> 1 0 -> 0 4 -> 4
IV -> II 4 -> 2 2 -> 2 0 -> 0
IV -> IV 1 -> 1 4 -> 4 4 -> 4
